TW201908311A - 化合物 - Google Patents
化合物Info
- Publication number
- TW201908311A TW201908311A TW107119972A TW107119972A TW201908311A TW 201908311 A TW201908311 A TW 201908311A TW 107119972 A TW107119972 A TW 107119972A TW 107119972 A TW107119972 A TW 107119972A TW 201908311 A TW201908311 A TW 201908311A
- Authority
- TW
- Taiwan
- Prior art keywords
- alkyl
- naphthyridin
- carboxamide
- substituted
- trans
- Prior art date
Links
- 150000001875 compounds Chemical class 0.000 title claims abstract description 175
- 238000000034 method Methods 0.000 claims abstract description 82
- 239000003112 inhibitor Substances 0.000 claims abstract description 35
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims abstract description 27
- 239000008194 pharmaceutical composition Substances 0.000 claims abstract description 15
- 206010013801 Duchenne Muscular Dystrophy Diseases 0.000 claims abstract description 12
- 208000035475 disorder Diseases 0.000 claims abstract description 12
- 102100029100 Hematopoietic prostaglandin D synthase Human genes 0.000 claims abstract description 11
- 101710082112 Hematopoietic prostaglandin D synthase Proteins 0.000 claims abstract description 11
- 125000000217 alkyl group Chemical group 0.000 claims description 275
- -1 methyl-tetrazolyl Chemical group 0.000 claims description 179
- 235000019000 fluorine Nutrition 0.000 claims description 149
- 229910052731 fluorine Inorganic materials 0.000 claims description 131
- 239000011737 fluorine Substances 0.000 claims description 125
- 125000001424 substituent group Chemical group 0.000 claims description 109
- 239000001257 hydrogen Substances 0.000 claims description 108
- 229910052739 hydrogen Inorganic materials 0.000 claims description 108
- YCKRFDGAMUMZLT-UHFFFAOYSA-N Fluorine atom Chemical compound [F] YCKRFDGAMUMZLT-UHFFFAOYSA-N 0.000 claims description 94
- 239000000460 chlorine Substances 0.000 claims description 94
- 229910052801 chlorine Inorganic materials 0.000 claims description 93
- ZAMOUSCENKQFHK-UHFFFAOYSA-N Chlorine atom Chemical compound [Cl] ZAMOUSCENKQFHK-UHFFFAOYSA-N 0.000 claims description 87
- 208000029549 Muscle injury Diseases 0.000 claims description 84
- 125000001153 fluoro group Chemical group F* 0.000 claims description 83
- 150000003839 salts Chemical class 0.000 claims description 82
- IJGRMHOSHXDMSA-UHFFFAOYSA-N nitrogen Substances N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 claims description 75
- 125000002393 azetidinyl group Chemical group 0.000 claims description 67
- 229910052760 oxygen Inorganic materials 0.000 claims description 66
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 claims description 63
- 229910052757 nitrogen Inorganic materials 0.000 claims description 63
- 229910052794 bromium Inorganic materials 0.000 claims description 62
- 239000001301 oxygen Substances 0.000 claims description 60
- WKBOTKDWSSQWDR-UHFFFAOYSA-N Bromine atom Chemical compound [Br] WKBOTKDWSSQWDR-UHFFFAOYSA-N 0.000 claims description 59
- GDTBXPJZTBHREO-UHFFFAOYSA-N bromine Substances BrBr GDTBXPJZTBHREO-UHFFFAOYSA-N 0.000 claims description 59
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims description 58
- 125000003545 alkoxy group Chemical group 0.000 claims description 56
- PNDPGZBMCMUPRI-UHFFFAOYSA-N iodine Chemical group II PNDPGZBMCMUPRI-UHFFFAOYSA-N 0.000 claims description 48
- 150000002431 hydrogen Chemical class 0.000 claims description 47
- 125000004093 cyano group Chemical group *C#N 0.000 claims description 43
- 125000006555 (C3-C5) cycloalkyl group Chemical group 0.000 claims description 40
- 125000000753 cycloalkyl group Chemical group 0.000 claims description 38
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 claims description 31
- 208000014674 injury Diseases 0.000 claims description 27
- 125000001995 cyclobutyl group Chemical group [H]C1([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 claims description 24
- 125000005842 heteroatom Chemical group 0.000 claims description 24
- 238000001356 surgical procedure Methods 0.000 claims description 24
- 125000000113 cyclohexyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C1([H])[H] 0.000 claims description 22
- 208000027418 Wounds and injury Diseases 0.000 claims description 20
- 230000006378 damage Effects 0.000 claims description 20
- 125000000592 heterocycloalkyl group Chemical group 0.000 claims description 20
- 241000282414 Homo sapiens Species 0.000 claims description 18
- 125000001559 cyclopropyl group Chemical group [H]C1([H])C([H])([H])C1([H])* 0.000 claims description 17
- 201000006938 muscular dystrophy Diseases 0.000 claims description 17
- 230000008439 repair process Effects 0.000 claims description 17
- 125000002971 oxazolyl group Chemical group 0.000 claims description 16
- 125000005913 (C3-C6) cycloalkyl group Chemical group 0.000 claims description 15
- 239000003814 drug Substances 0.000 claims description 14
- 201000010099 disease Diseases 0.000 claims description 13
- 125000001072 heteroaryl group Chemical group 0.000 claims description 13
- 210000003205 muscle Anatomy 0.000 claims description 13
- 125000004178 (C1-C4) alkyl group Chemical group 0.000 claims description 12
- 150000001412 amines Chemical class 0.000 claims description 12
- 125000003118 aryl group Chemical group 0.000 claims description 12
- 229910052727 yttrium Inorganic materials 0.000 claims description 12
- 208000015122 neurodegenerative disease Diseases 0.000 claims description 11
- 125000003386 piperidinyl group Chemical group 0.000 claims description 11
- 125000002757 morpholinyl group Chemical group 0.000 claims description 10
- 125000000719 pyrrolidinyl group Chemical group 0.000 claims description 10
- 206010050031 Muscle strain Diseases 0.000 claims description 9
- 208000006673 asthma Diseases 0.000 claims description 9
- 230000005764 inhibitory process Effects 0.000 claims description 9
- 241000282412 Homo Species 0.000 claims description 8
- 206010002026 amyotrophic lateral sclerosis Diseases 0.000 claims description 8
- 238000004519 manufacturing process Methods 0.000 claims description 8
- 208000034693 Laceration Diseases 0.000 claims description 7
- 125000004076 pyridyl group Chemical group 0.000 claims description 7
- LMUMMJCCZMWLEN-UHFFFAOYSA-N spiro[3.3]heptyl Chemical group [CH]1CCC11CCC1 LMUMMJCCZMWLEN-UHFFFAOYSA-N 0.000 claims description 7
- 230000035882 stress Effects 0.000 claims description 7
- 230000008736 traumatic injury Effects 0.000 claims description 7
- PVOAHINGSUIXLS-UHFFFAOYSA-N 1-Methylpiperazine Chemical group CN1CCNCC1 PVOAHINGSUIXLS-UHFFFAOYSA-N 0.000 claims description 6
- 210000001264 anterior cruciate ligament Anatomy 0.000 claims description 6
- 125000001820 oxy group Chemical group [*:1]O[*:2] 0.000 claims description 6
- 238000011084 recovery Methods 0.000 claims description 6
- 210000002435 tendon Anatomy 0.000 claims description 6
- 230000000472 traumatic effect Effects 0.000 claims description 6
- 206010010356 Congenital anomaly Diseases 0.000 claims description 5
- 208000023178 Musculoskeletal disease Diseases 0.000 claims description 5
- HONIICLYMWZJFZ-UHFFFAOYSA-N azetidine Chemical compound C1CNC1 HONIICLYMWZJFZ-UHFFFAOYSA-N 0.000 claims description 5
- 230000008901 benefit Effects 0.000 claims description 5
- 125000000484 butyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 claims description 5
- 125000001309 chloro group Chemical group Cl* 0.000 claims description 5
- 230000001684 chronic effect Effects 0.000 claims description 5
- 206010010121 compartment syndrome Diseases 0.000 claims description 5
- 239000003937 drug carrier Substances 0.000 claims description 5
- 201000000585 muscular atrophy Diseases 0.000 claims description 5
- 230000004770 neurodegeneration Effects 0.000 claims description 5
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 claims description 5
- 229910052717 sulfur Inorganic materials 0.000 claims description 5
- 208000006545 Chronic Obstructive Pulmonary Disease Diseases 0.000 claims description 4
- 208000034656 Contusions Diseases 0.000 claims description 4
- 201000004624 Dermatitis Diseases 0.000 claims description 4
- 206010012438 Dermatitis atopic Diseases 0.000 claims description 4
- 208000022559 Inflammatory bowel disease Diseases 0.000 claims description 4
- 201000004681 Psoriasis Diseases 0.000 claims description 4
- 208000026935 allergic disease Diseases 0.000 claims description 4
- 150000001409 amidines Chemical class 0.000 claims description 4
- 208000024744 aspirin-induced respiratory disease Diseases 0.000 claims description 4
- 201000008937 atopic dermatitis Diseases 0.000 claims description 4
- 201000009580 eosinophilic pneumonia Diseases 0.000 claims description 4
- 229910052740 iodine Inorganic materials 0.000 claims description 4
- 201000008482 osteoarthritis Diseases 0.000 claims description 4
- 206010039073 rheumatoid arthritis Diseases 0.000 claims description 4
- 208000011580 syndromic disease Diseases 0.000 claims description 4
- 125000004209 (C1-C8) alkyl group Chemical group 0.000 claims description 3
- 208000024827 Alzheimer disease Diseases 0.000 claims description 3
- 208000029323 Congenital myotonia Diseases 0.000 claims description 3
- 208000002740 Muscle Rigidity Diseases 0.000 claims description 3
- 208000000112 Myalgia Diseases 0.000 claims description 3
- 206010061533 Myotonia Diseases 0.000 claims description 3
- 208000010316 Myotonia congenita Diseases 0.000 claims description 3
- 208000036110 Neuroinflammatory disease Diseases 0.000 claims description 3
- 230000001154 acute effect Effects 0.000 claims description 3
- 238000002266 amputation Methods 0.000 claims description 3
- 125000004566 azetidin-1-yl group Chemical group N1(CCC1)* 0.000 claims description 3
- 125000003943 azolyl group Chemical group 0.000 claims description 3
- 230000009519 contusion Effects 0.000 claims description 3
- 238000002316 cosmetic surgery Methods 0.000 claims description 3
- 230000008878 coupling Effects 0.000 claims description 3
- 238000010168 coupling process Methods 0.000 claims description 3
- 238000005859 coupling reaction Methods 0.000 claims description 3
- 230000003111 delayed effect Effects 0.000 claims description 3
- 201000001981 dermatomyositis Diseases 0.000 claims description 3
- 125000004051 hexyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 claims description 3
- 238000011540 hip replacement Methods 0.000 claims description 3
- 238000013150 knee replacement Methods 0.000 claims description 3
- 230000007774 longterm Effects 0.000 claims description 3
- 208000015001 muscle soreness Diseases 0.000 claims description 3
- ONLRKTIYOMZEJM-UHFFFAOYSA-N n-methylmethanamine oxide Chemical compound C[NH+](C)[O-] ONLRKTIYOMZEJM-UHFFFAOYSA-N 0.000 claims description 3
- QJGQUHMNIGDVPM-UHFFFAOYSA-N nitrogen group Chemical group [N] QJGQUHMNIGDVPM-UHFFFAOYSA-N 0.000 claims description 3
- 125000004430 oxygen atom Chemical group O* 0.000 claims description 3
- 239000000546 pharmaceutical excipient Substances 0.000 claims description 3
- 208000005987 polymyositis Diseases 0.000 claims description 3
- 125000003831 tetrazolyl group Chemical group 0.000 claims description 3
- 125000002023 trifluoromethyl group Chemical group FC(F)(F)* 0.000 claims description 3
- 125000006273 (C1-C3) alkyl group Chemical group 0.000 claims description 2
- 206010001052 Acute respiratory distress syndrome Diseases 0.000 claims description 2
- 201000001320 Atherosclerosis Diseases 0.000 claims description 2
- 206010006448 Bronchiolitis Diseases 0.000 claims description 2
- 206010006458 Bronchitis chronic Diseases 0.000 claims description 2
- 206010006482 Bronchospasm Diseases 0.000 claims description 2
- LEAZFFHOYYSOPL-WKILWMFISA-N C(C)OC1=CC=C2C=C(C=NC2=N1)C(=O)N[C@@H]1CC[C@H](CC1)C(C)(C)O Chemical compound C(C)OC1=CC=C2C=C(C=NC2=N1)C(=O)N[C@@H]1CC[C@H](CC1)C(C)(C)O LEAZFFHOYYSOPL-WKILWMFISA-N 0.000 claims description 2
- WLMQWGKJPSXGSJ-UHFFFAOYSA-N C1(CC1)C1=CC=C2C=C(C=NC2=N1)C(=O)NC1CC2(C1)CC(C2)C(C)(C)O Chemical compound C1(CC1)C1=CC=C2C=C(C=NC2=N1)C(=O)NC1CC2(C1)CC(C2)C(C)(C)O WLMQWGKJPSXGSJ-UHFFFAOYSA-N 0.000 claims description 2
- VEKOTFOGNGVLSE-QAQDUYKDSA-N C1(CC1)C1=CC=C2C=C(C=NC2=N1)C(=O)N[C@@H]1CC[C@H](CC1)C(C)(C)O Chemical compound C1(CC1)C1=CC=C2C=C(C=NC2=N1)C(=O)N[C@@H]1CC[C@H](CC1)C(C)(C)O VEKOTFOGNGVLSE-QAQDUYKDSA-N 0.000 claims description 2
- SERIMSSARRQQMN-IIAWOOMASA-N C1(CC1)C1=CC=C2C=C(C=NC2=N1)C(=O)N[C@@H]1C[C@H](C1)N[C@@H](C(F)(F)F)CO Chemical compound C1(CC1)C1=CC=C2C=C(C=NC2=N1)C(=O)N[C@@H]1C[C@H](C1)N[C@@H](C(F)(F)F)CO SERIMSSARRQQMN-IIAWOOMASA-N 0.000 claims description 2
- FFNXMEXDSZNWMU-QAQDUYKDSA-N C1(CC1)C1=NC=C2C=C(C=NC2=C1)C(=O)N[C@@H]1CC[C@H](CC1)N1CC(C1)(F)F Chemical compound C1(CC1)C1=NC=C2C=C(C=NC2=C1)C(=O)N[C@@H]1CC[C@H](CC1)N1CC(C1)(F)F FFNXMEXDSZNWMU-QAQDUYKDSA-N 0.000 claims description 2
- XKUZPLRRSSZIFY-IYARVYRRSA-N C1(CC1)C1=NC=C2C=C(C=NC2=C1)C(=O)N[C@@H]1CC[C@H](CC1)N1CC(C1)F Chemical compound C1(CC1)C1=NC=C2C=C(C=NC2=C1)C(=O)N[C@@H]1CC[C@H](CC1)N1CC(C1)F XKUZPLRRSSZIFY-IYARVYRRSA-N 0.000 claims description 2
- AXXFKEFRABKWRH-ZWNDMSQQSA-N C1(CC1)C1=NC=C2C=C(C=NC2=C1)C(=O)N[C@@H]1CC[C@H](CC1)NC(C(F)F)C Chemical compound C1(CC1)C1=NC=C2C=C(C=NC2=C1)C(=O)N[C@@H]1CC[C@H](CC1)NC(C(F)F)C AXXFKEFRABKWRH-ZWNDMSQQSA-N 0.000 claims description 2
- VUDWYDGYAIGRSR-JCNLHEQBSA-N C1(CC1)NC1=NC=C2C=C(C=NC2=C1)C(=O)N[C@@H]1CC[C@H](CC1)C(C)(C)O Chemical compound C1(CC1)NC1=NC=C2C=C(C=NC2=C1)C(=O)N[C@@H]1CC[C@H](CC1)C(C)(C)O VUDWYDGYAIGRSR-JCNLHEQBSA-N 0.000 claims description 2
- XQEKUKQGJVFDDA-IYARVYRRSA-N C1(CCC1)C1=CC=C2C=C(C=NC2=N1)C(=O)N[C@@H]1CC[C@H](CC1)C(C)(C)O Chemical compound C1(CCC1)C1=CC=C2C=C(C=NC2=N1)C(=O)N[C@@H]1CC[C@H](CC1)C(C)(C)O XQEKUKQGJVFDDA-IYARVYRRSA-N 0.000 claims description 2
- ZPZZIXPCWHXJQL-GDLVEWKHSA-N C[C@H]1[C@@H](C(NC1)=O)NC(=O)C=1C=NC2=CC(=NC=C2C=1)N1[C@H](CC1)C Chemical compound C[C@H]1[C@@H](C(NC1)=O)NC(=O)C=1C=NC2=CC(=NC=C2C=1)N1[C@H](CC1)C ZPZZIXPCWHXJQL-GDLVEWKHSA-N 0.000 claims description 2
- HEFPZCLPLNUXQE-XJIFVNEVSA-N ClC=1C=C2C=C(C=NC2=NC=1N1[C@H](CC1)C)C(=O)NC1CC2(C1)CC(C2)C(C)(C)O Chemical compound ClC=1C=C2C=C(C=NC2=NC=1N1[C@H](CC1)C)C(=O)NC1CC2(C1)CC(C2)C(C)(C)O HEFPZCLPLNUXQE-XJIFVNEVSA-N 0.000 claims description 2
- VCKMVNTVPPOVAR-BFVZDQMLSA-N ClC=1C=C2C=C(C=NC2=NC=1N1[C@H](CC1)C)C(=O)N[C@@H]1C(NC[C@H]1C)=O Chemical compound ClC=1C=C2C=C(C=NC2=NC=1N1[C@H](CC1)C)C(=O)N[C@@H]1C(NC[C@H]1C)=O VCKMVNTVPPOVAR-BFVZDQMLSA-N 0.000 claims description 2
- RREFSIHJZPUKPM-JQFCIGGWSA-N ClC=1C=C2C=C(C=NC2=NC=1N1[C@H](CC1)C)C(=O)N[C@@H]1CC[C@H](CC1)C(C)(C)O Chemical compound ClC=1C=C2C=C(C=NC2=NC=1N1[C@H](CC1)C)C(=O)N[C@@H]1CC[C@H](CC1)C(C)(C)O RREFSIHJZPUKPM-JQFCIGGWSA-N 0.000 claims description 2
- JDCHHDUNSJQKLH-HDJSIYSDSA-N ClC=1C=C2C=C(C=NC2=NC=1OC)C(=O)N[C@@H]1CC[C@H](CC1)C(C)(C)O Chemical compound ClC=1C=C2C=C(C=NC2=NC=1OC)C(=O)N[C@@H]1CC[C@H](CC1)C(C)(C)O JDCHHDUNSJQKLH-HDJSIYSDSA-N 0.000 claims description 2
- 206010010741 Conjunctivitis Diseases 0.000 claims description 2
- 206010010744 Conjunctivitis allergic Diseases 0.000 claims description 2
- 206010011224 Cough Diseases 0.000 claims description 2
- 201000003883 Cystic fibrosis Diseases 0.000 claims description 2
- 208000006313 Delayed Hypersensitivity Diseases 0.000 claims description 2
- 206010012442 Dermatitis contact Diseases 0.000 claims description 2
- 206010012559 Developmental delay Diseases 0.000 claims description 2
- 206010014561 Emphysema Diseases 0.000 claims description 2
- 206010064212 Eosinophilic oesophagitis Diseases 0.000 claims description 2
- HXKGMUUDMQMZBZ-SHTZXODSSA-N FC(CNC1=CC=C2C=C(C=NC2=N1)C(=O)N[C@@H]1CC[C@H](CC1)C(C)(C)O)F Chemical compound FC(CNC1=CC=C2C=C(C=NC2=N1)C(=O)N[C@@H]1CC[C@H](CC1)C(C)(C)O)F HXKGMUUDMQMZBZ-SHTZXODSSA-N 0.000 claims description 2
- LDADYUHMTCETQE-JCNLHEQBSA-N FC1CN(C1)C1=CC=C2C=C(C=NC2=N1)C(=O)N[C@@H]1CC[C@H](CC1)C(C)(C)O Chemical compound FC1CN(C1)C1=CC=C2C=C(C=NC2=N1)C(=O)N[C@@H]1CC[C@H](CC1)C(C)(C)O LDADYUHMTCETQE-JCNLHEQBSA-N 0.000 claims description 2
- YRTPRAFIIIRXDY-JCNLHEQBSA-N FC1CN(C1)C1=NC=C2C=C(C=NC2=C1)C(=O)N[C@@H]1CC[C@H](CC1)C(C)(C)O Chemical compound FC1CN(C1)C1=NC=C2C=C(C=NC2=C1)C(=O)N[C@@H]1CC[C@H](CC1)C(C)(C)O YRTPRAFIIIRXDY-JCNLHEQBSA-N 0.000 claims description 2
- 208000004262 Food Hypersensitivity Diseases 0.000 claims description 2
- 206010016946 Food allergy Diseases 0.000 claims description 2
- 208000007882 Gastritis Diseases 0.000 claims description 2
- 206010020751 Hypersensitivity Diseases 0.000 claims description 2
- 206010069698 Langerhans' cell histiocytosis Diseases 0.000 claims description 2
- SIFFTETUZUGDHW-MEDUHNTESA-N N-[(3S)-4,4-dimethyl-2-oxopyrrolidin-3-yl]-7-[(2S)-2-methylazetidin-1-yl]-1,6-naphthyridine-3-carboxamide Chemical compound CC1([C@@H](C(NC1)=O)NC(=O)C=1C=NC2=CC(=NC=C2C=1)N1[C@H](CC1)C)C SIFFTETUZUGDHW-MEDUHNTESA-N 0.000 claims description 2
- NIRLZTBCUBDTJU-WKILWMFISA-N N1(CCC1)C1=C(C=C2C=C(C=NC2=N1)C(=O)N[C@@H]1CC[C@H](CC1)C(C)(C)O)Cl Chemical compound N1(CCC1)C1=C(C=C2C=C(C=NC2=N1)C(=O)N[C@@H]1CC[C@H](CC1)C(C)(C)O)Cl NIRLZTBCUBDTJU-WKILWMFISA-N 0.000 claims description 2
- HDYCPVXELQLTJY-LBPRGKRZSA-N N1(CCC1)C1=CC=C2C=C(C=NC2=N1)C(=O)N[C@@H]1C(NCC1)=O Chemical compound N1(CCC1)C1=CC=C2C=C(C=NC2=N1)C(=O)N[C@@H]1C(NCC1)=O HDYCPVXELQLTJY-LBPRGKRZSA-N 0.000 claims description 2
- YBOJDFGHCNHNOW-QAQDUYKDSA-N N1(CCC1)C1=NC=C2C=C(C=NC2=C1)C(=O)N[C@@H]1CC[C@H](CC1)C(C)(C)O Chemical compound N1(CCC1)C1=NC=C2C=C(C=NC2=C1)C(=O)N[C@@H]1CC[C@H](CC1)C(C)(C)O YBOJDFGHCNHNOW-QAQDUYKDSA-N 0.000 claims description 2
- PUSUTUHTCAZWBX-AWEZNQCLSA-N OC(C(=O)N1CCC(CC1)NC(=O)C=1C=NC2=CC(=NC=C2C=1)N1[C@H](CC1)C)(C)C Chemical compound OC(C(=O)N1CCC(CC1)NC(=O)C=1C=NC2=CC(=NC=C2C=1)N1[C@H](CC1)C)(C)C PUSUTUHTCAZWBX-AWEZNQCLSA-N 0.000 claims description 2
- UEKLMEOMMDQNEQ-WBAXXEDZSA-N OC(C)(C)[C@@H]1CC[C@H](CC1)NC(=O)C=1C=NC2=CC(=NC=C2C=1)N1[C@H](CC1)C Chemical compound OC(C)(C)[C@@H]1CC[C@H](CC1)NC(=O)C=1C=NC2=CC(=NC=C2C=1)N1[C@H](CC1)C UEKLMEOMMDQNEQ-WBAXXEDZSA-N 0.000 claims description 2
- YOLJUQJWAVHFQX-SHTZXODSSA-N OC(C)(C)[C@@H]1CC[C@H](CC1)NC(=O)C=1C=NC2=CC(=NC=C2C=1)OC Chemical compound OC(C)(C)[C@@H]1CC[C@H](CC1)NC(=O)C=1C=NC2=CC(=NC=C2C=1)OC YOLJUQJWAVHFQX-SHTZXODSSA-N 0.000 claims description 2
- ROWLOFVLOJIUBH-JREVSVDSSA-N OC(C)(C)[C@@H]1CC[C@H](CC1)NC(=O)C=1C=NC2=NC(=CC=C2C=1)N1C(CC1)C Chemical compound OC(C)(C)[C@@H]1CC[C@H](CC1)NC(=O)C=1C=NC2=NC(=CC=C2C=1)N1C(CC1)C ROWLOFVLOJIUBH-JREVSVDSSA-N 0.000 claims description 2
- JAGIAVJYFUFCRT-SHTZXODSSA-N OC(C)(C)[C@@H]1CC[C@H](CC1)NC(=O)C=1C=NC2=NC(=CC=C2C=1)OC Chemical compound OC(C)(C)[C@@H]1CC[C@H](CC1)NC(=O)C=1C=NC2=NC(=CC=C2C=1)OC JAGIAVJYFUFCRT-SHTZXODSSA-N 0.000 claims description 2
- LPPRCJPNXIMGPZ-SHTZXODSSA-N OC(C)(C)[C@@H]1CC[C@H](CC1)NC(=O)C=1C=NC2=NC(=CC=C2C=1)OCC(F)(F)F Chemical compound OC(C)(C)[C@@H]1CC[C@H](CC1)NC(=O)C=1C=NC2=NC(=CC=C2C=1)OCC(F)(F)F LPPRCJPNXIMGPZ-SHTZXODSSA-N 0.000 claims description 2
- 206010033645 Pancreatitis Diseases 0.000 claims description 2
- 208000013616 Respiratory Distress Syndrome Diseases 0.000 claims description 2
- 206010039085 Rhinitis allergic Diseases 0.000 claims description 2
- 206010052568 Urticaria chronic Diseases 0.000 claims description 2
- 208000009621 actinic keratosis Diseases 0.000 claims description 2
- 230000009471 action Effects 0.000 claims description 2
- 208000002205 allergic conjunctivitis Diseases 0.000 claims description 2
- 201000010105 allergic rhinitis Diseases 0.000 claims description 2
- 208000024998 atopic conjunctivitis Diseases 0.000 claims description 2
- 206010006451 bronchitis Diseases 0.000 claims description 2
- 230000007885 bronchoconstriction Effects 0.000 claims description 2
- 208000007451 chronic bronchitis Diseases 0.000 claims description 2
- 208000024376 chronic urticaria Diseases 0.000 claims description 2
- 208000010247 contact dermatitis Diseases 0.000 claims description 2
- 201000000708 eosinophilic esophagitis Diseases 0.000 claims description 2
- 208000003401 eosinophilic granuloma Diseases 0.000 claims description 2
- 235000020932 food allergy Nutrition 0.000 claims description 2
- 230000009610 hypersensitivity Effects 0.000 claims description 2
- 230000004968 inflammatory condition Effects 0.000 claims description 2
- 201000006417 multiple sclerosis Diseases 0.000 claims description 2
- 125000004433 nitrogen atom Chemical group N* 0.000 claims description 2
- 201000009732 pulmonary eosinophilia Diseases 0.000 claims description 2
- 208000005069 pulmonary fibrosis Diseases 0.000 claims description 2
- 230000001932 seasonal effect Effects 0.000 claims description 2
- 201000009890 sinusitis Diseases 0.000 claims description 2
- 210000002027 skeletal muscle Anatomy 0.000 claims description 2
- 230000006128 skin development Effects 0.000 claims description 2
- 208000001319 vasomotor rhinitis Diseases 0.000 claims description 2
- 208000020538 atrophic muscular disease Diseases 0.000 claims 2
- 230000029663 wound healing Effects 0.000 claims 2
- ZXOJWLAQYIYEHC-ZWNDMSQQSA-N C1(CC1)C1=CC=C2C=C(C=NC2=N1)C(=O)N[C@@H]1CC[C@H](CC1)NC(C(F)F)C Chemical compound C1(CC1)C1=CC=C2C=C(C=NC2=N1)C(=O)N[C@@H]1CC[C@H](CC1)NC(C(F)F)C ZXOJWLAQYIYEHC-ZWNDMSQQSA-N 0.000 claims 1
- SERIMSSARRQQMN-IJEWVQPXSA-N C1(CC1)C1=CC=C2C=C(C=NC2=N1)C(=O)N[C@@H]1C[C@@H](C1)N[C@@H](C(F)(F)F)CO Chemical compound C1(CC1)C1=CC=C2C=C(C=NC2=N1)C(=O)N[C@@H]1C[C@@H](C1)N[C@@H](C(F)(F)F)CO SERIMSSARRQQMN-IJEWVQPXSA-N 0.000 claims 1
- NWACIBVYYUDVDY-SHTZXODSSA-N C1(CC1)C1=CC=C2C=C(C=NC2=N1)C(=O)N[C@@H]1C[C@H](C1)C(C)(C)O Chemical compound C1(CC1)C1=CC=C2C=C(C=NC2=N1)C(=O)N[C@@H]1C[C@H](C1)C(C)(C)O NWACIBVYYUDVDY-SHTZXODSSA-N 0.000 claims 1
- YVZPWORJUVHQCS-JKIFEVAISA-N C1(CC1)C1=NC=C2C=C(C=NC2=C1)C(=O)N[C@@H]1C[C@@H](C1)N[C@@H](C(F)(F)F)CO Chemical compound C1(CC1)C1=NC=C2C=C(C=NC2=C1)C(=O)N[C@@H]1C[C@@H](C1)N[C@@H](C(F)(F)F)CO YVZPWORJUVHQCS-JKIFEVAISA-N 0.000 claims 1
- CPDHWRWFBRUHPX-GWCFXTLKSA-N C[C@@H]1N(CC1)C1=NC=C2C=C(C=NC2=C1)C(=O)N[C@@H]1C(NCC1)=O Chemical compound C[C@@H]1N(CC1)C1=NC=C2C=C(C=NC2=C1)C(=O)N[C@@H]1C(NCC1)=O CPDHWRWFBRUHPX-GWCFXTLKSA-N 0.000 claims 1
- QSQHSIMHBOHOJE-LBPRGKRZSA-N ClC=1C=C2C=C(C=NC2=NC=1C1CC1)C(=O)N[C@@H]1C(NCC1)=O Chemical compound ClC=1C=C2C=C(C=NC2=NC=1C1CC1)C(=O)N[C@@H]1C(NCC1)=O QSQHSIMHBOHOJE-LBPRGKRZSA-N 0.000 claims 1
- VCXOFSDLWOGOQQ-CQDKDKBSSA-N ClC=1C=C2C=C(C=NC2=NC=1N1[C@H](CC1)C)C(=O)N[C@@H]1C[C@H](C1)C(C)(C)O Chemical compound ClC=1C=C2C=C(C=NC2=NC=1N1[C@H](CC1)C)C(=O)N[C@@H]1C[C@H](C1)C(C)(C)O VCXOFSDLWOGOQQ-CQDKDKBSSA-N 0.000 claims 1
- 208000021642 Muscular disease Diseases 0.000 claims 1
- 201000009623 Myopathy Diseases 0.000 claims 1
- OZJANJJJUOPTTL-LBPRGKRZSA-N N1(CCC1)C1=NC=C2C=C(C=NC2=C1)C(=O)N[C@@H]1C(NCC1)=O Chemical compound N1(CCC1)C1=NC=C2C=C(C=NC2=C1)C(=O)N[C@@H]1C(NCC1)=O OZJANJJJUOPTTL-LBPRGKRZSA-N 0.000 claims 1
- ROWLOFVLOJIUBH-ZTFGCOKTSA-N OC(C)(C)[C@@H]1CC[C@H](CC1)NC(=O)C=1C=NC2=NC(=CC=C2C=1)N1[C@@H](CC1)C Chemical compound OC(C)(C)[C@@H]1CC[C@H](CC1)NC(=O)C=1C=NC2=NC(=CC=C2C=1)N1[C@@H](CC1)C ROWLOFVLOJIUBH-ZTFGCOKTSA-N 0.000 claims 1
- WOULUCUQPGBWEN-SHTZXODSSA-N OC(C)(C)[C@@H]1CC[C@H](CC1)NC(=O)C=1C=NC2=NC(=CC=C2C=1)NCC(F)(F)F Chemical compound OC(C)(C)[C@@H]1CC[C@H](CC1)NC(=O)C=1C=NC2=NC(=CC=C2C=1)NCC(F)(F)F WOULUCUQPGBWEN-SHTZXODSSA-N 0.000 claims 1
- ONLMMDDSVHGMJE-SHTZXODSSA-N OC(C)(C)[C@@H]1CC[C@H](CC1)NC(=O)C=1C=NC2=NC=CC=C2C=1 Chemical compound OC(C)(C)[C@@H]1CC[C@H](CC1)NC(=O)C=1C=NC2=NC=CC=C2C=1 ONLMMDDSVHGMJE-SHTZXODSSA-N 0.000 claims 1
- 230000000172 allergic effect Effects 0.000 claims 1
- 208000010668 atopic eczema Diseases 0.000 claims 1
- 208000032839 leukemia Diseases 0.000 claims 1
- 230000002232 neuromuscular Effects 0.000 claims 1
- 208000018360 neuromuscular disease Diseases 0.000 claims 1
- HKSQZEGSMBFHGC-UHFFFAOYSA-N pyrimidine-4-carboxamide Chemical compound NC(=O)C1=CC=NC=N1 HKSQZEGSMBFHGC-UHFFFAOYSA-N 0.000 claims 1
- 230000002401 inhibitory effect Effects 0.000 abstract description 23
- 230000000694 effects Effects 0.000 abstract description 10
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 238
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 227
- 239000011541 reaction mixture Substances 0.000 description 212
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 202
- VLKZOEOYAKHREP-UHFFFAOYSA-N n-Hexane Chemical compound CCCCCC VLKZOEOYAKHREP-UHFFFAOYSA-N 0.000 description 144
- 238000005481 NMR spectroscopy Methods 0.000 description 132
- 238000004895 liquid chromatography mass spectrometry Methods 0.000 description 119
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 105
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 97
- 239000007787 solid Substances 0.000 description 96
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 92
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 84
- CSNNHWWHGAXBCP-UHFFFAOYSA-L Magnesium sulfate Chemical compound [Mg+2].[O-][S+2]([O-])([O-])[O-] CSNNHWWHGAXBCP-UHFFFAOYSA-L 0.000 description 80
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 80
- 235000019439 ethyl acetate Nutrition 0.000 description 79
- 239000000243 solution Substances 0.000 description 76
- WYURNTSHIVDZCO-UHFFFAOYSA-N Tetrahydrofuran Chemical compound C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 description 73
- 239000000203 mixture Substances 0.000 description 67
- 238000006243 chemical reaction Methods 0.000 description 59
- 238000010898 silica gel chromatography Methods 0.000 description 59
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 44
- WMFOQBRAJBCJND-UHFFFAOYSA-M Lithium hydroxide Chemical compound [Li+].[OH-] WMFOQBRAJBCJND-UHFFFAOYSA-M 0.000 description 43
- 229910052943 magnesium sulfate Inorganic materials 0.000 description 40
- 235000019341 magnesium sulphate Nutrition 0.000 description 40
- JGFZNNIVVJXRND-UHFFFAOYSA-N N,N-Diisopropylethylamine (DIPEA) Chemical compound CCN(C(C)C)C(C)C JGFZNNIVVJXRND-UHFFFAOYSA-N 0.000 description 38
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 36
- YLQBMQCUIZJEEH-UHFFFAOYSA-N tetrahydrofuran Natural products C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 description 36
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 33
- ZMANZCXQSJIPKH-UHFFFAOYSA-N Triethylamine Chemical compound CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 description 33
- KDLHZDBZIXYQEI-UHFFFAOYSA-N palladium Substances [Pd] KDLHZDBZIXYQEI-UHFFFAOYSA-N 0.000 description 33
- 230000002829 reductive effect Effects 0.000 description 29
- VHUUQVKOLVNVRT-UHFFFAOYSA-N Ammonium hydroxide Chemical compound [NH4+].[OH-] VHUUQVKOLVNVRT-UHFFFAOYSA-N 0.000 description 24
- SECXISVLQFMRJM-UHFFFAOYSA-N N-Methylpyrrolidone Chemical compound CN1CCCC1=O SECXISVLQFMRJM-UHFFFAOYSA-N 0.000 description 24
- YXFVVABEGXRONW-UHFFFAOYSA-N Toluene Chemical compound CC1=CC=CC=C1 YXFVVABEGXRONW-UHFFFAOYSA-N 0.000 description 24
- 239000000908 ammonium hydroxide Substances 0.000 description 24
- 239000000706 filtrate Substances 0.000 description 22
- UIIMBOGNXHQVGW-DEQYMQKBSA-M Sodium bicarbonate-14C Chemical class [Na+].O[14C]([O-])=O UIIMBOGNXHQVGW-DEQYMQKBSA-M 0.000 description 21
- 239000000463 material Substances 0.000 description 20
- 238000003756 stirring Methods 0.000 description 19
- 239000002904 solvent Substances 0.000 description 18
- 238000010494 dissociation reaction Methods 0.000 description 17
- 230000005593 dissociations Effects 0.000 description 17
- 238000004007 reversed phase HPLC Methods 0.000 description 17
- JUJWROOIHBZHMG-UHFFFAOYSA-N Pyridine Chemical compound C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 description 16
- 239000012267 brine Substances 0.000 description 16
- XCHCVEIPPQFWIF-UHFFFAOYSA-N ethyl 7-chloro-1,8-naphthyridine-3-carboxylate Chemical compound CCOC(=O)c1cnc2nc(Cl)ccc2c1 XCHCVEIPPQFWIF-UHFFFAOYSA-N 0.000 description 16
- 239000010410 layer Substances 0.000 description 16
- HPALAKNZSZLMCH-UHFFFAOYSA-M sodium;chloride;hydrate Chemical compound O.[Na+].[Cl-] HPALAKNZSZLMCH-UHFFFAOYSA-M 0.000 description 16
- UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical compound [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 15
- 239000012535 impurity Substances 0.000 description 15
- 239000012044 organic layer Substances 0.000 description 15
- NXQGGXCHGDYOHB-UHFFFAOYSA-L cyclopenta-1,4-dien-1-yl(diphenyl)phosphane;dichloropalladium;iron(2+) Chemical compound [Fe+2].Cl[Pd]Cl.[CH-]1C=CC(P(C=2C=CC=CC=2)C=2C=CC=CC=2)=C1.[CH-]1C=CC(P(C=2C=CC=CC=2)C=2C=CC=CC=2)=C1 NXQGGXCHGDYOHB-UHFFFAOYSA-L 0.000 description 14
- 239000007788 liquid Substances 0.000 description 14
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Natural products CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 13
- ZMXDDKWLCZADIW-UHFFFAOYSA-N N,N-Dimethylformamide Chemical compound CN(C)C=O ZMXDDKWLCZADIW-UHFFFAOYSA-N 0.000 description 13
- 150000002148 esters Chemical class 0.000 description 13
- 229910052763 palladium Inorganic materials 0.000 description 13
- PUJDIJCNWFYVJX-UHFFFAOYSA-N benzyl carbamate Chemical compound NC(=O)OCC1=CC=CC=C1 PUJDIJCNWFYVJX-UHFFFAOYSA-N 0.000 description 12
- PMZURENOXWZQFD-UHFFFAOYSA-L Sodium Sulfate Chemical compound [Na+].[Na+].[O-]S([O-])(=O)=O PMZURENOXWZQFD-UHFFFAOYSA-L 0.000 description 11
- 229960000583 acetic acid Drugs 0.000 description 11
- 239000000843 powder Substances 0.000 description 11
- 239000002244 precipitate Substances 0.000 description 11
- 229920006395 saturated elastomer Polymers 0.000 description 11
- NUJOXMJBOLGQSY-UHFFFAOYSA-N manganese dioxide Chemical compound O=[Mn]=O NUJOXMJBOLGQSY-UHFFFAOYSA-N 0.000 description 10
- 239000012074 organic phase Substances 0.000 description 10
- DCKVNWZUADLDEH-UHFFFAOYSA-N sec-butyl acetate Chemical compound CCC(C)OC(C)=O DCKVNWZUADLDEH-UHFFFAOYSA-N 0.000 description 10
- 229910052938 sodium sulfate Inorganic materials 0.000 description 10
- 235000011152 sodium sulphate Nutrition 0.000 description 10
- 239000007858 starting material Substances 0.000 description 10
- UHOVQNZJYSORNB-UHFFFAOYSA-N Benzene Chemical compound C1=CC=CC=C1 UHOVQNZJYSORNB-UHFFFAOYSA-N 0.000 description 9
- VEXZGXHMUGYJMC-UHFFFAOYSA-M Chloride anion Chemical compound [Cl-] VEXZGXHMUGYJMC-UHFFFAOYSA-M 0.000 description 9
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 9
- 239000003921 oil Substances 0.000 description 9
- 235000019198 oils Nutrition 0.000 description 9
- 238000003828 vacuum filtration Methods 0.000 description 9
- DCIVAIUENFWRSZ-UHFFFAOYSA-N C1(CC1)C1=CC=C2C=C(C=NC2=N1)C(=O)OCC Chemical compound C1(CC1)C1=CC=C2C=C(C=NC2=N1)C(=O)OCC DCIVAIUENFWRSZ-UHFFFAOYSA-N 0.000 description 8
- BZLVMXJERCGZMT-UHFFFAOYSA-N Methyl tert-butyl ether Chemical compound COC(C)(C)C BZLVMXJERCGZMT-UHFFFAOYSA-N 0.000 description 8
- OFBQJSOFQDEBGM-UHFFFAOYSA-N Pentane Chemical compound CCCCC OFBQJSOFQDEBGM-UHFFFAOYSA-N 0.000 description 8
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 8
- 150000001335 aliphatic alkanes Chemical class 0.000 description 8
- PNEYBMLMFCGWSK-UHFFFAOYSA-N aluminium oxide Inorganic materials [O-2].[O-2].[O-2].[Al+3].[Al+3] PNEYBMLMFCGWSK-UHFFFAOYSA-N 0.000 description 8
- 125000004429 atom Chemical group 0.000 description 8
- 210000004027 cell Anatomy 0.000 description 8
- 238000004440 column chromatography Methods 0.000 description 8
- 230000007935 neutral effect Effects 0.000 description 8
- UMJSCPRVCHMLSP-UHFFFAOYSA-N pyridine Natural products COC1=CC=CN=C1 UMJSCPRVCHMLSP-UHFFFAOYSA-N 0.000 description 8
- WSLDOOZREJYCGB-UHFFFAOYSA-N 1,2-Dichloroethane Chemical compound ClCCCl WSLDOOZREJYCGB-UHFFFAOYSA-N 0.000 description 7
- IDPURXSQCKYKIJ-UHFFFAOYSA-N 1-(4-methoxyphenyl)methanamine Chemical group COC1=CC=C(CN)C=C1 IDPURXSQCKYKIJ-UHFFFAOYSA-N 0.000 description 7
- UGFAIRIUMAVXCW-UHFFFAOYSA-N Carbon monoxide Chemical compound [O+]#[C-] UGFAIRIUMAVXCW-UHFFFAOYSA-N 0.000 description 7
- KFHUEMDRSHWQNB-UHFFFAOYSA-N ClC1=NC=C2C=C(C=NC2=C1)C(=O)OCC Chemical compound ClC1=NC=C2C=C(C=NC2=C1)C(=O)OCC KFHUEMDRSHWQNB-UHFFFAOYSA-N 0.000 description 7
- 125000004432 carbon atom Chemical group C* 0.000 description 7
- 229910002091 carbon monoxide Inorganic materials 0.000 description 7
- 238000001816 cooling Methods 0.000 description 7
- 238000000605 extraction Methods 0.000 description 7
- 238000001914 filtration Methods 0.000 description 7
- 210000003630 histaminocyte Anatomy 0.000 description 7
- 239000012299 nitrogen atmosphere Substances 0.000 description 7
- 239000003208 petroleum Substances 0.000 description 7
- BHMBVRSPMRCCGG-OUTUXVNYSA-N prostaglandin D2 Chemical compound CCCCC[C@H](O)\C=C\[C@@H]1[C@@H](C\C=C/CCCC(O)=O)[C@@H](O)CC1=O BHMBVRSPMRCCGG-OUTUXVNYSA-N 0.000 description 7
- 125000006239 protecting group Chemical group 0.000 description 7
- 239000000126 substance Substances 0.000 description 7
- WXTMDXOMEHJXQO-UHFFFAOYSA-N 2,5-dihydroxybenzoic acid Chemical compound OC(=O)C1=CC(O)=CC=C1O WXTMDXOMEHJXQO-UHFFFAOYSA-N 0.000 description 6
- IOLHHGBKOCKPCY-UHFFFAOYSA-N 2-amino-6-chloropyridine-3-carbaldehyde Chemical compound NC1=NC(Cl)=CC=C1C=O IOLHHGBKOCKPCY-UHFFFAOYSA-N 0.000 description 6
- XKRFYHLGVUSROY-UHFFFAOYSA-N Argon Chemical compound [Ar] XKRFYHLGVUSROY-UHFFFAOYSA-N 0.000 description 6
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 6
- KWYUFKZDYYNOTN-UHFFFAOYSA-M Potassium hydroxide Chemical compound [OH-].[K+] KWYUFKZDYYNOTN-UHFFFAOYSA-M 0.000 description 6
- WQDUMFSSJAZKTM-UHFFFAOYSA-N Sodium methoxide Chemical compound [Na+].[O-]C WQDUMFSSJAZKTM-UHFFFAOYSA-N 0.000 description 6
- XJHCXCQVJFPJIK-UHFFFAOYSA-M caesium fluoride Chemical compound [F-].[Cs+] XJHCXCQVJFPJIK-UHFFFAOYSA-M 0.000 description 6
- 229910052799 carbon Inorganic materials 0.000 description 6
- 239000003795 chemical substances by application Substances 0.000 description 6
- 239000000470 constituent Substances 0.000 description 6
- 239000012280 lithium aluminium hydride Substances 0.000 description 6
- 230000003387 muscular Effects 0.000 description 6
- 239000000047 product Substances 0.000 description 6
- 238000010992 reflux Methods 0.000 description 6
- 238000007363 ring formation reaction Methods 0.000 description 6
- 208000024891 symptom Diseases 0.000 description 6
- FLBAYUMRQUHISI-UHFFFAOYSA-N 1,8-naphthyridine Chemical compound N1=CC=CC2=CC=CN=C21 FLBAYUMRQUHISI-UHFFFAOYSA-N 0.000 description 5
- NLXLAEXVIDQMFP-UHFFFAOYSA-N Ammonia chloride Chemical compound [NH4+].[Cl-] NLXLAEXVIDQMFP-UHFFFAOYSA-N 0.000 description 5
- MQPIMBXVEDXKEI-UHFFFAOYSA-N CSC=1N=CC2=C(N=1)N=CC(=C2)C(=O)OCC Chemical compound CSC=1N=CC2=C(N=1)N=CC(=C2)C(=O)OCC MQPIMBXVEDXKEI-UHFFFAOYSA-N 0.000 description 5
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 5
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 5
- 241000124008 Mammalia Species 0.000 description 5
- 208000021945 Tendon injury Diseases 0.000 description 5
- DTQVDTLACAAQTR-UHFFFAOYSA-N Trifluoroacetic acid Chemical compound OC(=O)C(F)(F)F DTQVDTLACAAQTR-UHFFFAOYSA-N 0.000 description 5
- 239000002253 acid Substances 0.000 description 5
- 150000001299 aldehydes Chemical class 0.000 description 5
- 125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 description 5
- 230000015572 biosynthetic process Effects 0.000 description 5
- 230000008859 change Effects 0.000 description 5
- USJRLGNYCQWLPF-UHFFFAOYSA-N chlorophosphane Chemical compound ClP USJRLGNYCQWLPF-UHFFFAOYSA-N 0.000 description 5
- UYWQUFXKFGHYNT-UHFFFAOYSA-N phenylmethyl ester of formic acid Natural products O=COCC1=CC=CC=C1 UYWQUFXKFGHYNT-UHFFFAOYSA-N 0.000 description 5
- 150000003180 prostaglandins Chemical class 0.000 description 5
- 239000011734 sodium Substances 0.000 description 5
- 229910052708 sodium Inorganic materials 0.000 description 5
- FJGSHZIXUIHUFP-UHFFFAOYSA-N (2-amino-6-chloropyridin-3-yl)methanol Chemical compound NC1=NC(Cl)=CC=C1CO FJGSHZIXUIHUFP-UHFFFAOYSA-N 0.000 description 4
- LTMRRSWNXVJMBA-UHFFFAOYSA-L 2,2-diethylpropanedioate Chemical compound CCC(CC)(C([O-])=O)C([O-])=O LTMRRSWNXVJMBA-UHFFFAOYSA-L 0.000 description 4
- HZNVUJQVZSTENZ-UHFFFAOYSA-N 2,3-dichloro-5,6-dicyano-1,4-benzoquinone Chemical compound ClC1=C(Cl)C(=O)C(C#N)=C(C#N)C1=O HZNVUJQVZSTENZ-UHFFFAOYSA-N 0.000 description 4
- HZAXFHJVJLSVMW-UHFFFAOYSA-N 2-Aminoethan-1-ol Chemical compound NCCO HZAXFHJVJLSVMW-UHFFFAOYSA-N 0.000 description 4
- ICSNLGPSRYBMBD-UHFFFAOYSA-N 2-aminopyridine Chemical compound NC1=CC=CC=N1 ICSNLGPSRYBMBD-UHFFFAOYSA-N 0.000 description 4
- NHQDETIJWKXCTC-UHFFFAOYSA-N 3-chloroperbenzoic acid Chemical compound OOC(=O)C1=CC=CC(Cl)=C1 NHQDETIJWKXCTC-UHFFFAOYSA-N 0.000 description 4
- VHYFNPMBLIVWCW-UHFFFAOYSA-N 4-Dimethylaminopyridine Chemical compound CN(C)C1=CC=NC=C1 VHYFNPMBLIVWCW-UHFFFAOYSA-N 0.000 description 4
- FGONQMFYFJRAIG-UHFFFAOYSA-N 4-amino-2-methylsulfanylpyrimidine-5-carbaldehyde Chemical compound CSC1=NC=C(C=O)C(N)=N1 FGONQMFYFJRAIG-UHFFFAOYSA-N 0.000 description 4
- MUDSDYNRBDKLGK-UHFFFAOYSA-N 4-methylquinoline Chemical compound C1=CC=C2C(C)=CC=NC2=C1 MUDSDYNRBDKLGK-UHFFFAOYSA-N 0.000 description 4
- PEDHUXRIIJIMDP-UHFFFAOYSA-N 6-bromo-1,8-naphthyridin-2-amine Chemical compound C1=C(Br)C=NC2=NC(N)=CC=C21 PEDHUXRIIJIMDP-UHFFFAOYSA-N 0.000 description 4
- QGZKDVFQNNGYKY-UHFFFAOYSA-N Ammonia Chemical group N QGZKDVFQNNGYKY-UHFFFAOYSA-N 0.000 description 4
- PAYRUJLWNCNPSJ-UHFFFAOYSA-N Aniline Chemical compound NC1=CC=CC=C1 PAYRUJLWNCNPSJ-UHFFFAOYSA-N 0.000 description 4
- 206010003694 Atrophy Diseases 0.000 description 4
- NJGFUCYEBBTDEW-UHFFFAOYSA-N C1(CCC1)C1=CC=C2C=C(C=NC2=N1)C(=O)O Chemical compound C1(CCC1)C1=CC=C2C=C(C=NC2=N1)C(=O)O NJGFUCYEBBTDEW-UHFFFAOYSA-N 0.000 description 4
- QMMFVYPAHWMCMS-UHFFFAOYSA-N Dimethyl sulfide Chemical compound CSC QMMFVYPAHWMCMS-UHFFFAOYSA-N 0.000 description 4
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 4
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 4
- OONRWDBKYVIGJA-UHFFFAOYSA-N FC1CN(C1)C1=NC=C2C=C(C=NC2=C1)C(=O)OCC Chemical compound FC1CN(C1)C1=NC=C2C=C(C=NC2=C1)C(=O)OCC OONRWDBKYVIGJA-UHFFFAOYSA-N 0.000 description 4
- XEEYBQQBJWHFJM-UHFFFAOYSA-N Iron Chemical compound [Fe] XEEYBQQBJWHFJM-UHFFFAOYSA-N 0.000 description 4
- PCLIMKBDDGJMGD-UHFFFAOYSA-N N-bromosuccinimide Chemical compound BrN1C(=O)CCC1=O PCLIMKBDDGJMGD-UHFFFAOYSA-N 0.000 description 4
- LOUPRKONTZGTKE-WZBLMQSHSA-N Quinine Chemical compound C([C@H]([C@H](C1)C=C)C2)C[N@@]1[C@@H]2[C@H](O)C1=CC=NC2=CC=C(OC)C=C21 LOUPRKONTZGTKE-WZBLMQSHSA-N 0.000 description 4
- CDBYLPFSWZWCQE-UHFFFAOYSA-L Sodium Carbonate Chemical compound [Na+].[Na+].[O-]C([O-])=O CDBYLPFSWZWCQE-UHFFFAOYSA-L 0.000 description 4
- 239000013543 active substance Substances 0.000 description 4
- 239000007864 aqueous solution Substances 0.000 description 4
- 238000005899 aromatization reaction Methods 0.000 description 4
- 230000037444 atrophy Effects 0.000 description 4
- HGQULGDOROIPJN-UHFFFAOYSA-N azetidin-1-ium;chloride Chemical compound Cl.C1CNC1 HGQULGDOROIPJN-UHFFFAOYSA-N 0.000 description 4
- IADUEWIQBXOCDZ-UHFFFAOYSA-N azetidine-2-carboxylic acid Chemical compound OC(=O)C1CCN1 IADUEWIQBXOCDZ-UHFFFAOYSA-N 0.000 description 4
- 230000006315 carbonylation Effects 0.000 description 4
- 238000005810 carbonylation reaction Methods 0.000 description 4
- 239000003153 chemical reaction reagent Substances 0.000 description 4
- 239000012043 crude product Substances 0.000 description 4
- 239000013078 crystal Substances 0.000 description 4
- PAFZNILMFXTMIY-UHFFFAOYSA-N cyclohexylamine Chemical compound NC1CCCCC1 PAFZNILMFXTMIY-UHFFFAOYSA-N 0.000 description 4
- 125000004494 ethyl ester group Chemical group 0.000 description 4
- FKRCODPIKNYEAC-UHFFFAOYSA-N ethyl propionate Chemical compound CCOC(=O)CC FKRCODPIKNYEAC-UHFFFAOYSA-N 0.000 description 4
- 239000012065 filter cake Substances 0.000 description 4
- RWSXRVCMGQZWBV-WDSKDSINSA-N glutathione Chemical compound OC(=O)[C@@H](N)CCC(=O)N[C@@H](CS)C(=O)NCC(O)=O RWSXRVCMGQZWBV-WDSKDSINSA-N 0.000 description 4
- 230000003394 haemopoietic effect Effects 0.000 description 4
- 125000000623 heterocyclic group Chemical group 0.000 description 4
- 238000004128 high performance liquid chromatography Methods 0.000 description 4
- 125000004435 hydrogen atom Chemical group [H]* 0.000 description 4
- 239000007924 injection Substances 0.000 description 4
- 238000002347 injection Methods 0.000 description 4
- 230000003274 myotonic effect Effects 0.000 description 4
- 210000000056 organ Anatomy 0.000 description 4
- 238000002360 preparation method Methods 0.000 description 4
- 238000010926 purge Methods 0.000 description 4
- 239000000741 silica gel Substances 0.000 description 4
- 229910002027 silica gel Inorganic materials 0.000 description 4
- 229910000030 sodium bicarbonate Inorganic materials 0.000 description 4
- 235000017557 sodium bicarbonate Nutrition 0.000 description 4
- LPXPTNMVRIOKMN-UHFFFAOYSA-M sodium nitrite Chemical compound [Na+].[O-]N=O LPXPTNMVRIOKMN-UHFFFAOYSA-M 0.000 description 4
- 239000000725 suspension Substances 0.000 description 4
- 238000003786 synthesis reaction Methods 0.000 description 4
- RIOQSEWOXXDEQQ-UHFFFAOYSA-N triphenylphosphine Chemical compound C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1 RIOQSEWOXXDEQQ-UHFFFAOYSA-N 0.000 description 4
- ZUTWFTHTKYXPNI-BYPYZUCNSA-N (2S)-2-methylazetidine-1-carboxylic acid Chemical compound C[C@H]1CCN1C(O)=O ZUTWFTHTKYXPNI-BYPYZUCNSA-N 0.000 description 3
- DLBWPRNUXWYLRN-BYPYZUCNSA-N (2s)-2-methylazetidine Chemical compound C[C@H]1CCN1 DLBWPRNUXWYLRN-BYPYZUCNSA-N 0.000 description 3
- WYQBCZUEZOFZFT-WCCKRBBISA-N (2s)-2-methylazetidine;hydrochloride Chemical compound Cl.C[C@H]1CCN1 WYQBCZUEZOFZFT-WCCKRBBISA-N 0.000 description 3
- CDVAQEBLCVPBNY-SCSAIBSYSA-N (3s)-3-amino-4,4-dimethylpyrrolidin-2-one Chemical compound CC1(C)CNC(=O)[C@H]1N CDVAQEBLCVPBNY-SCSAIBSYSA-N 0.000 description 3
- CUPAQOABYPHYPF-SCSAIBSYSA-N (3s)-3-azido-4,4-dimethyloxolan-2-one Chemical compound CC1(C)COC(=O)[C@H]1N=[N+]=[N-] CUPAQOABYPHYPF-SCSAIBSYSA-N 0.000 description 3
- XLVOWGDFXAVSFE-UHFFFAOYSA-N (4-amino-2-methylsulfanylpyrimidin-5-yl)methanol Chemical compound CSC1=NC=C(CO)C(N)=N1 XLVOWGDFXAVSFE-UHFFFAOYSA-N 0.000 description 3
- AVYMOPIIGPZZEH-UHFFFAOYSA-N (4-amino-6-chloropyridin-3-yl)methanol Chemical compound NC1=CC(Cl)=NC=C1CO AVYMOPIIGPZZEH-UHFFFAOYSA-N 0.000 description 3
- MQYCGLABCWGGMM-UHFFFAOYSA-N 1-(4-aminopiperidin-1-yl)-2-hydroxy-2-methylpropan-1-one Chemical compound CC(C)(O)C(=O)N1CCC(N)CC1 MQYCGLABCWGGMM-UHFFFAOYSA-N 0.000 description 3
- OISVCGZHLKNMSJ-UHFFFAOYSA-N 2,6-dimethylpyridine Chemical compound CC1=CC=CC(C)=N1 OISVCGZHLKNMSJ-UHFFFAOYSA-N 0.000 description 3
- WDUUTULTPGJJCK-UHFFFAOYSA-N 2-(2-aminospiro[3.3]heptan-6-yl)propan-2-ol Chemical compound NC1CC2(CC(C2)C(C)(C)O)C1 WDUUTULTPGJJCK-UHFFFAOYSA-N 0.000 description 3
- YIHPWULVQBWRRH-UHFFFAOYSA-N 2-(3-aminocyclobutyl)propan-2-ol Chemical compound CC(C)(O)C1CC(N)C1 YIHPWULVQBWRRH-UHFFFAOYSA-N 0.000 description 3
- ICARTDODMCKJKK-UHFFFAOYSA-N 2-(3-azidocyclobutyl)propan-2-ol Chemical compound N(=[N+]=[N-])C1CC(C1)C(C)(C)O ICARTDODMCKJKK-UHFFFAOYSA-N 0.000 description 3
- KDOAJEVCIZYWDI-UHFFFAOYSA-N 2-amino-5-bromopyridine-3-carbaldehyde Chemical compound NC1=NC=C(Br)C=C1C=O KDOAJEVCIZYWDI-UHFFFAOYSA-N 0.000 description 3
- OJDAOPCNPLUPJK-UHFFFAOYSA-N 3-bromo-7-chloro-1,6-naphthyridine Chemical compound C1=C(Br)C=C2C=NC(Cl)=CC2=N1 OJDAOPCNPLUPJK-UHFFFAOYSA-N 0.000 description 3
- PXFUWRWCKSLCLS-UHFFFAOYSA-N 3-fluoroazetidine;hydron;chloride Chemical compound Cl.FC1CNC1 PXFUWRWCKSLCLS-UHFFFAOYSA-N 0.000 description 3
- NNKLICLIBKMDOY-UHFFFAOYSA-N 3-methylidenecyclobutane-1-carboxylic acid Chemical compound OC(=O)C1CC(=C)C1 NNKLICLIBKMDOY-UHFFFAOYSA-N 0.000 description 3
- CGMIFAMRODWNJB-UHFFFAOYSA-N 4-amino-6-chloropyridine-3-carbaldehyde Chemical compound NC1=CC(Cl)=NC=C1C=O CGMIFAMRODWNJB-UHFFFAOYSA-N 0.000 description 3
- PQRIQHTXIOCYLQ-UHFFFAOYSA-N 6-bromo-2-cyclopropyl-1,8-naphthyridine Chemical compound BrC=1C=C2C=CC(=NC2=NC=1)C1CC1 PQRIQHTXIOCYLQ-UHFFFAOYSA-N 0.000 description 3
- HBAQYPYDRFILMT-UHFFFAOYSA-N 8-[3-(1-cyclopropylpyrazol-4-yl)-1H-pyrazolo[4,3-d]pyrimidin-5-yl]-3-methyl-3,8-diazabicyclo[3.2.1]octan-2-one Chemical class C1(CC1)N1N=CC(=C1)C1=NNC2=C1N=C(N=C2)N1C2C(N(CC1CC2)C)=O HBAQYPYDRFILMT-UHFFFAOYSA-N 0.000 description 3
- WFDIJRYMOXRFFG-UHFFFAOYSA-N Acetic anhydride Chemical compound CC(=O)OC(C)=O WFDIJRYMOXRFFG-UHFFFAOYSA-N 0.000 description 3
- WVDDGKGOMKODPV-UHFFFAOYSA-N Benzyl alcohol Chemical compound OCC1=CC=CC=C1 WVDDGKGOMKODPV-UHFFFAOYSA-N 0.000 description 3
- BSAMPDHGTZOLRG-UHFFFAOYSA-N BrC=1C=C2C=C(C(=NC2=NC=1)N)Cl Chemical compound BrC=1C=C2C=C(C(=NC2=NC=1)N)Cl BSAMPDHGTZOLRG-UHFFFAOYSA-N 0.000 description 3
- MOXBYCYSOICRNL-UHFFFAOYSA-N C1(CC1)C1=NC=C2C=C(C=NC2=C1)C(=O)O Chemical compound C1(CC1)C1=NC=C2C=C(C=NC2=C1)C(=O)O MOXBYCYSOICRNL-UHFFFAOYSA-N 0.000 description 3
- XYIFTVXYNCUNRE-UHFFFAOYSA-N C1(CC1)C1=NC=C2C=C(C=NC2=C1)C(=O)OCC Chemical compound C1(CC1)C1=NC=C2C=C(C=NC2=C1)C(=O)OCC XYIFTVXYNCUNRE-UHFFFAOYSA-N 0.000 description 3
- SYQOOWNXZAACRS-UHFFFAOYSA-N C1(CC1)NC1=NC=C2C=C(C=NC2=C1)C(=O)OCC Chemical compound C1(CC1)NC1=NC=C2C=C(C=NC2=C1)C(=O)OCC SYQOOWNXZAACRS-UHFFFAOYSA-N 0.000 description 3
- RMCGQHMRBNHCTN-UHFFFAOYSA-N CC1N(CC1)C1=CC=C2C=C(C=NC2=N1)C(=O)OCC Chemical compound CC1N(CC1)C1=CC=C2C=C(C=NC2=N1)C(=O)OCC RMCGQHMRBNHCTN-UHFFFAOYSA-N 0.000 description 3
- NRNBDVCWOQUURL-UHFFFAOYSA-N CC1N(CC1)C1=NC=C2C=C(C=NC2=C1)C(=O)OCC Chemical compound CC1N(CC1)C1=NC=C2C=C(C=NC2=C1)C(=O)OCC NRNBDVCWOQUURL-UHFFFAOYSA-N 0.000 description 3
- XHGDUUKTZMROSX-UHFFFAOYSA-N CN(C1=NC=C2C=C(C=NC2=C1)C(=O)OCC)C Chemical compound CN(C1=NC=C2C=C(C=NC2=C1)C(=O)OCC)C XHGDUUKTZMROSX-UHFFFAOYSA-N 0.000 description 3
- NVNARDIRFUEWJG-UHFFFAOYSA-N CS(=O)(=O)C=1N=CC2=C(N=1)N=CC(=C2)C(=O)OCC Chemical compound CS(=O)(=O)C=1N=CC2=C(N=1)N=CC(=C2)C(=O)OCC NVNARDIRFUEWJG-UHFFFAOYSA-N 0.000 description 3
- FGACWEVQABQVBZ-UHFFFAOYSA-N CSC=1N=CC2=C(N=1)N=CC(=C2)C(=O)O Chemical compound CSC=1N=CC2=C(N=1)N=CC(=C2)C(=O)O FGACWEVQABQVBZ-UHFFFAOYSA-N 0.000 description 3
- CURLTUGMZLYLDI-UHFFFAOYSA-N Carbon dioxide Chemical compound O=C=O CURLTUGMZLYLDI-UHFFFAOYSA-N 0.000 description 3
- LQBMNDHGNZXOGR-UHFFFAOYSA-N ClC=1C=C2C=C(C=NC2=NC=1C1CC1)C(=O)OCC Chemical compound ClC=1C=C2C=C(C=NC2=NC=1C1CC1)C(=O)OCC LQBMNDHGNZXOGR-UHFFFAOYSA-N 0.000 description 3
- UWAMLPVERRGVLF-UHFFFAOYSA-N ClC=1C=C2C=C(C=NC2=NC=1O)C(=O)OCC Chemical compound ClC=1C=C2C=C(C=NC2=NC=1O)C(=O)OCC UWAMLPVERRGVLF-UHFFFAOYSA-N 0.000 description 3
- WBPPBGNCPYCGBW-UHFFFAOYSA-N ClC=1C=C2C=C(C=NC2=NC=1OC)C(=O)O Chemical compound ClC=1C=C2C=C(C=NC2=NC=1OC)C(=O)O WBPPBGNCPYCGBW-UHFFFAOYSA-N 0.000 description 3
- XTHFKEDIFFGKHM-UHFFFAOYSA-N Dimethoxyethane Chemical compound COCCOC XTHFKEDIFFGKHM-UHFFFAOYSA-N 0.000 description 3
- STJZLNKWIAKGRT-UHFFFAOYSA-N FC(CNC1=CC=C2C=C(C=NC2=N1)C(=O)OCC)F Chemical compound FC(CNC1=CC=C2C=C(C=NC2=N1)C(=O)OCC)F STJZLNKWIAKGRT-UHFFFAOYSA-N 0.000 description 3
- CCWOIJGBHZOTBZ-UHFFFAOYSA-N FC1CN(C1)C1=CC=C2C=C(C=NC2=N1)C(=O)OCC Chemical compound FC1CN(C1)C1=CC=C2C=C(C=NC2=N1)C(=O)OCC CCWOIJGBHZOTBZ-UHFFFAOYSA-N 0.000 description 3
- KRHYYFGTRYWZRS-UHFFFAOYSA-M Fluoride anion Chemical compound [F-] KRHYYFGTRYWZRS-UHFFFAOYSA-M 0.000 description 3
- 102000003960 Ligases Human genes 0.000 description 3
- 108090000364 Ligases Proteins 0.000 description 3
- AFVFQIVMOAPDHO-UHFFFAOYSA-N Methanesulfonic acid Chemical compound CS(O)(=O)=O AFVFQIVMOAPDHO-UHFFFAOYSA-N 0.000 description 3
- ZEQGRKYLIYUDKO-UHFFFAOYSA-N N.OC(=O)c1cnc2cc(ncc2c1)N1CC(F)C1 Chemical compound N.OC(=O)c1cnc2cc(ncc2c1)N1CC(F)C1 ZEQGRKYLIYUDKO-UHFFFAOYSA-N 0.000 description 3
- ZIWVYLZWAHCOOV-UHFFFAOYSA-N N1(CCC1)C1=C(C=C2C=C(C=NC2=N1)C(=O)OCC)Cl Chemical compound N1(CCC1)C1=C(C=C2C=C(C=NC2=N1)C(=O)OCC)Cl ZIWVYLZWAHCOOV-UHFFFAOYSA-N 0.000 description 3
- GPVUHWFQILWMHE-UHFFFAOYSA-N N1(CCC1)C1=CC=C2C=C(C=NC2=N1)C(=O)OCC Chemical compound N1(CCC1)C1=CC=C2C=C(C=NC2=N1)C(=O)OCC GPVUHWFQILWMHE-UHFFFAOYSA-N 0.000 description 3
- ZZQBYAOAAJBRQG-UHFFFAOYSA-N N1(CCC1)C1=NC=C2C=C(C=NC2=C1)C(=O)OCC Chemical compound N1(CCC1)C1=NC=C2C=C(C=NC2=C1)C(=O)OCC ZZQBYAOAAJBRQG-UHFFFAOYSA-N 0.000 description 3
- LAJDHQPQDMLJNF-UHFFFAOYSA-N N1(CCC1)C=1N=CC2=C(N=1)N=CC(=C2)C(=O)OCC Chemical compound N1(CCC1)C=1N=CC2=C(N=1)N=CC(=C2)C(=O)OCC LAJDHQPQDMLJNF-UHFFFAOYSA-N 0.000 description 3
- LRJRFOGUILAGFX-UHFFFAOYSA-N NC1=C(C=C2C=C(C=NC2=N1)C(=O)OCC)Cl Chemical compound NC1=C(C=C2C=C(C=NC2=N1)C(=O)OCC)Cl LRJRFOGUILAGFX-UHFFFAOYSA-N 0.000 description 3
- WAVSQEUZDOZEKT-UHFFFAOYSA-N NC1=CC=C2C=C(C=NC2=N1)C(=O)OCC Chemical compound NC1=CC=C2C=C(C=NC2=N1)C(=O)OCC WAVSQEUZDOZEKT-UHFFFAOYSA-N 0.000 description 3
- INOCYAMIKBRWQK-BWZBUEFSSA-N N[C@@H]1CC[C@H](CC1)N[C@H](CO)C(F)(F)F Chemical compound N[C@@H]1CC[C@H](CC1)N[C@H](CO)C(F)(F)F INOCYAMIKBRWQK-BWZBUEFSSA-N 0.000 description 3
- PVNIIMVLHYAWGP-UHFFFAOYSA-N Niacin Chemical compound OC(=O)C1=CC=CN=C1 PVNIIMVLHYAWGP-UHFFFAOYSA-N 0.000 description 3
- 102000048176 Prostaglandin-D synthases Human genes 0.000 description 3
- 108030003866 Prostaglandin-D synthases Proteins 0.000 description 3
- 238000006069 Suzuki reaction reaction Methods 0.000 description 3
- 238000002441 X-ray diffraction Methods 0.000 description 3
- HCHKCACWOHOZIP-UHFFFAOYSA-N Zinc Chemical compound [Zn] HCHKCACWOHOZIP-UHFFFAOYSA-N 0.000 description 3
- XMEVZEMJXYDCFH-BYPYZUCNSA-N [(3r)-4,4-dimethyl-2-oxooxolan-3-yl] trifluoromethanesulfonate Chemical compound CC1(C)COC(=O)[C@@H]1OS(=O)(=O)C(F)(F)F XMEVZEMJXYDCFH-BYPYZUCNSA-N 0.000 description 3
- 238000004458 analytical method Methods 0.000 description 3
- 229910052786 argon Inorganic materials 0.000 description 3
- HKVFISRIUUGTIB-UHFFFAOYSA-O azanium;cerium;nitrate Chemical compound [NH4+].[Ce].[O-][N+]([O-])=O HKVFISRIUUGTIB-UHFFFAOYSA-O 0.000 description 3
- 150000001539 azetidines Chemical group 0.000 description 3
- 125000004744 butyloxycarbonyl group Chemical group 0.000 description 3
- 239000003054 catalyst Substances 0.000 description 3
- 238000012512 characterization method Methods 0.000 description 3
- CSJLBAMHHLJAAS-UHFFFAOYSA-N diethylaminosulfur trifluoride Chemical compound CCN(CC)S(F)(F)F CSJLBAMHHLJAAS-UHFFFAOYSA-N 0.000 description 3
- ZUOUZKKEUPVFJK-UHFFFAOYSA-N diphenyl Chemical compound C1=CC=CC=C1C1=CC=CC=C1 ZUOUZKKEUPVFJK-UHFFFAOYSA-N 0.000 description 3
- 229940079593 drug Drugs 0.000 description 3
- 239000000839 emulsion Substances 0.000 description 3
- OAQIVHCEAFDMTK-UHFFFAOYSA-N ethyl 4-amino-6-chloropyridine-3-carboxylate Chemical compound CCOC(=O)C1=CN=C(Cl)C=C1N OAQIVHCEAFDMTK-UHFFFAOYSA-N 0.000 description 3
- HLDJVFVGCSIZJT-UHFFFAOYSA-N ethyl 6-chloro-4-[(4-methoxyphenyl)methylamino]pyridine-3-carboxylate Chemical compound CCOC(=O)C1=CN=C(Cl)C=C1NCC1=CC=C(OC)C=C1 HLDJVFVGCSIZJT-UHFFFAOYSA-N 0.000 description 3
- XDVPPYFFLIAQOD-UHFFFAOYSA-N ethyl 7-chloro-2-methylsulfanylpyrido[2,3-d]pyrimidine-6-carboxylate Chemical compound ClC=1C(=CC2=C(N=C(N=C2)SC)N=1)C(=O)OCC XDVPPYFFLIAQOD-UHFFFAOYSA-N 0.000 description 3
- 150000004677 hydrates Chemical class 0.000 description 3
- 239000005457 ice water Substances 0.000 description 3
- 230000001965 increasing effect Effects 0.000 description 3
- 150000002576 ketones Chemical class 0.000 description 3
- KQBFVOXBMCUNDE-UHFFFAOYSA-M lithium 7-(2,2-difluoroethylamino)-1,8-naphthyridine-3-carboxylate Chemical compound [Li+].FC(CNC1=CC=C2C=C(C=NC2=N1)C(=O)[O-])F KQBFVOXBMCUNDE-UHFFFAOYSA-M 0.000 description 3
- ISPYVDNETJDQER-UHFFFAOYSA-M lithium 7-(2-methylazetidin-1-yl)-1,6-naphthyridine-3-carboxylate Chemical compound [Li+].CC1N(CC1)C1=NC=C2C=C(C=NC2=C1)C(=O)[O-] ISPYVDNETJDQER-UHFFFAOYSA-M 0.000 description 3
- QJYIUFOOZGLEQX-UHFFFAOYSA-M lithium 7-(2-methylazetidin-1-yl)-1,8-naphthyridine-3-carboxylate Chemical compound [Li+].CC1N(CC1)C1=CC=C2C=C(C=NC2=N1)C(=O)[O-] QJYIUFOOZGLEQX-UHFFFAOYSA-M 0.000 description 3
- MIWSKVCJVMETNW-UHFFFAOYSA-M lithium 7-(3-fluoroazetidin-1-yl)-1,8-naphthyridine-3-carboxylate Chemical compound [Li+].FC1CN(C1)C1=CC=C2C=C(C=NC2=N1)C(=O)[O-] MIWSKVCJVMETNW-UHFFFAOYSA-M 0.000 description 3
- BUDMTJQITRSEBU-UHFFFAOYSA-M lithium 7-(azetidin-1-yl)-1,8-naphthyridine-3-carboxylate Chemical compound [Li+].N1(CCC1)C1=CC=C2C=C(C=NC2=N1)C(=O)[O-] BUDMTJQITRSEBU-UHFFFAOYSA-M 0.000 description 3
- FEEQSNIATCPPJU-UHFFFAOYSA-M lithium 7-(cyclopropylamino)-1,6-naphthyridine-3-carboxylate Chemical compound [Li+].C1(CC1)NC1=NC=C2C=C(C=NC2=C1)C(=O)[O-] FEEQSNIATCPPJU-UHFFFAOYSA-M 0.000 description 3
- 230000001404 mediated effect Effects 0.000 description 3
- NCVJWTXXDYXDCL-UHFFFAOYSA-N methyl 6-chloro-7-methoxy-1,8-naphthyridine-3-carboxylate Chemical compound ClC=1C=C2C=C(C=NC2=NC=1OC)C(=O)OC NCVJWTXXDYXDCL-UHFFFAOYSA-N 0.000 description 3
- 239000002808 molecular sieve Substances 0.000 description 3
- 230000004220 muscle function Effects 0.000 description 3
- 238000007911 parenteral administration Methods 0.000 description 3
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 description 3
- 150000003138 primary alcohols Chemical class 0.000 description 3
- 230000008569 process Effects 0.000 description 3
- 238000000746 purification Methods 0.000 description 3
- 102000005962 receptors Human genes 0.000 description 3
- 108020003175 receptors Proteins 0.000 description 3
- 239000002002 slurry Substances 0.000 description 3
- URGAHOPLAPQHLN-UHFFFAOYSA-N sodium aluminosilicate Chemical compound [Na+].[Al+3].[O-][Si]([O-])=O.[O-][Si]([O-])=O URGAHOPLAPQHLN-UHFFFAOYSA-N 0.000 description 3
- 239000012453 solvate Substances 0.000 description 3
- QAOWNCQODCNURD-UHFFFAOYSA-N sulfuric acid Substances OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 3
- 238000004808 supercritical fluid chromatography Methods 0.000 description 3
- 210000001519 tissue Anatomy 0.000 description 3
- JOXIMZWYDAKGHI-UHFFFAOYSA-N toluene-4-sulfonic acid Chemical compound CC1=CC=C(S(O)(=O)=O)C=C1 JOXIMZWYDAKGHI-UHFFFAOYSA-N 0.000 description 3
- STDVCZWWAATUKN-SCSAIBSYSA-N (2r)-2-(hydroxymethyl)azetidine-1-carboxylic acid Chemical compound OC[C@H]1CCN1C(O)=O STDVCZWWAATUKN-SCSAIBSYSA-N 0.000 description 2
- HIRRLLQTXSVEDV-HSHFZTNMSA-N (2r)-2-amino-3,3,3-trifluoropropan-1-ol;hydrochloride Chemical compound Cl.OC[C@@H](N)C(F)(F)F HIRRLLQTXSVEDV-HSHFZTNMSA-N 0.000 description 2
- FCZGCQDOFWAOCM-DMTCNVIQSA-N (3s,4r)-3-amino-4-methylpyrrolidin-2-one Chemical compound C[C@@H]1CNC(=O)[C@H]1N FCZGCQDOFWAOCM-DMTCNVIQSA-N 0.000 description 2
- VSOSXKMEQPYESP-UHFFFAOYSA-N 1,6-naphthyridine Chemical compound C1=CN=CC2=CC=CN=C21 VSOSXKMEQPYESP-UHFFFAOYSA-N 0.000 description 2
- FPIRBHDGWMWJEP-UHFFFAOYSA-N 1-hydroxy-7-azabenzotriazole Chemical compound C1=CN=C2N(O)N=NC2=C1 FPIRBHDGWMWJEP-UHFFFAOYSA-N 0.000 description 2
- VBICKXHEKHSIBG-UHFFFAOYSA-N 1-monostearoylglycerol Chemical compound CCCCCCCCCCCCCCCCCC(=O)OCC(O)CO VBICKXHEKHSIBG-UHFFFAOYSA-N 0.000 description 2
- RKMGAJGJIURJSJ-UHFFFAOYSA-N 2,2,6,6-tetramethylpiperidine Chemical compound CC1(C)CCCC(C)(C)N1 RKMGAJGJIURJSJ-UHFFFAOYSA-N 0.000 description 2
- OZAIFHULBGXAKX-UHFFFAOYSA-N 2-(2-cyanopropan-2-yldiazenyl)-2-methylpropanenitrile Chemical compound N#CC(C)(C)N=NC(C)(C)C#N OZAIFHULBGXAKX-UHFFFAOYSA-N 0.000 description 2
- ZGNHPCRHLPUTNF-XCLFUZPHSA-N 2-[(3S,4R)-1-(5-methoxyquinolin-8-yl)-4-methyl-2-oxopyrrolidin-3-yl]isoindole-1,3-dione Chemical compound COC1=C2C=CC=NC2=C(C=C1)N1C([C@H]([C@@H](C1)C)N1C(C2=CC=CC=C2C1=O)=O)=O ZGNHPCRHLPUTNF-XCLFUZPHSA-N 0.000 description 2
- INERBKPRIWEQRQ-UHFFFAOYSA-N 2-amino-6-chloropyridine-3-carboxylic acid Chemical compound NC1=NC(Cl)=CC=C1C(O)=O INERBKPRIWEQRQ-UHFFFAOYSA-N 0.000 description 2
- IZHVBANLECCAGF-UHFFFAOYSA-N 2-hydroxy-3-(octadecanoyloxy)propyl octadecanoate Chemical compound CCCCCCCCCCCCCCCCCC(=O)OCC(O)COC(=O)CCCCCCCCCCCCCCCCC IZHVBANLECCAGF-UHFFFAOYSA-N 0.000 description 2
- WYQBCZUEZOFZFT-UHFFFAOYSA-N 2-methylazetidine;hydrochloride Chemical compound Cl.CC1CCN1 WYQBCZUEZOFZFT-UHFFFAOYSA-N 0.000 description 2
- FZCQRWUMUILOMZ-UHFFFAOYSA-N 3-(2-hydroxypropan-2-yl)cyclobutan-1-ol Chemical compound OC(C)(C)C1CC(C1)O FZCQRWUMUILOMZ-UHFFFAOYSA-N 0.000 description 2
- SZQSVGZFSOUXPL-UHFFFAOYSA-N 3-amino-1-methylcyclobutan-1-ol;hydrochloride Chemical compound Cl.CC1(O)CC(N)C1 SZQSVGZFSOUXPL-UHFFFAOYSA-N 0.000 description 2
- ZRWMAMOBIQQJSA-UHFFFAOYSA-N 3-methylidenecyclobutane-1-carbonitrile Chemical compound C=C1CC(C#N)C1 ZRWMAMOBIQQJSA-UHFFFAOYSA-N 0.000 description 2
- YYROPELSRYBVMQ-UHFFFAOYSA-N 4-toluenesulfonyl chloride Chemical compound CC1=CC=C(S(Cl)(=O)=O)C=C1 YYROPELSRYBVMQ-UHFFFAOYSA-N 0.000 description 2
- FDRQPJFIYRJIAM-UHFFFAOYSA-N 6-chloro-7-cyclopropyl-1,8-naphthyridine-3-carboxylic acid Chemical compound ClC=1C=C2C=C(C=NC2=NC=1C1CC1)C(=O)O FDRQPJFIYRJIAM-UHFFFAOYSA-N 0.000 description 2
- JJTNLWSCFYERCK-UHFFFAOYSA-N 7h-pyrrolo[2,3-d]pyrimidine Chemical compound N1=CN=C2NC=CC2=C1 JJTNLWSCFYERCK-UHFFFAOYSA-N 0.000 description 2
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 2
- IADUEWIQBXOCDZ-VKHMYHEASA-N Azetidine-2-carboxylic acid Natural products OC(=O)[C@@H]1CCN1 IADUEWIQBXOCDZ-VKHMYHEASA-N 0.000 description 2
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 2
- JJXSXNGOUVZKGD-UHFFFAOYSA-N C1(=CC=CC=C1)C(C1=CC=CC=C1)NC1CC2(CC(C2)C(C)(C)O)C1 Chemical compound C1(=CC=CC=C1)C(C1=CC=CC=C1)NC1CC2(CC(C2)C(C)(C)O)C1 JJXSXNGOUVZKGD-UHFFFAOYSA-N 0.000 description 2
- QZOONBQMWAUZEG-UHFFFAOYSA-N C1(CC1)C1=CC=C2C=C(C=NC2=N1)C(=O)O Chemical compound C1(CC1)C1=CC=C2C=C(C=NC2=N1)C(=O)O QZOONBQMWAUZEG-UHFFFAOYSA-N 0.000 description 2
- CXSYDHSBSMFBLU-UHFFFAOYSA-N C1(CC1)OOB(OO)O Chemical compound C1(CC1)OOB(OO)O CXSYDHSBSMFBLU-UHFFFAOYSA-N 0.000 description 2
- WKVXIOVFRLNUAE-UHFFFAOYSA-N C1(CCC1)C1=CC=C2C=C(C=NC2=N1)C(=O)OCC Chemical compound C1(CCC1)C1=CC=C2C=C(C=NC2=N1)C(=O)OCC WKVXIOVFRLNUAE-UHFFFAOYSA-N 0.000 description 2
- UCLPTFQPYWKGFV-UHFFFAOYSA-N COC1=CC=C2C=C(C=NC2=N1)C(=O)O Chemical compound COC1=CC=C2C=C(C=NC2=N1)C(=O)O UCLPTFQPYWKGFV-UHFFFAOYSA-N 0.000 description 2
- LNWHZKWLVBSQDK-UHFFFAOYSA-N COC1=NC=C2C=C(C=NC2=C1)C(=O)O Chemical compound COC1=NC=C2C=C(C=NC2=C1)C(=O)O LNWHZKWLVBSQDK-UHFFFAOYSA-N 0.000 description 2
- XYVQIUTTYTUJQH-ZETCQYMHSA-N C[C@H]1CCN1c1nc2ncc(cc2cc1Cl)C(O)=O Chemical compound C[C@H]1CCN1c1nc2ncc(cc2cc1Cl)C(O)=O XYVQIUTTYTUJQH-ZETCQYMHSA-N 0.000 description 2
- KXDHJXZQYSOELW-UHFFFAOYSA-M Carbamate Chemical compound NC([O-])=O KXDHJXZQYSOELW-UHFFFAOYSA-M 0.000 description 2
- 235000001258 Cinchona calisaya Nutrition 0.000 description 2
- XUKNQIFHJYPDLT-UHFFFAOYSA-N ClC=1C=C2C=C(C=NC2=NC=1Cl)C(=O)OCC Chemical compound ClC=1C=C2C=C(C=NC2=NC=1Cl)C(=O)OCC XUKNQIFHJYPDLT-UHFFFAOYSA-N 0.000 description 2
- FEWJPZIEWOKRBE-JCYAYHJZSA-N Dextrotartaric acid Chemical compound OC(=O)[C@H](O)[C@@H](O)C(O)=O FEWJPZIEWOKRBE-JCYAYHJZSA-N 0.000 description 2
- QOSSAOTZNIDXMA-UHFFFAOYSA-N Dicylcohexylcarbodiimide Chemical compound C1CCCCC1N=C=NC1CCCCC1 QOSSAOTZNIDXMA-UHFFFAOYSA-N 0.000 description 2
- ROSDSFDQCJNGOL-UHFFFAOYSA-N Dimethylamine Chemical compound CNC ROSDSFDQCJNGOL-UHFFFAOYSA-N 0.000 description 2
- 102000004190 Enzymes Human genes 0.000 description 2
- 108090000790 Enzymes Proteins 0.000 description 2
- 108010037362 Extracellular Matrix Proteins Proteins 0.000 description 2
- 102000010834 Extracellular Matrix Proteins Human genes 0.000 description 2
- KZABDUWNGQIHKX-VTQGQFRNSA-N FC(C(C)N[C@@H]1CC[C@H](CC1)N)F Chemical compound FC(C(C)N[C@@H]1CC[C@H](CC1)N)F KZABDUWNGQIHKX-VTQGQFRNSA-N 0.000 description 2
- WTKBLEXYWCDJFM-UHFFFAOYSA-N FC(CNC1=CC=C2C=C(C=NC2=N1)C(=O)OCC)(F)F Chemical compound FC(CNC1=CC=C2C=C(C=NC2=N1)C(=O)OCC)(F)F WTKBLEXYWCDJFM-UHFFFAOYSA-N 0.000 description 2
- QIZWSBTVLYFXND-UHFFFAOYSA-N FC(COC1=CC=C2C=C(C=NC2=N1)C(=O)O)(F)F Chemical compound FC(COC1=CC=C2C=C(C=NC2=N1)C(=O)O)(F)F QIZWSBTVLYFXND-UHFFFAOYSA-N 0.000 description 2
- UNIFYQCEYIQKIT-KYZUINATSA-N FC1CN(C1)[C@@H]1CC[C@H](CC1)N Chemical compound FC1CN(C1)[C@@H]1CC[C@H](CC1)N UNIFYQCEYIQKIT-KYZUINATSA-N 0.000 description 2
- 108010024636 Glutathione Proteins 0.000 description 2
- OAKJQQAXSVQMHS-UHFFFAOYSA-N Hydrazine Chemical compound NN OAKJQQAXSVQMHS-UHFFFAOYSA-N 0.000 description 2
- MHAJPDPJQMAIIY-UHFFFAOYSA-N Hydrogen peroxide Chemical compound OO MHAJPDPJQMAIIY-UHFFFAOYSA-N 0.000 description 2
- SIKJAQJRHWYJAI-UHFFFAOYSA-N Indole Chemical compound C1=CC=C2NC=CC2=C1 SIKJAQJRHWYJAI-UHFFFAOYSA-N 0.000 description 2
- ONIBWKKTOPOVIA-BYPYZUCNSA-N L-Proline Chemical compound OC(=O)[C@@H]1CCCN1 ONIBWKKTOPOVIA-BYPYZUCNSA-N 0.000 description 2
- HNDVDQJCIGZPNO-YFKPBYRVSA-N L-histidine Chemical compound OC(=O)[C@@H](N)CC1=CN=CN1 HNDVDQJCIGZPNO-YFKPBYRVSA-N 0.000 description 2
- JVTAAEKCZFNVCJ-UHFFFAOYSA-M Lactate Chemical compound CC(O)C([O-])=O JVTAAEKCZFNVCJ-UHFFFAOYSA-M 0.000 description 2
- 239000012359 Methanesulfonyl chloride Substances 0.000 description 2
- WAEHMXXCPCMGRP-GFCCVEGCSA-N N(=[N+]=[N-])[C@@H]1C(N(CC1(C)C)CC1=CC=C(C=C1)OC)=O Chemical compound N(=[N+]=[N-])[C@@H]1C(N(CC1(C)C)CC1=CC=C(C=C1)OC)=O WAEHMXXCPCMGRP-GFCCVEGCSA-N 0.000 description 2
- MXANCUPRVRBBHI-SCSAIBSYSA-N N(=[N+]=[N-])[C@@H]1C(NCC1(C)C)=O Chemical compound N(=[N+]=[N-])[C@@H]1C(NCC1(C)C)=O MXANCUPRVRBBHI-SCSAIBSYSA-N 0.000 description 2
- MBBZMMPHUWSWHV-BDVNFPICSA-N N-methylglucamine Chemical compound CNC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO MBBZMMPHUWSWHV-BDVNFPICSA-N 0.000 description 2
- GZYYGLVMEUNVGO-JMMWHDCWSA-N NC1CC(C1)N[C@H](CO)C(F)(F)F Chemical compound NC1CC(C1)N[C@H](CO)C(F)(F)F GZYYGLVMEUNVGO-JMMWHDCWSA-N 0.000 description 2
- 206010028980 Neoplasm Diseases 0.000 description 2
- BMKIXPHJWKMOPO-UHFFFAOYSA-N O1CC11CC(C1)NC(OCC1=CC=CC=C1)=O Chemical compound O1CC11CC(C1)NC(OCC1=CC=CC=C1)=O BMKIXPHJWKMOPO-UHFFFAOYSA-N 0.000 description 2
- NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 description 2
- GLUUGHFHXGJENI-UHFFFAOYSA-N Piperazine Chemical compound C1CNCCN1 GLUUGHFHXGJENI-UHFFFAOYSA-N 0.000 description 2
- NQRYJNQNLNOLGT-UHFFFAOYSA-N Piperidine Chemical compound C1CCNCC1 NQRYJNQNLNOLGT-UHFFFAOYSA-N 0.000 description 2
- XBDQKXXYIPTUBI-UHFFFAOYSA-M Propionate Chemical compound CCC([O-])=O XBDQKXXYIPTUBI-UHFFFAOYSA-M 0.000 description 2
- 108050000258 Prostaglandin D receptors Proteins 0.000 description 2
- 102000009389 Prostaglandin D receptors Human genes 0.000 description 2
- CZPWVGJYEJSRLH-UHFFFAOYSA-N Pyrimidine Chemical compound C1=CN=CN=C1 CZPWVGJYEJSRLH-UHFFFAOYSA-N 0.000 description 2
- SMWDFEZZVXVKRB-UHFFFAOYSA-N Quinoline Chemical compound N1=CC=CC2=CC=CC=C21 SMWDFEZZVXVKRB-UHFFFAOYSA-N 0.000 description 2
- PXIPVTKHYLBLMZ-UHFFFAOYSA-N Sodium azide Chemical compound [Na+].[N-]=[N+]=[N-] PXIPVTKHYLBLMZ-UHFFFAOYSA-N 0.000 description 2
- NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical compound [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 description 2
- BBKCOQYMKGEAAJ-UHFFFAOYSA-M [Br-].[Zn+]C1CCC1 Chemical compound [Br-].[Zn+]C1CCC1 BBKCOQYMKGEAAJ-UHFFFAOYSA-M 0.000 description 2
- UCUXQZKWWUKJGN-UHFFFAOYSA-N [Li].N1(CCC1)C=1N=CC2=C(N1)N=CC(=C2)C(=O)O Chemical compound [Li].N1(CCC1)C=1N=CC2=C(N1)N=CC(=C2)C(=O)O UCUXQZKWWUKJGN-UHFFFAOYSA-N 0.000 description 2
- KXKVLQRXCPHEJC-UHFFFAOYSA-N acetic acid trimethyl ester Natural products COC(C)=O KXKVLQRXCPHEJC-UHFFFAOYSA-N 0.000 description 2
- 238000007171 acid catalysis Methods 0.000 description 2
- 239000004480 active ingredient Substances 0.000 description 2
- 230000011759 adipose tissue development Effects 0.000 description 2
- 229910021529 ammonia Inorganic materials 0.000 description 2
- 235000019270 ammonium chloride Nutrition 0.000 description 2
- YZXBAPSDXZZRGB-DOFZRALJSA-N arachidonic acid Chemical compound CCCCC\C=C/C\C=C/C\C=C/C\C=C/CCCC(O)=O YZXBAPSDXZZRGB-DOFZRALJSA-N 0.000 description 2
- 150000004945 aromatic hydrocarbons Chemical group 0.000 description 2
- 210000001130 astrocyte Anatomy 0.000 description 2
- UPABQMWFWCMOFV-UHFFFAOYSA-N benethamine Chemical compound C=1C=CC=CC=1CNCCC1=CC=CC=C1 UPABQMWFWCMOFV-UHFFFAOYSA-N 0.000 description 2
- JUHORIMYRDESRB-UHFFFAOYSA-N benzathine Chemical compound C=1C=CC=CC=1CNCCNCC1=CC=CC=C1 JUHORIMYRDESRB-UHFFFAOYSA-N 0.000 description 2
- HYOKBMVQTGNOCY-UHFFFAOYSA-N benzyl n-(3-methylidenecyclobutyl)carbamate Chemical compound C1C(=C)CC1NC(=O)OCC1=CC=CC=C1 HYOKBMVQTGNOCY-UHFFFAOYSA-N 0.000 description 2
- VHXBIBFCJISKFA-UHFFFAOYSA-N benzyl n-(4-oxocyclohexyl)carbamate Chemical compound C=1C=CC=CC=1COC(=O)NC1CCC(=O)CC1 VHXBIBFCJISKFA-UHFFFAOYSA-N 0.000 description 2
- WGQKYBSKWIADBV-UHFFFAOYSA-N benzylamine Chemical compound NCC1=CC=CC=C1 WGQKYBSKWIADBV-UHFFFAOYSA-N 0.000 description 2
- 125000001584 benzyloxycarbonyl group Chemical group C(=O)(OCC1=CC=CC=C1)* 0.000 description 2
- 125000002619 bicyclic group Chemical group 0.000 description 2
- MUALRAIOVNYAIW-UHFFFAOYSA-N binap Chemical compound C1=CC=CC=C1P(C=1C(=C2C=CC=CC2=CC=1)C=1C2=CC=CC=C2C=CC=1P(C=1C=CC=CC=1)C=1C=CC=CC=1)C1=CC=CC=C1 MUALRAIOVNYAIW-UHFFFAOYSA-N 0.000 description 2
- 230000004071 biological effect Effects 0.000 description 2
- 235000010290 biphenyl Nutrition 0.000 description 2
- 239000004305 biphenyl Substances 0.000 description 2
- XGIUDIMNNMKGDE-UHFFFAOYSA-N bis(trimethylsilyl)azanide Chemical compound C[Si](C)(C)[N-][Si](C)(C)C XGIUDIMNNMKGDE-UHFFFAOYSA-N 0.000 description 2
- UORVGPXVDQYIDP-UHFFFAOYSA-N borane Chemical compound B UORVGPXVDQYIDP-UHFFFAOYSA-N 0.000 description 2
- 229940098773 bovine serum albumin Drugs 0.000 description 2
- 125000004106 butoxy group Chemical group [*]OC([H])([H])C([H])([H])C(C([H])([H])[H])([H])[H] 0.000 description 2
- FJDQFPXHSGXQBY-UHFFFAOYSA-L caesium carbonate Chemical compound [Cs+].[Cs+].[O-]C([O-])=O FJDQFPXHSGXQBY-UHFFFAOYSA-L 0.000 description 2
- 229910000024 caesium carbonate Inorganic materials 0.000 description 2
- 201000011510 cancer Diseases 0.000 description 2
- KXDHJXZQYSOELW-UHFFFAOYSA-N carbonic acid monoamide Natural products NC(O)=O KXDHJXZQYSOELW-UHFFFAOYSA-N 0.000 description 2
- 150000001732 carboxylic acid derivatives Chemical class 0.000 description 2
- 239000000969 carrier Substances 0.000 description 2
- 230000003197 catalytic effect Effects 0.000 description 2
- WRJWRGBVPUUDLA-UHFFFAOYSA-N chlorosulfonyl isocyanate Chemical compound ClS(=O)(=O)N=C=O WRJWRGBVPUUDLA-UHFFFAOYSA-N 0.000 description 2
- LOUPRKONTZGTKE-UHFFFAOYSA-N cinchonine Natural products C1C(C(C2)C=C)CCN2C1C(O)C1=CC=NC2=CC=C(OC)C=C21 LOUPRKONTZGTKE-UHFFFAOYSA-N 0.000 description 2
- 239000013065 commercial product Substances 0.000 description 2
- 238000002591 computed tomography Methods 0.000 description 2
- 230000005494 condensation Effects 0.000 description 2
- ORTQZVOHEJQUHG-UHFFFAOYSA-L copper(II) chloride Chemical compound Cl[Cu]Cl ORTQZVOHEJQUHG-UHFFFAOYSA-L 0.000 description 2
- 238000002425 crystallisation Methods 0.000 description 2
- 230000008025 crystallization Effects 0.000 description 2
- 125000001511 cyclopentyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 description 2
- 210000004443 dendritic cell Anatomy 0.000 description 2
- 230000001419 dependent effect Effects 0.000 description 2
- 238000010586 diagram Methods 0.000 description 2
- 125000001028 difluoromethyl group Chemical group [H]C(F)(F)* 0.000 description 2
- HBNBMOGARBJBHS-UHFFFAOYSA-N dimethylarsane Chemical compound C[AsH]C HBNBMOGARBJBHS-UHFFFAOYSA-N 0.000 description 2
- 238000004090 dissolution Methods 0.000 description 2
- 238000009826 distribution Methods 0.000 description 2
- MOTZDAYCYVMXPC-UHFFFAOYSA-N dodecyl hydrogen sulfate Chemical compound CCCCCCCCCCCCOS(O)(=O)=O MOTZDAYCYVMXPC-UHFFFAOYSA-N 0.000 description 2
- 229940043264 dodecyl sulfate Drugs 0.000 description 2
- VYFYYTLLBUKUHU-UHFFFAOYSA-N dopamine Chemical compound NCCC1=CC=C(O)C(O)=C1 VYFYYTLLBUKUHU-UHFFFAOYSA-N 0.000 description 2
- 239000002552 dosage form Substances 0.000 description 2
- 238000003379 elimination reaction Methods 0.000 description 2
- 229940088598 enzyme Drugs 0.000 description 2
- 229950000206 estolate Drugs 0.000 description 2
- 229940031098 ethanolamine Drugs 0.000 description 2
- SIALOQYKFQEKOG-UHFFFAOYSA-N ethyl 3,3-diethoxypropanoate Chemical compound CCOC(OCC)CC(=O)OCC SIALOQYKFQEKOG-UHFFFAOYSA-N 0.000 description 2
- QINRQIZOBCQKAZ-UHFFFAOYSA-N ethyl 4-amino-2-methylsulfanylpyrimidine-5-carboxylate Chemical compound CCOC(=O)C1=CN=C(SC)N=C1N QINRQIZOBCQKAZ-UHFFFAOYSA-N 0.000 description 2
- VYKHTMPJBCGURB-VIFPVBQESA-N ethyl 6-chloro-7-[(2S)-2-methylazetidin-1-yl]-1,8-naphthyridine-3-carboxylate Chemical compound ClC=1C=C2C=C(C=NC2=NC=1N1[C@H](CC1)C)C(=O)OCC VYKHTMPJBCGURB-VIFPVBQESA-N 0.000 description 2
- NRNBDVCWOQUURL-JTQLQIEISA-N ethyl 7-[(2S)-2-methylazetidin-1-yl]-1,6-naphthyridine-3-carboxylate Chemical compound C[C@@H]1N(CC1)C1=NC=C2C=C(C=NC2=C1)C(=O)OCC NRNBDVCWOQUURL-JTQLQIEISA-N 0.000 description 2
- GXEKVCTWBHOPFY-UHFFFAOYSA-N ethyl 7-oxo-8H-1,8-naphthyridine-3-carboxylate Chemical compound OC1=CC=C2C=C(C=NC2=N1)C(=O)OCC GXEKVCTWBHOPFY-UHFFFAOYSA-N 0.000 description 2
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 2
- 210000002744 extracellular matrix Anatomy 0.000 description 2
- 239000007789 gas Substances 0.000 description 2
- 229960003180 glutathione Drugs 0.000 description 2
- 238000001727 in vivo Methods 0.000 description 2
- 229910052742 iron Inorganic materials 0.000 description 2
- 229960003284 iron Drugs 0.000 description 2
- AWJUIBRHMBBTKR-UHFFFAOYSA-N isoquinoline Chemical compound C1=NC=CC2=CC=CC=C21 AWJUIBRHMBBTKR-UHFFFAOYSA-N 0.000 description 2
- 208000037805 labour Diseases 0.000 description 2
- 229940001447 lactate Drugs 0.000 description 2
- LNPXBBNMYBNDLG-UHFFFAOYSA-M lithium 7-(2,2,2-trifluoroethylamino)-1,8-naphthyridine-3-carboxylate Chemical compound [Li+].FC(CNC1=CC=C2C=C(C=NC2=N1)C(=O)[O-])(F)F LNPXBBNMYBNDLG-UHFFFAOYSA-M 0.000 description 2
- BFIGDAGDBNWOKI-UHFFFAOYSA-M lithium 7-(azetidin-1-yl)-1,6-naphthyridine-3-carboxylate Chemical compound [Li+].N1(CCC1)C1=NC=C2C=C(C=NC2=C1)C(=O)[O-] BFIGDAGDBNWOKI-UHFFFAOYSA-M 0.000 description 2
- YNESATAKKCNGOF-UHFFFAOYSA-N lithium bis(trimethylsilyl)amide Chemical compound [Li+].C[Si](C)(C)[N-][Si](C)(C)C YNESATAKKCNGOF-UHFFFAOYSA-N 0.000 description 2
- 229910003002 lithium salt Inorganic materials 0.000 description 2
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 2
- NXPHGHWWQRMDIA-UHFFFAOYSA-M magnesium;carbanide;bromide Chemical compound [CH3-].[Mg+2].[Br-] NXPHGHWWQRMDIA-UHFFFAOYSA-M 0.000 description 2
- 238000002844 melting Methods 0.000 description 2
- 230000008018 melting Effects 0.000 description 2
- QARBMVPHQWIHKH-UHFFFAOYSA-N methanesulfonyl chloride Chemical compound CS(Cl)(=O)=O QARBMVPHQWIHKH-UHFFFAOYSA-N 0.000 description 2
- KPVYGLFZWUGNOJ-UHFFFAOYSA-N methyl 2-oxospiro[3.3]heptane-6-carboxylate Chemical compound C1C(C(=O)OC)CC21CC(=O)C2 KPVYGLFZWUGNOJ-UHFFFAOYSA-N 0.000 description 2
- OSWTXCSCDKIANQ-UHFFFAOYSA-N methyl 3-methylidenecyclobutane-1-carboxylate Chemical compound COC(=O)C1CC(=C)C1 OSWTXCSCDKIANQ-UHFFFAOYSA-N 0.000 description 2
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 2
- MBABOKRGFJTBAE-UHFFFAOYSA-N methyl methanesulfonate Chemical compound COS(C)(=O)=O MBABOKRGFJTBAE-UHFFFAOYSA-N 0.000 description 2
- DVSDBMFJEQPWNO-UHFFFAOYSA-N methyllithium Chemical compound C[Li] DVSDBMFJEQPWNO-UHFFFAOYSA-N 0.000 description 2
- 125000002816 methylsulfanyl group Chemical group [H]C([H])([H])S[*] 0.000 description 2
- 210000000274 microglia Anatomy 0.000 description 2
- 238000002156 mixing Methods 0.000 description 2
- 238000010369 molecular cloning Methods 0.000 description 2
- 239000001788 mono and diglycerides of fatty acids Substances 0.000 description 2
- 125000002950 monocyclic group Chemical group 0.000 description 2
- KVKFRMCSXWQSNT-UHFFFAOYSA-N n,n'-dimethylethane-1,2-diamine Chemical compound CNCCNC KVKFRMCSXWQSNT-UHFFFAOYSA-N 0.000 description 2
- SYSQUGFVNFXIIT-UHFFFAOYSA-N n-[4-(1,3-benzoxazol-2-yl)phenyl]-4-nitrobenzenesulfonamide Chemical class C1=CC([N+](=O)[O-])=CC=C1S(=O)(=O)NC1=CC=C(C=2OC3=CC=CC=C3N=2)C=C1 SYSQUGFVNFXIIT-UHFFFAOYSA-N 0.000 description 2
- 230000017074 necrotic cell death Effects 0.000 description 2
- 235000001968 nicotinic acid Nutrition 0.000 description 2
- 239000011664 nicotinic acid Substances 0.000 description 2
- QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 description 2
- 125000004043 oxo group Chemical group O=* 0.000 description 2
- NXJCBFBQEVOTOW-UHFFFAOYSA-L palladium(2+);dihydroxide Chemical compound O[Pd]O NXJCBFBQEVOTOW-UHFFFAOYSA-L 0.000 description 2
- PIBWKRNGBLPSSY-UHFFFAOYSA-L palladium(II) chloride Chemical compound Cl[Pd]Cl PIBWKRNGBLPSSY-UHFFFAOYSA-L 0.000 description 2
- 239000012071 phase Substances 0.000 description 2
- 230000000704 physical effect Effects 0.000 description 2
- IUBQJLUDMLPAGT-UHFFFAOYSA-N potassium bis(trimethylsilyl)amide Chemical compound C[Si](C)(C)N([K])[Si](C)(C)C IUBQJLUDMLPAGT-UHFFFAOYSA-N 0.000 description 2
- BWHMMNNQKKPAPP-UHFFFAOYSA-L potassium carbonate Chemical compound [K+].[K+].[O-]C([O-])=O BWHMMNNQKKPAPP-UHFFFAOYSA-L 0.000 description 2
- 230000002265 prevention Effects 0.000 description 2
- 229960002429 proline Drugs 0.000 description 2
- 125000001436 propyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])[H] 0.000 description 2
- BBEAQIROQSPTKN-UHFFFAOYSA-N pyrene Chemical compound C1=CC=C2C=CC3=CC=CC4=CC=C1C2=C43 BBEAQIROQSPTKN-UHFFFAOYSA-N 0.000 description 2
- VHNQIURBCCNWDN-UHFFFAOYSA-N pyridine-2,6-diamine Chemical compound NC1=CC=CC(N)=N1 VHNQIURBCCNWDN-UHFFFAOYSA-N 0.000 description 2
- UDJFFSGCRRMVFH-UHFFFAOYSA-N pyrido[2,3-d]pyrimidine Chemical compound N1=CN=CC2=CC=CN=C21 UDJFFSGCRRMVFH-UHFFFAOYSA-N 0.000 description 2
- GRZGUKKCQPXOIY-UHFFFAOYSA-N pyrido[2,3-d]pyrimidine-2-carboxamide Chemical compound N1=C(N=CC2=C1N=CC=C2)C(=O)N GRZGUKKCQPXOIY-UHFFFAOYSA-N 0.000 description 2
- HNJBEVLQSNELDL-UHFFFAOYSA-N pyrrolidin-2-one Chemical compound O=C1CCCN1 HNJBEVLQSNELDL-UHFFFAOYSA-N 0.000 description 2
- 229960000948 quinine Drugs 0.000 description 2
- 230000009467 reduction Effects 0.000 description 2
- QZAYGJVTTNCVMB-UHFFFAOYSA-N serotonin Chemical compound C1=C(O)C=C2C(CCN)=CNC2=C1 QZAYGJVTTNCVMB-UHFFFAOYSA-N 0.000 description 2
- 229910000029 sodium carbonate Inorganic materials 0.000 description 2
- 239000011780 sodium chloride Substances 0.000 description 2
- 235000010288 sodium nitrite Nutrition 0.000 description 2
- 239000012321 sodium triacetoxyborohydride Substances 0.000 description 2
- 239000007790 solid phase Substances 0.000 description 2
- 238000000527 sonication Methods 0.000 description 2
- PFNFFQXMRSDOHW-UHFFFAOYSA-N spermine Chemical compound NCCCNCCCCNCCCN PFNFFQXMRSDOHW-UHFFFAOYSA-N 0.000 description 2
- VNFWTIYUKDMAOP-UHFFFAOYSA-N sphos Chemical group COC1=CC=CC(OC)=C1C1=CC=CC=C1P(C1CCCCC1)C1CCCCC1 VNFWTIYUKDMAOP-UHFFFAOYSA-N 0.000 description 2
- BDHFUVZGWQCTTF-UHFFFAOYSA-M sulfonate Chemical compound [O-]S(=O)=O BDHFUVZGWQCTTF-UHFFFAOYSA-M 0.000 description 2
- 239000011593 sulfur Substances 0.000 description 2
- 239000006188 syrup Substances 0.000 description 2
- 235000020357 syrup Nutrition 0.000 description 2
- 229940095064 tartrate Drugs 0.000 description 2
- FPGGTKZVZWFYPV-UHFFFAOYSA-M tetrabutylammonium fluoride Chemical compound [F-].CCCC[N+](CCCC)(CCCC)CCCC FPGGTKZVZWFYPV-UHFFFAOYSA-M 0.000 description 2
- FYSNRJHAOHDILO-UHFFFAOYSA-N thionyl chloride Chemical compound ClS(Cl)=O FYSNRJHAOHDILO-UHFFFAOYSA-N 0.000 description 2
- 230000000699 topical effect Effects 0.000 description 2
- VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 description 2
- 238000002054 transplantation Methods 0.000 description 2
- KPZSTOVTJYRDIO-UHFFFAOYSA-K trichlorocerium;heptahydrate Chemical compound O.O.O.O.O.O.O.Cl[Ce](Cl)Cl KPZSTOVTJYRDIO-UHFFFAOYSA-K 0.000 description 2
- IMNIMPAHZVJRPE-UHFFFAOYSA-N triethylenediamine Chemical compound C1CN2CCN1CC2 IMNIMPAHZVJRPE-UHFFFAOYSA-N 0.000 description 2
- AQRLNPVMDITEJU-UHFFFAOYSA-N triethylsilane Chemical compound CC[SiH](CC)CC AQRLNPVMDITEJU-UHFFFAOYSA-N 0.000 description 2
- WJKHJLXJJJATHN-UHFFFAOYSA-N triflic anhydride Chemical compound FC(F)(F)S(=O)(=O)OS(=O)(=O)C(F)(F)F WJKHJLXJJJATHN-UHFFFAOYSA-N 0.000 description 2
- LENZDBCJOHFCAS-UHFFFAOYSA-N tris Chemical compound OCC(N)(CO)CO LENZDBCJOHFCAS-UHFFFAOYSA-N 0.000 description 2
- 229910052725 zinc Inorganic materials 0.000 description 2
- 239000011701 zinc Substances 0.000 description 2
- LSPHULWDVZXLIL-UHFFFAOYSA-N (+/-)-Camphoric acid Chemical compound CC1(C)C(C(O)=O)CCC1(C)C(O)=O LSPHULWDVZXLIL-UHFFFAOYSA-N 0.000 description 1
- SNICXCGAKADSCV-JTQLQIEISA-N (-)-Nicotine Chemical compound CN1CCC[C@H]1C1=CC=CN=C1 SNICXCGAKADSCV-JTQLQIEISA-N 0.000 description 1
- ASHXUACJFCZHLR-JTQLQIEISA-O (2S)-1-benzyl-2-methylazetidin-1-ium Chemical compound C[C@H]1CC[N@H+]1Cc1ccccc1 ASHXUACJFCZHLR-JTQLQIEISA-O 0.000 description 1
- ASHXUACJFCZHLR-JTQLQIEISA-N (2s)-1-benzyl-2-methylazetidine Chemical compound C[C@H]1CCN1CC1=CC=CC=C1 ASHXUACJFCZHLR-JTQLQIEISA-N 0.000 description 1
- UUIPGCXIZVZSEC-JTQLQIEISA-N (2s)-2-(1,3-dioxoisoindol-2-yl)-3-methylbutanoic acid Chemical compound C1=CC=C2C(=O)N([C@@H](C(C)C)C(O)=O)C(=O)C2=C1 UUIPGCXIZVZSEC-JTQLQIEISA-N 0.000 description 1
- BMQDAIUNAGXSKR-UHFFFAOYSA-N (3-hydroxy-2,3-dimethylbutan-2-yl)oxyboronic acid Chemical compound CC(C)(O)C(C)(C)OB(O)O BMQDAIUNAGXSKR-UHFFFAOYSA-N 0.000 description 1
- ZFMFMEQJPXKZKK-UHFFFAOYSA-N (3-oxocyclobutyl)carbamic acid Chemical compound OC(=O)NC1CC(=O)C1 ZFMFMEQJPXKZKK-UHFFFAOYSA-N 0.000 description 1
- GHOKWGTUZJEAQD-ZETCQYMHSA-N (D)-(+)-Pantothenic acid Chemical compound OCC(C)(C)[C@@H](O)C(=O)NCCC(O)=O GHOKWGTUZJEAQD-ZETCQYMHSA-N 0.000 description 1
- IADUEWIQBXOCDZ-GSVOUGTGSA-N (R)-azetidine-2-carboxylic acid Chemical compound OC(=O)[C@H]1CCN1 IADUEWIQBXOCDZ-GSVOUGTGSA-N 0.000 description 1
- PUPZLCDOIYMWBV-SCSAIBSYSA-N (R)-butane-1,3-diol Chemical compound C[C@@H](O)CCO PUPZLCDOIYMWBV-SCSAIBSYSA-N 0.000 description 1
- MIOPJNTWMNEORI-XVKPBYJWSA-N (R)-camphorsulfonic acid Chemical compound C1C[C@]2(CS(O)(=O)=O)C(=O)C[C@H]1C2(C)C MIOPJNTWMNEORI-XVKPBYJWSA-N 0.000 description 1
- KZPYGQFFRCFCPP-UHFFFAOYSA-N 1,1'-bis(diphenylphosphino)ferrocene Chemical compound [Fe+2].C1=CC=C[C-]1P(C=1C=CC=CC=1)C1=CC=CC=C1.C1=CC=C[C-]1P(C=1C=CC=CC=1)C1=CC=CC=C1 KZPYGQFFRCFCPP-UHFFFAOYSA-N 0.000 description 1
- XHILZHAQBOLGFD-UHFFFAOYSA-N 1,1-difluoropropan-2-one Chemical compound CC(=O)C(F)F XHILZHAQBOLGFD-UHFFFAOYSA-N 0.000 description 1
- BCNBMSZKALBQEF-UHFFFAOYSA-N 1,3-dimethylpyrrolidin-2-one Chemical compound CC1CCN(C)C1=O BCNBMSZKALBQEF-UHFFFAOYSA-N 0.000 description 1
- CRADWWWVIYEAFR-UHFFFAOYSA-N 1,8-naphthyridin-2-amine Chemical compound C1=CC=NC2=NC(N)=CC=C21 CRADWWWVIYEAFR-UHFFFAOYSA-N 0.000 description 1
- 150000005058 1,8-naphthyridines Chemical class 0.000 description 1
- ASOKPJOREAFHNY-UHFFFAOYSA-N 1-Hydroxybenzotriazole Chemical compound C1=CC=C2N(O)N=NC2=C1 ASOKPJOREAFHNY-UHFFFAOYSA-N 0.000 description 1
- ASHXUACJFCZHLR-UHFFFAOYSA-N 1-benzyl-2-methylazetidine Chemical compound CC1CCN1CC1=CC=CC=C1 ASHXUACJFCZHLR-UHFFFAOYSA-N 0.000 description 1
- HVCFCNAITDHQFX-UHFFFAOYSA-N 1-cyclopropylethanone Chemical compound CC(=O)C1CC1 HVCFCNAITDHQFX-UHFFFAOYSA-N 0.000 description 1
- LMDZBCPBFSXMTL-UHFFFAOYSA-N 1-ethyl-3-(3-dimethylaminopropyl)carbodiimide Chemical compound CCN=C=NCCCN(C)C LMDZBCPBFSXMTL-UHFFFAOYSA-N 0.000 description 1
- RPABADYMEMUBEC-UHFFFAOYSA-N 1-oxaspiro[4.5]decan-8-one Chemical compound C1CC(=O)CCC11OCCC1 RPABADYMEMUBEC-UHFFFAOYSA-N 0.000 description 1
- VHRUMKCAEVRUBK-GODQJPCRSA-N 15-deoxy-Delta(12,14)-prostaglandin J2 Chemical compound CCCCC\C=C\C=C1/[C@@H](C\C=C/CCCC(O)=O)C=CC1=O VHRUMKCAEVRUBK-GODQJPCRSA-N 0.000 description 1
- ZFRUGZMCGCYBRC-UHFFFAOYSA-N 1h-1,8-naphthyridin-2-one Chemical compound C1=CC=NC2=NC(O)=CC=C21 ZFRUGZMCGCYBRC-UHFFFAOYSA-N 0.000 description 1
- QUKPALAWEPMWOS-UHFFFAOYSA-N 1h-pyrazolo[3,4-d]pyrimidine Chemical compound C1=NC=C2C=NNC2=N1 QUKPALAWEPMWOS-UHFFFAOYSA-N 0.000 description 1
- QKZMLBNEFKGPOZ-UHFFFAOYSA-N 1h-pyrazolo[4,3-c]pyridine Chemical compound C1=N[CH]C2=C=NNC2=C1 QKZMLBNEFKGPOZ-UHFFFAOYSA-N 0.000 description 1
- WFZCVZZPXZKOPL-UHFFFAOYSA-N 1h-pyrrolo[3,2-c]pyridine Chemical compound N1=CC=C2N[C]=CC2=C1 WFZCVZZPXZKOPL-UHFFFAOYSA-N 0.000 description 1
- UFUIZPCXYRUNPZ-UHFFFAOYSA-N 2,2,2-trichloroethanimidamide;hydrochloride Chemical compound Cl.NC(=N)C(Cl)(Cl)Cl UFUIZPCXYRUNPZ-UHFFFAOYSA-N 0.000 description 1
- KIPSRYDSZQRPEA-UHFFFAOYSA-N 2,2,2-trifluoroethanamine Chemical compound NCC(F)(F)F KIPSRYDSZQRPEA-UHFFFAOYSA-N 0.000 description 1
- OVRWUZYZECPJOB-UHFFFAOYSA-N 2,2-difluoroethanamine Chemical compound NCC(F)F OVRWUZYZECPJOB-UHFFFAOYSA-N 0.000 description 1
- NGQQUXXTDZADNX-UHFFFAOYSA-N 2,3,4,5-tetrachlorofuran Chemical compound ClC=1OC(Cl)=C(Cl)C=1Cl NGQQUXXTDZADNX-UHFFFAOYSA-N 0.000 description 1
- MAKFMOSBBNKPMS-UHFFFAOYSA-N 2,3-dichloropyridine Chemical compound ClC1=CC=CN=C1Cl MAKFMOSBBNKPMS-UHFFFAOYSA-N 0.000 description 1
- RKXNLMZRERZATJ-UHFFFAOYSA-N 2,3-dihydro-1H-indole Chemical compound C1=CC=C2NCCC2=C1.C1=CC=C2NCCC2=C1 RKXNLMZRERZATJ-UHFFFAOYSA-N 0.000 description 1
- OMCWDFRSERNLDX-XCBNKYQSSA-N 2-[(3S,4R)-4-methyl-2-oxopyrrolidin-3-yl]isoindole-1,3-dione Chemical compound C[C@@H]1CNC(=O)[C@H]1N1C(=O)c2ccccc2C1=O OMCWDFRSERNLDX-XCBNKYQSSA-N 0.000 description 1
- JKMHFZQWWAIEOD-UHFFFAOYSA-N 2-[4-(2-hydroxyethyl)piperazin-1-yl]ethanesulfonic acid Chemical compound OCC[NH+]1CCN(CCS([O-])(=O)=O)CC1 JKMHFZQWWAIEOD-UHFFFAOYSA-N 0.000 description 1
- NXMFJCRMSDRXLD-UHFFFAOYSA-N 2-aminopyridine-3-carbaldehyde Chemical compound NC1=NC=CC=C1C=O NXMFJCRMSDRXLD-UHFFFAOYSA-N 0.000 description 1
- FUSFWUFSEJXMRQ-UHFFFAOYSA-N 2-bromo-1,1-dimethoxyethane Chemical compound COC(CBr)OC FUSFWUFSEJXMRQ-UHFFFAOYSA-N 0.000 description 1
- BCMGOTDNNMLUBS-UHFFFAOYSA-N 2-bromo-1,8-naphthyridine Chemical compound C1=CC=NC2=NC(Br)=CC=C21 BCMGOTDNNMLUBS-UHFFFAOYSA-N 0.000 description 1
- SURMYNZXHKLDFO-UHFFFAOYSA-N 2-bromopropanedial Chemical compound O=CC(Br)C=O SURMYNZXHKLDFO-UHFFFAOYSA-N 0.000 description 1
- HTIZLJISEUYGSA-UHFFFAOYSA-N 2-chloro-1,8-naphthyridine Chemical compound C1=CC=NC2=NC(Cl)=CC=C21 HTIZLJISEUYGSA-UHFFFAOYSA-N 0.000 description 1
- 125000000954 2-hydroxyethyl group Chemical group [H]C([*])([H])C([H])([H])O[H] 0.000 description 1
- XWKFPIODWVPXLX-UHFFFAOYSA-N 2-methyl-5-methylpyridine Natural products CC1=CC=C(C)N=C1 XWKFPIODWVPXLX-UHFFFAOYSA-N 0.000 description 1
- ASRYRQIALCSPLM-UHFFFAOYSA-N 2-methylidenecyclobutane-1-carboxylic acid Chemical compound OC(=O)C1CCC1=C ASRYRQIALCSPLM-UHFFFAOYSA-N 0.000 description 1
- KCMCIQNPQUSQKQ-UHFFFAOYSA-N 2-oxido-1,2,5-oxadiazol-2-ium Chemical group [O-][N+]1=CC=NO1 KCMCIQNPQUSQKQ-UHFFFAOYSA-N 0.000 description 1
- 238000005084 2D-nuclear magnetic resonance Methods 0.000 description 1
- HDBGBTNNPRCVND-UHFFFAOYSA-N 3,3,3-trifluoropropan-1-ol Chemical compound OCCC(F)(F)F HDBGBTNNPRCVND-UHFFFAOYSA-N 0.000 description 1
- HSHOEFCXJCXSMR-UHFFFAOYSA-N 3,3-difluoroazepine Chemical compound FC1(C=NC=CC=C1)F HSHOEFCXJCXSMR-UHFFFAOYSA-N 0.000 description 1
- CDBAEFXTCRKJPZ-UHFFFAOYSA-N 3,3-difluoroazetidine;hydron;chloride Chemical compound Cl.FC1(F)CNC1 CDBAEFXTCRKJPZ-UHFFFAOYSA-N 0.000 description 1
- WRSZLHTTXPEKBD-UHFFFAOYSA-N 3-bromo-1,6-naphthyridine Chemical compound C1=CN=CC2=CC(Br)=CN=C21 WRSZLHTTXPEKBD-UHFFFAOYSA-N 0.000 description 1
- PDZZZAWKYMHGLA-UHFFFAOYSA-N 3-bromo-1,8-naphthyridine Chemical compound N1=CC=CC2=CC(Br)=CN=C21 PDZZZAWKYMHGLA-UHFFFAOYSA-N 0.000 description 1
- ALKYHXVLJMQRLQ-UHFFFAOYSA-M 3-carboxynaphthalen-2-olate Chemical compound C1=CC=C2C=C(C([O-])=O)C(O)=CC2=C1 ALKYHXVLJMQRLQ-UHFFFAOYSA-M 0.000 description 1
- 125000004575 3-pyrrolidinyl group Chemical group [H]N1C([H])([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 description 1
- UBOOKRVGOBKDMM-UHFFFAOYSA-N 3h-imidazo[4,5-c]pyridine Chemical compound C1=NC=C2NC=NC2=C1 UBOOKRVGOBKDMM-UHFFFAOYSA-N 0.000 description 1
- RBZIUUQFRGHPGE-UHFFFAOYSA-N 4-(benzhydrylamino)cyclohexan-1-one Chemical compound C1CC(=O)CCC1NC(C2=CC=CC=C2)C3=CC=CC=C3 RBZIUUQFRGHPGE-UHFFFAOYSA-N 0.000 description 1
- TZQGXAHOROZEKN-UHFFFAOYSA-N 4-(benzhydryloxy)-1-[3-(1h-tetraazol-5-yl)propyl]piperidine Chemical compound N=1N=NNC=1CCCN(CC1)CCC1OC(C=1C=CC=CC=1)C1=CC=CC=C1 TZQGXAHOROZEKN-UHFFFAOYSA-N 0.000 description 1
- QCXJEYYXVJIFCE-UHFFFAOYSA-M 4-acetamidobenzoate Chemical compound CC(=O)NC1=CC=C(C([O-])=O)C=C1 QCXJEYYXVJIFCE-UHFFFAOYSA-M 0.000 description 1
- HVBSAKJJOYLTQU-UHFFFAOYSA-M 4-aminobenzenesulfonate Chemical compound NC1=CC=C(S([O-])(=O)=O)C=C1 HVBSAKJJOYLTQU-UHFFFAOYSA-M 0.000 description 1
- WUBBRNOQWQTFEX-UHFFFAOYSA-M 4-aminosalicylate(1-) Chemical compound NC1=CC=C(C([O-])=O)C(O)=C1 WUBBRNOQWQTFEX-UHFFFAOYSA-M 0.000 description 1
- GAMYYCRTACQSBR-UHFFFAOYSA-N 4-azabenzimidazole Chemical compound C1=CC=C2NC=NC2=N1 GAMYYCRTACQSBR-UHFFFAOYSA-N 0.000 description 1
- 229960000549 4-dimethylaminophenol Drugs 0.000 description 1
- 125000004217 4-methoxybenzyl group Chemical group [H]C1=C([H])C(=C([H])C([H])=C1OC([H])([H])[H])C([H])([H])* 0.000 description 1
- ODHCTXKNWHHXJC-VKHMYHEASA-N 5-oxo-L-proline Chemical compound OC(=O)[C@@H]1CCC(=O)N1 ODHCTXKNWHHXJC-VKHMYHEASA-N 0.000 description 1
- LVYMZKRQJPYEII-UHFFFAOYSA-N 6-bromopyrido[2,3-d]pyrimidine Chemical compound N1=CN=CC2=CC(Br)=CN=C21 LVYMZKRQJPYEII-UHFFFAOYSA-N 0.000 description 1
- FHVDTGUDJYJELY-UHFFFAOYSA-N 6-{[2-carboxy-4,5-dihydroxy-6-(phosphanyloxy)oxan-3-yl]oxy}-4,5-dihydroxy-3-phosphanyloxane-2-carboxylic acid Chemical compound O1C(C(O)=O)C(P)C(O)C(O)C1OC1C(C(O)=O)OC(OP)C(O)C1O FHVDTGUDJYJELY-UHFFFAOYSA-N 0.000 description 1
- PJMAOVIRNDKEOW-UHFFFAOYSA-N 7-amino-1,8-naphthyridine-3-carboxylic acid Chemical compound NC1=CC=C2C=C(C=NC2=N1)C(=O)O PJMAOVIRNDKEOW-UHFFFAOYSA-N 0.000 description 1
- ZCYVEMRRCGMTRW-UHFFFAOYSA-N 7553-56-2 Chemical compound [I] ZCYVEMRRCGMTRW-UHFFFAOYSA-N 0.000 description 1
- YIUIVFFUEVPRIU-UHFFFAOYSA-N 8-chlorotheophylline Chemical compound O=C1N(C)C(=O)N(C)C2=NC(Cl)=N[C]21 YIUIVFFUEVPRIU-UHFFFAOYSA-N 0.000 description 1
- OZAIFHULBGXAKX-VAWYXSNFSA-N AIBN Substances N#CC(C)(C)\N=N\C(C)(C)C#N OZAIFHULBGXAKX-VAWYXSNFSA-N 0.000 description 1
- QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 description 1
- 229920001817 Agar Polymers 0.000 description 1
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 1
- 208000037259 Amyloid Plaque Diseases 0.000 description 1
- WWGUAFRTAYMNHU-UHFFFAOYSA-N Benzyl 4-piperidinylcarbamate Chemical compound C=1C=CC=CC=1COC(=O)NC1CCNCC1 WWGUAFRTAYMNHU-UHFFFAOYSA-N 0.000 description 1
- FERIUCNNQQJTOY-UHFFFAOYSA-M Butyrate Chemical compound CCCC([O-])=O FERIUCNNQQJTOY-UHFFFAOYSA-M 0.000 description 1
- FERIUCNNQQJTOY-UHFFFAOYSA-N Butyric acid Natural products CCCC(O)=O FERIUCNNQQJTOY-UHFFFAOYSA-N 0.000 description 1
- VYKXRGMTYCBTDB-UHFFFAOYSA-N C(C)OC1=CC=C2C=C(C=NC2=N1)C(=O)O Chemical compound C(C)OC1=CC=C2C=C(C=NC2=N1)C(=O)O VYKXRGMTYCBTDB-UHFFFAOYSA-N 0.000 description 1
- NMDOTNIRCPRXFY-UHFFFAOYSA-N C(C)OC1=NC2=NC=CC=C2C=C1C(=O)O Chemical compound C(C)OC1=NC2=NC=CC=C2C=C1C(=O)O NMDOTNIRCPRXFY-UHFFFAOYSA-N 0.000 description 1
- GTZAXLIPIYHBDR-QAQDUYKDSA-N C1(CC1)C1=CC=C2C=C(C=NC2=N1)C(=O)N[C@@H]1CC[C@H](CC1)N1CC(C1)(F)F Chemical compound C1(CC1)C1=CC=C2C=C(C=NC2=N1)C(=O)N[C@@H]1CC[C@H](CC1)N1CC(C1)(F)F GTZAXLIPIYHBDR-QAQDUYKDSA-N 0.000 description 1
- PBTVTOUOBIGPBV-LBPRGKRZSA-N C1(CC1)C1=NC=C2C=C(C=NC2=C1)C(=O)N[C@@H]1C(NCC1)=O Chemical compound C1(CC1)C1=NC=C2C=C(C=NC2=C1)C(=O)N[C@@H]1C(NCC1)=O PBTVTOUOBIGPBV-LBPRGKRZSA-N 0.000 description 1
- MBUCSCBKQYAHAP-QAQDUYKDSA-N C1(CC1)C1=NC=C2C=C(C=NC2=C1)C(=O)N[C@@H]1CC[C@H](CC1)C(C)(C)O Chemical compound C1(CC1)C1=NC=C2C=C(C=NC2=C1)C(=O)N[C@@H]1CC[C@H](CC1)C(C)(C)O MBUCSCBKQYAHAP-QAQDUYKDSA-N 0.000 description 1
- NTMIRLYSNJNTGO-GPMSIDNRSA-N C1(CC1)C1=NC=C2C=C(C=NC2=C1)C(=O)N[C@@H]1CC[C@H](CC1)N[C@@H](C(F)(F)F)CO Chemical compound C1(CC1)C1=NC=C2C=C(C=NC2=C1)C(=O)N[C@@H]1CC[C@H](CC1)N[C@@H](C(F)(F)F)CO NTMIRLYSNJNTGO-GPMSIDNRSA-N 0.000 description 1
- GZQNZDQCLQQOJM-SHTZXODSSA-N C1(CC1)C1=NC=C2C=C(C=NC2=C1)C(=O)N[C@@H]1C[C@H](C1)C(C)(C)O Chemical compound C1(CC1)C1=NC=C2C=C(C=NC2=C1)C(=O)N[C@@H]1C[C@H](C1)C(C)(C)O GZQNZDQCLQQOJM-SHTZXODSSA-N 0.000 description 1
- YVZPWORJUVHQCS-CKEIUWERSA-N C1(CC1)C1=NC=C2C=C(C=NC2=C1)C(=O)N[C@@H]1C[C@H](C1)N[C@@H](C(F)(F)F)CO Chemical compound C1(CC1)C1=NC=C2C=C(C=NC2=C1)C(=O)N[C@@H]1C[C@H](C1)N[C@@H](C(F)(F)F)CO YVZPWORJUVHQCS-CKEIUWERSA-N 0.000 description 1
- BLGXZWFIVFMQGF-UHFFFAOYSA-N C1(CCC1)C1=CC=C2C=C(C=NC2=N1)C(=O)OC1CCC1 Chemical compound C1(CCC1)C1=CC=C2C=C(C=NC2=N1)C(=O)OC1CCC1 BLGXZWFIVFMQGF-UHFFFAOYSA-N 0.000 description 1
- JQVBZZUMWRXDSQ-JOCQHMNTSA-N C1C[C@@H](N)CC[C@@H]1NC(=O)OCC1=CC=CC=C1 Chemical compound C1C[C@@H](N)CC[C@@H]1NC(=O)OCC1=CC=CC=C1 JQVBZZUMWRXDSQ-JOCQHMNTSA-N 0.000 description 1
- 238000011814 C57BL/6N mouse Methods 0.000 description 1
- XNCMWRCLGVMPFR-UHFFFAOYSA-N CCS(O)(=O)=O.CCOS(O)(=O)=O Chemical compound CCS(O)(=O)=O.CCOS(O)(=O)=O XNCMWRCLGVMPFR-UHFFFAOYSA-N 0.000 description 1
- HAWROWOTWNGFIH-UHFFFAOYSA-N COC(=O)C1CC2(C1)CC(C2)NC(C2=CC=CC=C2)C2=CC=CC=C2 Chemical compound COC(=O)C1CC2(C1)CC(C2)NC(C2=CC=CC=C2)C2=CC=CC=C2 HAWROWOTWNGFIH-UHFFFAOYSA-N 0.000 description 1
- YNIVGBINBZKQAY-UHFFFAOYSA-N CSC=1N=CC2=C(N=1)N=C(C(=C2)C(=O)OCC)SC Chemical compound CSC=1N=CC2=C(N=1)N=C(C(=C2)C(=O)OCC)SC YNIVGBINBZKQAY-UHFFFAOYSA-N 0.000 description 1
- DKPZJWVILJDGJE-VWMHFEHESA-N C[C@@H]1NCC1.CC(C)(C(CC1)CC2=O)C12OS(C)(=O)=O Chemical compound C[C@@H]1NCC1.CC(C)(C(CC1)CC2=O)C12OS(C)(=O)=O DKPZJWVILJDGJE-VWMHFEHESA-N 0.000 description 1
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 1
- OKTJSMMVPCPJKN-NJFSPNSNSA-N Carbon-14 Chemical compound [14C] OKTJSMMVPCPJKN-NJFSPNSNSA-N 0.000 description 1
- 241000191368 Chlorobi Species 0.000 description 1
- VYZAMTAEIAYCRO-UHFFFAOYSA-N Chromium Chemical compound [Cr] VYZAMTAEIAYCRO-UHFFFAOYSA-N 0.000 description 1
- KRKNYBCHXYNGOX-UHFFFAOYSA-K Citrate Chemical compound [O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O KRKNYBCHXYNGOX-UHFFFAOYSA-K 0.000 description 1
- KZDKQCFPLZOPFF-UHFFFAOYSA-N Cl.COc1ccc(N)c2ncccc12 Chemical compound Cl.COc1ccc(N)c2ncccc12 KZDKQCFPLZOPFF-UHFFFAOYSA-N 0.000 description 1
- MTXONXMUEPKXGA-WKILWMFISA-N ClC=1C=C2C=C(C=NC2=NC=1C1CC1)C(=O)N[C@@H]1CC[C@H](CC1)C(C)(C)O Chemical compound ClC=1C=C2C=C(C=NC2=NC=1C1CC1)C(=O)N[C@@H]1CC[C@H](CC1)C(C)(C)O MTXONXMUEPKXGA-WKILWMFISA-N 0.000 description 1
- RYZPVTJHBJPDMD-HDJSIYSDSA-N ClC=1C=C2C=C(C=NC2=NC=1C1CC1)C(=O)N[C@@H]1C[C@H](C1)C(C)(C)O Chemical compound ClC=1C=C2C=C(C=NC2=NC=1C1CC1)C(=O)N[C@@H]1C[C@H](C1)C(C)(C)O RYZPVTJHBJPDMD-HDJSIYSDSA-N 0.000 description 1
- TYXOMAHVRFTKOQ-ZANVPECISA-N ClC=1C=C2C=C(C=NC2=NC=1N1[C@H](CC1)C)C(=O)N[C@@H]1C(NCC1)=O Chemical compound ClC=1C=C2C=C(C=NC2=NC=1N1[C@H](CC1)C)C(=O)N[C@@H]1C(NCC1)=O TYXOMAHVRFTKOQ-ZANVPECISA-N 0.000 description 1
- RYGMFSIKBFXOCR-UHFFFAOYSA-N Copper Chemical compound [Cu] RYGMFSIKBFXOCR-UHFFFAOYSA-N 0.000 description 1
- 229910021592 Copper(II) chloride Inorganic materials 0.000 description 1
- XDTMQSROBMDMFD-UHFFFAOYSA-N Cyclohexane Chemical compound C1CCCCC1 XDTMQSROBMDMFD-UHFFFAOYSA-N 0.000 description 1
- HTJDQJBWANPRPF-UHFFFAOYSA-N Cyclopropylamine Chemical compound NC1CC1 HTJDQJBWANPRPF-UHFFFAOYSA-N 0.000 description 1
- RGHNJXZEOKUKBD-SQOUGZDYSA-M D-gluconate Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C([O-])=O RGHNJXZEOKUKBD-SQOUGZDYSA-M 0.000 description 1
- AEMOLEFTQBMNLQ-AQKNRBDQSA-N D-glucopyranuronic acid Chemical compound OC1O[C@H](C(O)=O)[C@@H](O)[C@H](O)[C@H]1O AEMOLEFTQBMNLQ-AQKNRBDQSA-N 0.000 description 1
- 208000016192 Demyelinating disease Diseases 0.000 description 1
- 206010012305 Demyelination Diseases 0.000 description 1
- YZCKVEUIGOORGS-OUBTZVSYSA-N Deuterium Chemical compound [2H] YZCKVEUIGOORGS-OUBTZVSYSA-N 0.000 description 1
- ZNZYKNKBJPZETN-WELNAUFTSA-N Dialdehyde 11678 Chemical compound N1C2=CC=CC=C2C2=C1[C@H](C[C@H](/C(=C/O)C(=O)OC)[C@@H](C=C)C=O)NCC2 ZNZYKNKBJPZETN-WELNAUFTSA-N 0.000 description 1
- NVTRPRFAWJGJAJ-UHFFFAOYSA-L EDTA monocalcium salt Chemical compound [Ca+2].OC(=O)CN(CC([O-])=O)CCN(CC(O)=O)CC([O-])=O NVTRPRFAWJGJAJ-UHFFFAOYSA-L 0.000 description 1
- PIICEJLVQHRZGT-UHFFFAOYSA-N Ethylenediamine Chemical compound NCCN PIICEJLVQHRZGT-UHFFFAOYSA-N 0.000 description 1
- GEZJCGRHMVVVEU-ZKCHVHJHSA-N FC1(CN(C1)[C@@H]1CC[C@H](CC1)N)F Chemical compound FC1(CN(C1)[C@@H]1CC[C@H](CC1)N)F GEZJCGRHMVVVEU-ZKCHVHJHSA-N 0.000 description 1
- OJGWJVLZVVQFOX-ZKCHVHJHSA-N FC1(CN(C1)[C@@H]1CC[C@H](CC1)NC(O)=O)F Chemical compound FC1(CN(C1)[C@@H]1CC[C@H](CC1)NC(O)=O)F OJGWJVLZVVQFOX-ZKCHVHJHSA-N 0.000 description 1
- 206010016654 Fibrosis Diseases 0.000 description 1
- PNKUSGQVOMIXLU-UHFFFAOYSA-N Formamidine Chemical compound NC=N PNKUSGQVOMIXLU-UHFFFAOYSA-N 0.000 description 1
- BDAGIHXWWSANSR-UHFFFAOYSA-M Formate Chemical compound [O-]C=O BDAGIHXWWSANSR-UHFFFAOYSA-M 0.000 description 1
- 102000011652 Formyl peptide receptors Human genes 0.000 description 1
- 108010076288 Formyl peptide receptors Proteins 0.000 description 1
- VZCYOOQTPOCHFL-OWOJBTEDSA-N Fumaric acid Chemical compound OC(=O)\C=C\C(O)=O VZCYOOQTPOCHFL-OWOJBTEDSA-N 0.000 description 1
- 102000003688 G-Protein-Coupled Receptors Human genes 0.000 description 1
- 108090000045 G-Protein-Coupled Receptors Proteins 0.000 description 1
- 108010010803 Gelatin Proteins 0.000 description 1
- 206010018341 Gliosis Diseases 0.000 description 1
- DHCLVCXQIBBOPH-UHFFFAOYSA-N Glycerol 2-phosphate Chemical compound OCC(CO)OP(O)(O)=O DHCLVCXQIBBOPH-UHFFFAOYSA-N 0.000 description 1
- AEMRFAOFKBGASW-UHFFFAOYSA-M Glycolate Chemical compound OCC([O-])=O AEMRFAOFKBGASW-UHFFFAOYSA-M 0.000 description 1
- 239000007821 HATU Substances 0.000 description 1
- 239000007995 HEPES buffer Substances 0.000 description 1
- 229910004373 HOAc Inorganic materials 0.000 description 1
- 241000162682 Heterogen Species 0.000 description 1
- CPELXLSAUQHCOX-UHFFFAOYSA-N Hydrogen bromide Chemical compound Br CPELXLSAUQHCOX-UHFFFAOYSA-N 0.000 description 1
- 102000009438 IgE Receptors Human genes 0.000 description 1
- 108010073816 IgE Receptors Proteins 0.000 description 1
- 102000004195 Isomerases Human genes 0.000 description 1
- 108090000769 Isomerases Proteins 0.000 description 1
- CKLJMWTZIZZHCS-REOHCLBHSA-N L-aspartic acid Chemical compound OC(=O)[C@@H](N)CC(O)=O CKLJMWTZIZZHCS-REOHCLBHSA-N 0.000 description 1
- WHUUTDBJXJRKMK-VKHMYHEASA-N L-glutamic acid Chemical compound OC(=O)[C@@H](N)CCC(O)=O WHUUTDBJXJRKMK-VKHMYHEASA-N 0.000 description 1
- KDXKERNSBIXSRK-YFKPBYRVSA-N L-lysine Chemical compound NCCCC[C@H](N)C(O)=O KDXKERNSBIXSRK-YFKPBYRVSA-N 0.000 description 1
- 229930182821 L-proline Natural products 0.000 description 1
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
- YDQJXVYGARVLRT-UHFFFAOYSA-N Lepidine Natural products C=1C=CC(CC=2NC=CN=2)=CC=1OC=1C(OC)=CC=CC=1CC1=NC=CN1 YDQJXVYGARVLRT-UHFFFAOYSA-N 0.000 description 1
- 240000007472 Leucaena leucocephala Species 0.000 description 1
- 235000010643 Leucaena leucocephala Nutrition 0.000 description 1
- 239000002841 Lewis acid Substances 0.000 description 1
- WHXSMMKQMYFTQS-UHFFFAOYSA-N Lithium Chemical compound [Li] WHXSMMKQMYFTQS-UHFFFAOYSA-N 0.000 description 1
- 239000012448 Lithium borohydride Substances 0.000 description 1
- 239000004472 Lysine Substances 0.000 description 1
- KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 description 1
- FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 description 1
- OFOBLEOULBTSOW-UHFFFAOYSA-L Malonate Chemical compound [O-]C(=O)CC([O-])=O OFOBLEOULBTSOW-UHFFFAOYSA-L 0.000 description 1
- 241000699666 Mus <mouse, genus> Species 0.000 description 1
- 101100407310 Mus musculus Ptgdr2 gene Proteins 0.000 description 1
- 241000699670 Mus sp. Species 0.000 description 1
- 206010068871 Myotonic dystrophy Diseases 0.000 description 1
- MNXUOINROUSURF-GFCCVEGCSA-N N(=[N+]=[N-])[C@H](C(=O)NCC1=CC=C(C=C1)OC)C(CO)(C)C Chemical compound N(=[N+]=[N-])[C@H](C(=O)NCC1=CC=C(C=C1)OC)C(CO)(C)C MNXUOINROUSURF-GFCCVEGCSA-N 0.000 description 1
- QIAFMBKCNZACKA-UHFFFAOYSA-N N-benzoylglycine Chemical compound OC(=O)CNC(=O)C1=CC=CC=C1 QIAFMBKCNZACKA-UHFFFAOYSA-N 0.000 description 1
- UEEJHVSXFDXPFK-UHFFFAOYSA-N N-dimethylaminoethanol Chemical compound CN(C)CCO UEEJHVSXFDXPFK-UHFFFAOYSA-N 0.000 description 1
- BMOARJBSKMIHNQ-UHFFFAOYSA-N N1=CC=CC2=CC=CN=C12.[Cl] Chemical compound N1=CC=CC2=CC=CN=C12.[Cl] BMOARJBSKMIHNQ-UHFFFAOYSA-N 0.000 description 1
- 229910002651 NO3 Inorganic materials 0.000 description 1
- UFWIBTONFRDIAS-UHFFFAOYSA-N Naphthalene Chemical compound C1=CC=CC2=CC=CC=C21 UFWIBTONFRDIAS-UHFFFAOYSA-N 0.000 description 1
- DFPAKSUCGFBDDF-UHFFFAOYSA-N Nicotinamide Chemical compound NC(=O)C1=CC=CN=C1 DFPAKSUCGFBDDF-UHFFFAOYSA-N 0.000 description 1
- NHNBFGGVMKEFGY-UHFFFAOYSA-N Nitrate Chemical compound [O-][N+]([O-])=O NHNBFGGVMKEFGY-UHFFFAOYSA-N 0.000 description 1
- UEKLMEOMMDQNEQ-ZTFGCOKTSA-N OC(C)(C)[C@@H]1CC[C@H](CC1)NC(=O)C=1C=NC2=CC(=NC=C2C=1)N1[C@@H](CC1)C Chemical compound OC(C)(C)[C@@H]1CC[C@H](CC1)NC(=O)C=1C=NC2=CC(=NC=C2C=1)N1[C@@H](CC1)C UEKLMEOMMDQNEQ-ZTFGCOKTSA-N 0.000 description 1
- BOOFHDUNARYLHJ-SHTZXODSSA-N OC(C)(C)[C@@H]1CC[C@H](CC1)NC(=O)C=1C=NC2=CC=NC=C2C=1 Chemical compound OC(C)(C)[C@@H]1CC[C@H](CC1)NC(=O)C=1C=NC2=CC=NC=C2C=1 BOOFHDUNARYLHJ-SHTZXODSSA-N 0.000 description 1
- ROWLOFVLOJIUBH-WBAXXEDZSA-N OC(C)(C)[C@@H]1CC[C@H](CC1)NC(=O)C=1C=NC2=NC(=CC=C2C=1)N1[C@H](CC1)C Chemical compound OC(C)(C)[C@@H]1CC[C@H](CC1)NC(=O)C=1C=NC2=NC(=CC=C2C=1)N1[C@H](CC1)C ROWLOFVLOJIUBH-WBAXXEDZSA-N 0.000 description 1
- 208000008589 Obesity Diseases 0.000 description 1
- 229910019142 PO4 Inorganic materials 0.000 description 1
- 108010016731 PPAR gamma Proteins 0.000 description 1
- 244000131316 Panax pseudoginseng Species 0.000 description 1
- 235000005035 Panax pseudoginseng ssp. pseudoginseng Nutrition 0.000 description 1
- 235000003140 Panax quinquefolius Nutrition 0.000 description 1
- 235000019483 Peanut oil Nutrition 0.000 description 1
- 229920002230 Pectic acid Polymers 0.000 description 1
- 102100038825 Peroxisome proliferator-activated receptor gamma Human genes 0.000 description 1
- OAICVXFJPJFONN-UHFFFAOYSA-N Phosphorus Chemical compound [P] OAICVXFJPJFONN-UHFFFAOYSA-N 0.000 description 1
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 1
- ONIBWKKTOPOVIA-UHFFFAOYSA-N Proline Natural products OC(=O)C1CCCN1 ONIBWKKTOPOVIA-UHFFFAOYSA-N 0.000 description 1
- 102100033279 Prostaglandin-H2 D-isomerase Human genes 0.000 description 1
- 101710145576 Prostaglandin-H2 D-isomerase Proteins 0.000 description 1
- 102000001708 Protein Isoforms Human genes 0.000 description 1
- 108010029485 Protein Isoforms Proteins 0.000 description 1
- LCTONWCANYUPML-UHFFFAOYSA-M Pyruvate Chemical compound CC(=O)C([O-])=O LCTONWCANYUPML-UHFFFAOYSA-M 0.000 description 1
- 229940124639 Selective inhibitor Drugs 0.000 description 1
- KEAYESYHFKHZAL-UHFFFAOYSA-N Sodium Chemical compound [Na] KEAYESYHFKHZAL-UHFFFAOYSA-N 0.000 description 1
- 229920002472 Starch Polymers 0.000 description 1
- 235000021355 Stearic acid Nutrition 0.000 description 1
- 229910000831 Steel Inorganic materials 0.000 description 1
- 229930006000 Sucrose Natural products 0.000 description 1
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 1
- QAOWNCQODCNURD-UHFFFAOYSA-L Sulfate Chemical compound [O-]S([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-L 0.000 description 1
- UCKMPCXJQFINFW-UHFFFAOYSA-N Sulphide Chemical compound [S-2] UCKMPCXJQFINFW-UHFFFAOYSA-N 0.000 description 1
- ZMZDMBWJUHKJPS-UHFFFAOYSA-M Thiocyanate anion Chemical compound [S-]C#N ZMZDMBWJUHKJPS-UHFFFAOYSA-M 0.000 description 1
- 102000003938 Thromboxane Receptors Human genes 0.000 description 1
- 108090000300 Thromboxane Receptors Proteins 0.000 description 1
- RHQDFWAXVIIEBN-UHFFFAOYSA-N Trifluoroethanol Chemical compound OCC(F)(F)F RHQDFWAXVIIEBN-UHFFFAOYSA-N 0.000 description 1
- 239000007983 Tris buffer Substances 0.000 description 1
- FNOLLIPINDCSLQ-UHFFFAOYSA-N [Ir+].C1CCCC=CCC1 Chemical class [Ir+].C1CCCC=CCC1 FNOLLIPINDCSLQ-UHFFFAOYSA-N 0.000 description 1
- LUBXGBJCPAOBNR-FJXQXJEOSA-N [Li].ClC=1C=C2C=C(C=NC2=NC1N1[C@H](CC1)C)C(=O)O Chemical compound [Li].ClC=1C=C2C=C(C=NC2=NC1N1[C@H](CC1)C)C(=O)O LUBXGBJCPAOBNR-FJXQXJEOSA-N 0.000 description 1
- ZBIKORITPGTTGI-UHFFFAOYSA-N [acetyloxy(phenyl)-$l^{3}-iodanyl] acetate Chemical compound CC(=O)OI(OC(C)=O)C1=CC=CC=C1 ZBIKORITPGTTGI-UHFFFAOYSA-N 0.000 description 1
- SORGEQQSQGNZFI-UHFFFAOYSA-N [azido(phenoxy)phosphoryl]oxybenzene Chemical compound C=1C=CC=CC=1OP(=O)(N=[N+]=[N-])OC1=CC=CC=C1 SORGEQQSQGNZFI-UHFFFAOYSA-N 0.000 description 1
- DHKHKXVYLBGOIT-UHFFFAOYSA-N acetaldehyde Diethyl Acetal Natural products CCOC(C)OCC DHKHKXVYLBGOIT-UHFFFAOYSA-N 0.000 description 1
- 150000001241 acetals Chemical class 0.000 description 1
- IPBVNPXQWQGGJP-UHFFFAOYSA-N acetic acid phenyl ester Natural products CC(=O)OC1=CC=CC=C1 IPBVNPXQWQGGJP-UHFFFAOYSA-N 0.000 description 1
- 230000003213 activating effect Effects 0.000 description 1
- 230000004913 activation Effects 0.000 description 1
- TTWYZDPBDWHJOR-IDIVVRGQSA-L adenosine triphosphate disodium Chemical compound [Na+].[Na+].C1=NC=2C(N)=NC=NC=2N1[C@@H]1O[C@H](COP(O)(=O)OP(O)(=O)OP([O-])([O-])=O)[C@@H](O)[C@H]1O TTWYZDPBDWHJOR-IDIVVRGQSA-L 0.000 description 1
- WNLRTRBMVRJNCN-UHFFFAOYSA-L adipate(2-) Chemical compound [O-]C(=O)CCCCC([O-])=O WNLRTRBMVRJNCN-UHFFFAOYSA-L 0.000 description 1
- 239000008272 agar Substances 0.000 description 1
- 235000010419 agar Nutrition 0.000 description 1
- 229940072056 alginate Drugs 0.000 description 1
- 235000010443 alginic acid Nutrition 0.000 description 1
- 229920000615 alginic acid Polymers 0.000 description 1
- 239000013566 allergen Substances 0.000 description 1
- AEMOLEFTQBMNLQ-BKBMJHBISA-N alpha-D-galacturonic acid Chemical compound O[C@H]1O[C@H](C(O)=O)[C@H](O)[C@H](O)[C@H]1O AEMOLEFTQBMNLQ-BKBMJHBISA-N 0.000 description 1
- HSFWRNGVRCDJHI-UHFFFAOYSA-N alpha-acetylene Natural products C#C HSFWRNGVRCDJHI-UHFFFAOYSA-N 0.000 description 1
- 229910052782 aluminium Inorganic materials 0.000 description 1
- XAGFODPZIPBFFR-UHFFFAOYSA-N aluminium Chemical compound [Al] XAGFODPZIPBFFR-UHFFFAOYSA-N 0.000 description 1
- 229910000147 aluminium phosphate Inorganic materials 0.000 description 1
- 125000000539 amino acid group Chemical group 0.000 description 1
- 239000003708 ampul Substances 0.000 description 1
- 238000010171 animal model Methods 0.000 description 1
- 210000000612 antigen-presenting cell Anatomy 0.000 description 1
- 239000006286 aqueous extract Substances 0.000 description 1
- 239000008346 aqueous phase Substances 0.000 description 1
- 229940114079 arachidonic acid Drugs 0.000 description 1
- 235000021342 arachidonic acid Nutrition 0.000 description 1
- 210000001367 artery Anatomy 0.000 description 1
- 229940072107 ascorbate Drugs 0.000 description 1
- 235000010323 ascorbic acid Nutrition 0.000 description 1
- 239000011668 ascorbic acid Substances 0.000 description 1
- 229940009098 aspartate Drugs 0.000 description 1
- 208000037875 astrocytosis Diseases 0.000 description 1
- 230000007341 astrogliosis Effects 0.000 description 1
- 239000012298 atmosphere Substances 0.000 description 1
- 125000005602 azabenzimidazolyl group Chemical group 0.000 description 1
- KVVMXWRFYAGASO-UHFFFAOYSA-N azetidine-1-carboxylic acid Chemical compound OC(=O)N1CCC1 KVVMXWRFYAGASO-UHFFFAOYSA-N 0.000 description 1
- 229940076134 benzene Drugs 0.000 description 1
- SRSXLGNVWSONIS-UHFFFAOYSA-M benzenesulfonate Chemical compound [O-]S(=O)(=O)C1=CC=CC=C1 SRSXLGNVWSONIS-UHFFFAOYSA-M 0.000 description 1
- 125000003785 benzimidazolyl group Chemical group N1=C(NC2=C1C=CC=C2)* 0.000 description 1
- 125000004618 benzofuryl group Chemical group O1C(=CC2=C1C=CC=C2)* 0.000 description 1
- WPYMKLBDIGXBTP-UHFFFAOYSA-N benzoic acid Chemical compound OC(=O)C1=CC=CC=C1 WPYMKLBDIGXBTP-UHFFFAOYSA-N 0.000 description 1
- 125000005872 benzooxazolyl group Chemical group 0.000 description 1
- 125000001164 benzothiazolyl group Chemical group S1C(=NC2=C1C=CC=C2)* 0.000 description 1
- 125000004196 benzothienyl group Chemical group S1C(=CC2=C1C=CC=C2)* 0.000 description 1
- MAENYQXBWMNRPA-UHFFFAOYSA-N benzyl N-[1-(2-hydroxy-2-methylpropanoyl)piperidin-4-yl]carbamate Chemical compound OC(C(=O)N1CCC(CC1)NC(OCC1=CC=CC=C1)=O)(C)C MAENYQXBWMNRPA-UHFFFAOYSA-N 0.000 description 1
- KOABFMKJXORINX-WXRRBKDZSA-N benzyl N-[3-[[(2R)-1,1,1-trifluoro-3-hydroxypropan-2-yl]amino]cyclobutyl]carbamate Chemical compound FC([C@@H](CO)NC1CC(C1)NC(OCC1=CC=CC=C1)=O)(F)F KOABFMKJXORINX-WXRRBKDZSA-N 0.000 description 1
- BLHUMHFUYMYSKC-UHFFFAOYSA-N benzyl N-hexan-2-ylcarbamate Chemical compound CCCCC(C)NC(=O)OCc1ccccc1 BLHUMHFUYMYSKC-UHFFFAOYSA-N 0.000 description 1
- 235000019445 benzyl alcohol Nutrition 0.000 description 1
- IFVTZJHWGZSXFD-UHFFFAOYSA-N biphenylene Chemical group C1=CC=C2C3=CC=CC=C3C2=C1 IFVTZJHWGZSXFD-UHFFFAOYSA-N 0.000 description 1
- 229910052797 bismuth Inorganic materials 0.000 description 1
- JCXGWMGPZLAOME-UHFFFAOYSA-N bismuth atom Chemical compound [Bi] JCXGWMGPZLAOME-UHFFFAOYSA-N 0.000 description 1
- 229910000085 borane Inorganic materials 0.000 description 1
- MCQRPQCQMGVWIQ-UHFFFAOYSA-N boron;methylsulfanylmethane Chemical compound [B].CSC MCQRPQCQMGVWIQ-UHFFFAOYSA-N 0.000 description 1
- 210000004556 brain Anatomy 0.000 description 1
- 230000005587 bubbling Effects 0.000 description 1
- 239000007853 buffer solution Substances 0.000 description 1
- 125000004369 butenyl group Chemical group C(=CCC)* 0.000 description 1
- WOBLPDAWNVAVAS-UHFFFAOYSA-N butyl carboxy carbonate Chemical compound CCCCOC(=O)OC(O)=O WOBLPDAWNVAVAS-UHFFFAOYSA-N 0.000 description 1
- AGNSFFFLYAPLCT-UHFFFAOYSA-O butylazanium;azide Chemical compound [N-]=[N+]=[N-].CCCC[NH3+] AGNSFFFLYAPLCT-UHFFFAOYSA-O 0.000 description 1
- 229910052791 calcium Inorganic materials 0.000 description 1
- 239000011575 calcium Substances 0.000 description 1
- 229960005069 calcium Drugs 0.000 description 1
- PASHVRUKOFIRIK-UHFFFAOYSA-L calcium sulfate dihydrate Chemical compound O.O.[Ca+2].[O-]S([O-])(=O)=O PASHVRUKOFIRIK-UHFFFAOYSA-L 0.000 description 1
- MIOPJNTWMNEORI-UHFFFAOYSA-N camphorsulfonic acid Chemical compound C1CC2(CS(O)(=O)=O)C(=O)CC1C2(C)C MIOPJNTWMNEORI-UHFFFAOYSA-N 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- RYTLGWCJESCDMY-UHFFFAOYSA-N carbamimidoyl chloride Chemical compound NC(Cl)=N RYTLGWCJESCDMY-UHFFFAOYSA-N 0.000 description 1
- 239000001569 carbon dioxide Substances 0.000 description 1
- 229910002092 carbon dioxide Inorganic materials 0.000 description 1
- 235000011089 carbon dioxide Nutrition 0.000 description 1
- 125000002915 carbonyl group Chemical group [*:2]C([*:1])=O 0.000 description 1
- 150000001735 carboxylic acids Chemical class 0.000 description 1
- 238000006555 catalytic reaction Methods 0.000 description 1
- 230000020411 cell activation Effects 0.000 description 1
- 210000003169 central nervous system Anatomy 0.000 description 1
- XMPZTFVPEKAKFH-UHFFFAOYSA-P ceric ammonium nitrate Chemical compound [NH4+].[NH4+].[Ce+4].[O-][N+]([O-])=O.[O-][N+]([O-])=O.[O-][N+]([O-])=O.[O-][N+]([O-])=O.[O-][N+]([O-])=O.[O-][N+]([O-])=O XMPZTFVPEKAKFH-UHFFFAOYSA-P 0.000 description 1
- 239000013000 chemical inhibitor Substances 0.000 description 1
- 238000001311 chemical methods and process Methods 0.000 description 1
- 239000007795 chemical reaction product Substances 0.000 description 1
- VDANGULDQQJODZ-UHFFFAOYSA-N chloroprocaine Chemical compound CCN(CC)CCOC(=O)C1=CC=C(N)C=C1Cl VDANGULDQQJODZ-UHFFFAOYSA-N 0.000 description 1
- 229960002023 chloroprocaine Drugs 0.000 description 1
- IJOOHPMOJXWVHK-UHFFFAOYSA-N chlorotrimethylsilane Chemical compound C[Si](C)(C)Cl IJOOHPMOJXWVHK-UHFFFAOYSA-N 0.000 description 1
- OEYIOHPDSNJKLS-UHFFFAOYSA-N choline Chemical compound C[N+](C)(C)CCO OEYIOHPDSNJKLS-UHFFFAOYSA-N 0.000 description 1
- 229960001231 choline Drugs 0.000 description 1
- 229910052804 chromium Inorganic materials 0.000 description 1
- 239000011651 chromium Substances 0.000 description 1
- 238000003200 chromosome mapping Methods 0.000 description 1
- 229940114081 cinnamate Drugs 0.000 description 1
- 238000005352 clarification Methods 0.000 description 1
- CJXAEXPPLWQRFR-UHFFFAOYSA-N clemizole Chemical compound C1=CC(Cl)=CC=C1CN1C2=CC=CC=C2N=C1CN1CCCC1 CJXAEXPPLWQRFR-UHFFFAOYSA-N 0.000 description 1
- 229950002020 clemizole Drugs 0.000 description 1
- 238000011260 co-administration Methods 0.000 description 1
- 239000000084 colloidal system Substances 0.000 description 1
- 239000012230 colorless oil Substances 0.000 description 1
- 238000009833 condensation Methods 0.000 description 1
- 238000006482 condensation reaction Methods 0.000 description 1
- 238000004132 cross linking Methods 0.000 description 1
- 238000006880 cross-coupling reaction Methods 0.000 description 1
- 125000004122 cyclic group Chemical group 0.000 description 1
- KTHXBEHDVMTNOH-UHFFFAOYSA-N cyclobutanol Chemical compound OC1CCC1 KTHXBEHDVMTNOH-UHFFFAOYSA-N 0.000 description 1
- 125000001047 cyclobutenyl group Chemical group C1(=CCC1)* 0.000 description 1
- 125000000582 cycloheptyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C1([H])[H] 0.000 description 1
- HPXRVTGHNJAIIH-UHFFFAOYSA-N cyclohexanol Chemical compound OC1CCCCC1 HPXRVTGHNJAIIH-UHFFFAOYSA-N 0.000 description 1
- 125000000596 cyclohexenyl group Chemical group C1(=CCCCC1)* 0.000 description 1
- SNRCKKQHDUIRIY-UHFFFAOYSA-L cyclopenta-1,4-dien-1-yl(diphenyl)phosphane;dichloromethane;dichloropalladium;iron(2+) Chemical compound [Fe+2].ClCCl.Cl[Pd]Cl.C1=C[CH-]C(P(C=2C=CC=CC=2)C=2C=CC=CC=2)=C1.C1=C[CH-]C(P(C=2C=CC=CC=2)C=2C=CC=CC=2)=C1 SNRCKKQHDUIRIY-UHFFFAOYSA-L 0.000 description 1
- 125000002433 cyclopentenyl group Chemical group C1(=CCCC1)* 0.000 description 1
- 229960002887 deanol Drugs 0.000 description 1
- GHVNFZFCNZKVNT-UHFFFAOYSA-M decanoate Chemical compound CCCCCCCCCC([O-])=O GHVNFZFCNZKVNT-UHFFFAOYSA-M 0.000 description 1
- 125000002704 decyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- 239000007857 degradation product Substances 0.000 description 1
- 230000001627 detrimental effect Effects 0.000 description 1
- 229910052805 deuterium Inorganic materials 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 230000018109 developmental process Effects 0.000 description 1
- 206010012601 diabetes mellitus Diseases 0.000 description 1
- 239000012973 diazabicyclooctane Substances 0.000 description 1
- RAABOESOVLLHRU-UHFFFAOYSA-N diazene Chemical compound N=N RAABOESOVLLHRU-UHFFFAOYSA-N 0.000 description 1
- 229910000071 diazene Inorganic materials 0.000 description 1
- 238000006193 diazotization reaction Methods 0.000 description 1
- 235000005911 diet Nutrition 0.000 description 1
- 230000037213 diet Effects 0.000 description 1
- ZBCBWPMODOFKDW-UHFFFAOYSA-N diethanolamine Chemical compound OCCNCCO ZBCBWPMODOFKDW-UHFFFAOYSA-N 0.000 description 1
- HPNMFZURTQLUMO-UHFFFAOYSA-N diethylamine Chemical compound CCNCC HPNMFZURTQLUMO-UHFFFAOYSA-N 0.000 description 1
- UCXUKTLCVSGCNR-UHFFFAOYSA-N diethylsilane Chemical compound CC[SiH2]CC UCXUKTLCVSGCNR-UHFFFAOYSA-N 0.000 description 1
- OOKFLLNDYNWCHK-UHFFFAOYSA-N difluoromethyl(trimethyl)silane Chemical compound C[Si](C)(C)C(F)F OOKFLLNDYNWCHK-UHFFFAOYSA-N 0.000 description 1
- 125000004852 dihydrofuranyl group Chemical group O1C(CC=C1)* 0.000 description 1
- 239000003085 diluting agent Substances 0.000 description 1
- 239000012972 dimethylethanolamine Substances 0.000 description 1
- CHVYWISGAZDJOG-UHFFFAOYSA-N disodium;diazide Chemical compound [Na+].[Na+].[N-]=[N+]=[N-].[N-]=[N+]=[N-] CHVYWISGAZDJOG-UHFFFAOYSA-N 0.000 description 1
- POULHZVOKOAJMA-UHFFFAOYSA-M dodecanoate Chemical compound CCCCCCCCCCCC([O-])=O POULHZVOKOAJMA-UHFFFAOYSA-M 0.000 description 1
- 229960003638 dopamine Drugs 0.000 description 1
- 231100000673 dose–response relationship Toxicity 0.000 description 1
- 238000009510 drug design Methods 0.000 description 1
- 229940009662 edetate Drugs 0.000 description 1
- 229960001484 edetic acid Drugs 0.000 description 1
- 239000003480 eluent Substances 0.000 description 1
- 229950005627 embonate Drugs 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 150000002085 enols Chemical class 0.000 description 1
- 210000002919 epithelial cell Anatomy 0.000 description 1
- AFAXGSQYZLGZPG-UHFFFAOYSA-L ethane-1,2-disulfonate Chemical compound [O-]S(=O)(=O)CCS([O-])(=O)=O AFAXGSQYZLGZPG-UHFFFAOYSA-L 0.000 description 1
- CCIVGXIOQKPBKL-UHFFFAOYSA-M ethanesulfonate Chemical compound CCS([O-])(=O)=O CCIVGXIOQKPBKL-UHFFFAOYSA-M 0.000 description 1
- JFWURCREFDQUTD-UHFFFAOYSA-N ethyl 1,8-naphthyridine-3-carboxylate Chemical compound N1=CC=CC2=CC(C(=O)OCC)=CN=C21 JFWURCREFDQUTD-UHFFFAOYSA-N 0.000 description 1
- JBNGZIXONGGHIT-UHFFFAOYSA-N ethyl 2-amino-6-chloropyridine-3-carboxylate Chemical compound CCOC(=O)C1=CC=C(Cl)N=C1N JBNGZIXONGGHIT-UHFFFAOYSA-N 0.000 description 1
- KTVUZBJHOAPDGC-UHFFFAOYSA-N ethyl 3-hydroxycyclobutane-1-carboxylate Chemical compound CCOC(=O)C1CC(O)C1 KTVUZBJHOAPDGC-UHFFFAOYSA-N 0.000 description 1
- AAUBVINEXCCXOK-UHFFFAOYSA-N ethyl 4,6-dichloropyridine-3-carboxylate Chemical compound CCOC(=O)C1=CN=C(Cl)C=C1Cl AAUBVINEXCCXOK-UHFFFAOYSA-N 0.000 description 1
- SNNHLSHDDGJVDM-UHFFFAOYSA-N ethyl 4-chloro-2-methylsulfanylpyrimidine-5-carboxylate Chemical compound CCOC(=O)C1=CN=C(SC)N=C1Cl SNNHLSHDDGJVDM-UHFFFAOYSA-N 0.000 description 1
- 238000003810 ethyl acetate extraction Methods 0.000 description 1
- DEQYTNZJHKPYEZ-UHFFFAOYSA-N ethyl acetate;heptane Chemical compound CCOC(C)=O.CCCCCCC DEQYTNZJHKPYEZ-UHFFFAOYSA-N 0.000 description 1
- OAYLNYINCPYISS-UHFFFAOYSA-N ethyl acetate;hexane Chemical compound CCCCCC.CCOC(C)=O OAYLNYINCPYISS-UHFFFAOYSA-N 0.000 description 1
- 229940012017 ethylenediamine Drugs 0.000 description 1
- 229940071106 ethylenediaminetetraacetate Drugs 0.000 description 1
- 125000000219 ethylidene group Chemical group [H]C(=[*])C([H])([H])[H] 0.000 description 1
- 125000002534 ethynyl group Chemical group [H]C#C* 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 238000013265 extended release Methods 0.000 description 1
- 239000000284 extract Substances 0.000 description 1
- 210000003414 extremity Anatomy 0.000 description 1
- 230000001815 facial effect Effects 0.000 description 1
- 229960004979 fampridine Drugs 0.000 description 1
- 230000004761 fibrosis Effects 0.000 description 1
- 238000011049 filling Methods 0.000 description 1
- GVEPBJHOBDJJJI-UHFFFAOYSA-N fluoranthrene Natural products C1=CC(C2=CC=CC=C22)=C3C2=CC=CC3=C1 GVEPBJHOBDJJJI-UHFFFAOYSA-N 0.000 description 1
- 125000003983 fluorenyl group Chemical group C1(=CC=CC=2C3=CC=CC=C3CC12)* 0.000 description 1
- 238000011010 flushing procedure Methods 0.000 description 1
- WSFSSNUMVMOOMR-UHFFFAOYSA-N formaldehyde Substances O=C WSFSSNUMVMOOMR-UHFFFAOYSA-N 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- ZYXBIOIYWUIXSM-UHFFFAOYSA-N furo[2,3-c]pyridine Chemical compound C1=NC=C2OC=CC2=C1 ZYXBIOIYWUIXSM-UHFFFAOYSA-N 0.000 description 1
- KQGXYVJZOMKLSA-UHFFFAOYSA-N furo[2,3-d]pyrimidine Chemical compound N1=CN=C2OC=CC2=C1 KQGXYVJZOMKLSA-UHFFFAOYSA-N 0.000 description 1
- 125000002541 furyl group Chemical group 0.000 description 1
- DSLZVSRJTYRBFB-DUHBMQHGSA-N galactaric acid Chemical compound OC(=O)[C@H](O)[C@@H](O)[C@@H](O)[C@H](O)C(O)=O DSLZVSRJTYRBFB-DUHBMQHGSA-N 0.000 description 1
- 239000008273 gelatin Substances 0.000 description 1
- 229920000159 gelatin Polymers 0.000 description 1
- 239000007903 gelatin capsule Substances 0.000 description 1
- 235000019322 gelatine Nutrition 0.000 description 1
- 235000011852 gelatine desserts Nutrition 0.000 description 1
- 229940114119 gentisate Drugs 0.000 description 1
- 235000008434 ginseng Nutrition 0.000 description 1
- 239000012362 glacial acetic acid Substances 0.000 description 1
- 239000011521 glass Substances 0.000 description 1
- 229960001731 gluceptate Drugs 0.000 description 1
- KWMLJOLKUYYJFJ-VFUOTHLCSA-N glucoheptonic acid Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)[C@@H](O)C(O)=O KWMLJOLKUYYJFJ-VFUOTHLCSA-N 0.000 description 1
- 229940050410 gluconate Drugs 0.000 description 1
- 229940097042 glucuronate Drugs 0.000 description 1
- 229930195712 glutamate Natural products 0.000 description 1
- 229940049906 glutamate Drugs 0.000 description 1
- JFCQEDHGNNZCLN-UHFFFAOYSA-N glutaric acid Chemical compound OC(=O)CCCC(O)=O JFCQEDHGNNZCLN-UHFFFAOYSA-N 0.000 description 1
- 229940074045 glyceryl distearate Drugs 0.000 description 1
- 229940075507 glyceryl monostearate Drugs 0.000 description 1
- 229940046257 glyceryl phosphate Drugs 0.000 description 1
- 239000010440 gypsum Substances 0.000 description 1
- 229910052602 gypsum Inorganic materials 0.000 description 1
- 229910052736 halogen Inorganic materials 0.000 description 1
- 125000005843 halogen group Chemical group 0.000 description 1
- 238000005658 halogenation reaction Methods 0.000 description 1
- 150000002367 halogens Chemical class 0.000 description 1
- 230000011132 hemopoiesis Effects 0.000 description 1
- 239000008241 heterogeneous mixture Substances 0.000 description 1
- IPCSVZSSVZVIGE-UHFFFAOYSA-M hexadecanoate Chemical compound CCCCCCCCCCCCCCCC([O-])=O IPCSVZSSVZVIGE-UHFFFAOYSA-M 0.000 description 1
- 229960002885 histidine Drugs 0.000 description 1
- 229940088597 hormone Drugs 0.000 description 1
- 239000005556 hormone Substances 0.000 description 1
- 210000005260 human cell Anatomy 0.000 description 1
- XGIHQYAWBCFNPY-AZOCGYLKSA-N hydrabamine Chemical compound C([C@@H]12)CC3=CC(C(C)C)=CC=C3[C@@]2(C)CCC[C@@]1(C)CNCCNC[C@@]1(C)[C@@H]2CCC3=CC(C(C)C)=CC=C3[C@@]2(C)CCC1 XGIHQYAWBCFNPY-AZOCGYLKSA-N 0.000 description 1
- 150000007857 hydrazones Chemical class 0.000 description 1
- 150000002430 hydrocarbons Chemical group 0.000 description 1
- XMBWDFGMSWQBCA-UHFFFAOYSA-N hydrogen iodide Chemical compound I XMBWDFGMSWQBCA-UHFFFAOYSA-N 0.000 description 1
- ZMZDMBWJUHKJPS-UHFFFAOYSA-N hydrogen thiocyanate Natural products SC#N ZMZDMBWJUHKJPS-UHFFFAOYSA-N 0.000 description 1
- QAOWNCQODCNURD-UHFFFAOYSA-M hydrogensulfate Chemical compound OS([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-M 0.000 description 1
- NPZTUJOABDZTLV-UHFFFAOYSA-N hydroxybenzotriazole Substances O=C1C=CC=C2NNN=C12 NPZTUJOABDZTLV-UHFFFAOYSA-N 0.000 description 1
- 125000002883 imidazolyl group Chemical group 0.000 description 1
- 210000002865 immune cell Anatomy 0.000 description 1
- 239000007943 implant Substances 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 201000008319 inclusion body myositis Diseases 0.000 description 1
- 125000003453 indazolyl group Chemical group N1N=C(C2=C1C=CC=C2)* 0.000 description 1
- PZOUSPYUWWUPPK-UHFFFAOYSA-N indole Natural products CC1=CC=CC2=C1C=CN2 PZOUSPYUWWUPPK-UHFFFAOYSA-N 0.000 description 1
- RKJUIXBNRJVNHR-UHFFFAOYSA-N indolenine Natural products C1=CC=C2CC=NC2=C1 RKJUIXBNRJVNHR-UHFFFAOYSA-N 0.000 description 1
- 125000001041 indolyl group Chemical group 0.000 description 1
- 230000006698 induction Effects 0.000 description 1
- 230000001939 inductive effect Effects 0.000 description 1
- 210000004969 inflammatory cell Anatomy 0.000 description 1
- 238000001802 infusion Methods 0.000 description 1
- 239000004615 ingredient Substances 0.000 description 1
- 230000003993 interaction Effects 0.000 description 1
- UEXQBEVWFZKHNB-UHFFFAOYSA-N intermediate 29 Natural products C1=CC(N)=CC=C1NC1=NC=CC=N1 UEXQBEVWFZKHNB-UHFFFAOYSA-N 0.000 description 1
- 238000007918 intramuscular administration Methods 0.000 description 1
- 238000007913 intrathecal administration Methods 0.000 description 1
- 238000001990 intravenous administration Methods 0.000 description 1
- 238000007914 intraventricular administration Methods 0.000 description 1
- 239000011630 iodine Substances 0.000 description 1
- INQOMBQAUSQDDS-UHFFFAOYSA-N iodomethane Chemical compound IC INQOMBQAUSQDDS-UHFFFAOYSA-N 0.000 description 1
- OWFXIOWLTKNBAP-UHFFFAOYSA-N isoamyl nitrite Chemical compound CC(C)CCON=O OWFXIOWLTKNBAP-UHFFFAOYSA-N 0.000 description 1
- 125000000959 isobutyl group Chemical group [H]C([H])([H])C([H])(C([H])([H])[H])C([H])([H])* 0.000 description 1
- KQNPFQTWMSNSAP-UHFFFAOYSA-N isobutyric acid Chemical compound CC(C)C(O)=O KQNPFQTWMSNSAP-UHFFFAOYSA-N 0.000 description 1
- 125000000904 isoindolyl group Chemical group C=1(NC=C2C=CC=CC12)* 0.000 description 1
- 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 1
- 125000002183 isoquinolinyl group Chemical group C1(=NC=CC2=CC=CC=C12)* 0.000 description 1
- 125000001786 isothiazolyl group Chemical group 0.000 description 1
- 239000008101 lactose Substances 0.000 description 1
- 229940070765 laurate Drugs 0.000 description 1
- 210000000265 leukocyte Anatomy 0.000 description 1
- 150000007517 lewis acids Chemical class 0.000 description 1
- 239000003446 ligand Substances 0.000 description 1
- 230000000670 limiting effect Effects 0.000 description 1
- 239000006194 liquid suspension Substances 0.000 description 1
- 229910052744 lithium Inorganic materials 0.000 description 1
- ISPYVDNETJDQER-QRPNPIFTSA-M lithium 7-[(2S)-2-methylazetidin-1-yl]-1,6-naphthyridine-3-carboxylate Chemical compound C[C@@H]1N(CC1)C1=NC=C2C=C(C=NC2=C1)C(=O)[O-].[Li+] ISPYVDNETJDQER-QRPNPIFTSA-M 0.000 description 1
- 159000000002 lithium salts Chemical class 0.000 description 1
- NRUBUZBAZRTHHX-UHFFFAOYSA-N lithium;propan-2-ylazanide Chemical compound [Li+].CC(C)[NH-] NRUBUZBAZRTHHX-UHFFFAOYSA-N 0.000 description 1
- 239000007937 lozenge Substances 0.000 description 1
- 210000002540 macrophage Anatomy 0.000 description 1
- 239000011777 magnesium Substances 0.000 description 1
- 229910052749 magnesium Inorganic materials 0.000 description 1
- 235000019359 magnesium stearate Nutrition 0.000 description 1
- 229940049920 malate Drugs 0.000 description 1
- VZCYOOQTPOCHFL-UPHRSURJSA-N maleic acid Chemical compound OC(=O)\C=C/C(O)=O VZCYOOQTPOCHFL-UPHRSURJSA-N 0.000 description 1
- BJEPYKJPYRNKOW-UHFFFAOYSA-N malic acid Chemical compound OC(=O)C(O)CC(O)=O BJEPYKJPYRNKOW-UHFFFAOYSA-N 0.000 description 1
- IWYDHOAUDWTVEP-UHFFFAOYSA-M mandelate Chemical compound [O-]C(=O)C(O)C1=CC=CC=C1 IWYDHOAUDWTVEP-UHFFFAOYSA-M 0.000 description 1
- 239000011159 matrix material Substances 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 238000013160 medical therapy Methods 0.000 description 1
- 229960003194 meglumine Drugs 0.000 description 1
- 208000030159 metabolic disease Diseases 0.000 description 1
- 230000002503 metabolic effect Effects 0.000 description 1
- 230000004060 metabolic process Effects 0.000 description 1
- 239000002207 metabolite Substances 0.000 description 1
- 229910052751 metal Inorganic materials 0.000 description 1
- 239000002184 metal Substances 0.000 description 1
- GXHMMDRXHUIUMN-UHFFFAOYSA-N methanesulfonic acid Chemical compound CS(O)(=O)=O.CS(O)(=O)=O GXHMMDRXHUIUMN-UHFFFAOYSA-N 0.000 description 1
- FUZYFWJHBYRPIP-UHFFFAOYSA-N methyl 2-methylheptanoate Chemical compound CCCCCC(C)C(=O)OC FUZYFWJHBYRPIP-UHFFFAOYSA-N 0.000 description 1
- 150000004702 methyl esters Chemical class 0.000 description 1
- JZMJDSHXVKJFKW-UHFFFAOYSA-M methyl sulfate(1-) Chemical compound COS([O-])(=O)=O JZMJDSHXVKJFKW-UHFFFAOYSA-M 0.000 description 1
- GDOPTJXRTPNYNR-UHFFFAOYSA-N methyl-cyclopentane Natural products CC1CCCC1 GDOPTJXRTPNYNR-UHFFFAOYSA-N 0.000 description 1
- 239000002480 mineral oil Substances 0.000 description 1
- 235000010446 mineral oil Nutrition 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 239000012452 mother liquor Substances 0.000 description 1
- 238000010172 mouse model Methods 0.000 description 1
- 230000009756 muscle regeneration Effects 0.000 description 1
- 208000017445 musculoskeletal system disease Diseases 0.000 description 1
- 210000001087 myotubule Anatomy 0.000 description 1
- ACYBVNYNIZTUIL-UHFFFAOYSA-N n'-benzylethane-1,2-diamine Chemical compound NCCNCC1=CC=CC=C1 ACYBVNYNIZTUIL-UHFFFAOYSA-N 0.000 description 1
- 125000004108 n-butyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- 125000004123 n-propyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- 125000001624 naphthyl group Chemical group 0.000 description 1
- 125000004593 naphthyridinyl group Chemical group N1=C(C=CC2=CC=CN=C12)* 0.000 description 1
- 230000001338 necrotic effect Effects 0.000 description 1
- 101150006061 neur gene Proteins 0.000 description 1
- 210000004498 neuroglial cell Anatomy 0.000 description 1
- 238000002610 neuroimaging Methods 0.000 description 1
- 230000003959 neuroinflammation Effects 0.000 description 1
- 229960002715 nicotine Drugs 0.000 description 1
- SNICXCGAKADSCV-UHFFFAOYSA-N nicotine Natural products CN1CCCC1C1=CC=CN=C1 SNICXCGAKADSCV-UHFFFAOYSA-N 0.000 description 1
- 229960003512 nicotinic acid Drugs 0.000 description 1
- 231100000252 nontoxic Toxicity 0.000 description 1
- 230000003000 nontoxic effect Effects 0.000 description 1
- 239000012038 nucleophile Substances 0.000 description 1
- 235000020824 obesity Nutrition 0.000 description 1
- OQCDKBAXFALNLD-UHFFFAOYSA-N octadecanoic acid Natural products CCCCCCCC(C)CCCCCCCCC(O)=O OQCDKBAXFALNLD-UHFFFAOYSA-N 0.000 description 1
- WWZKQHOCKIZLMA-UHFFFAOYSA-M octanoate Chemical compound CCCCCCCC([O-])=O WWZKQHOCKIZLMA-UHFFFAOYSA-M 0.000 description 1
- 229940049964 oleate Drugs 0.000 description 1
- ZQPPMHVWECSIRJ-KTKRTIGZSA-M oleate Chemical compound CCCCCCCC\C=C/CCCCCCCC([O-])=O ZQPPMHVWECSIRJ-KTKRTIGZSA-M 0.000 description 1
- 239000004006 olive oil Substances 0.000 description 1
- 235000008390 olive oil Nutrition 0.000 description 1
- RXCVUXLCNLVYIA-UHFFFAOYSA-N orthocarbonic acid Chemical compound OC(O)(O)O RXCVUXLCNLVYIA-UHFFFAOYSA-N 0.000 description 1
- 125000003566 oxetanyl group Chemical group 0.000 description 1
- GSWAOPJLTADLTN-UHFFFAOYSA-N oxidanimine Chemical compound [O-][NH3+] GSWAOPJLTADLTN-UHFFFAOYSA-N 0.000 description 1
- 229910003445 palladium oxide Inorganic materials 0.000 description 1
- LXNAVEXFUKBNMK-UHFFFAOYSA-N palladium(II) acetate Substances [Pd].CC(O)=O.CC(O)=O LXNAVEXFUKBNMK-UHFFFAOYSA-N 0.000 description 1
- YJVFFLUZDVXJQI-UHFFFAOYSA-L palladium(ii) acetate Chemical compound [Pd+2].CC([O-])=O.CC([O-])=O YJVFFLUZDVXJQI-UHFFFAOYSA-L 0.000 description 1
- JQPTYAILLJKUCY-UHFFFAOYSA-N palladium(ii) oxide Chemical compound [O-2].[Pd+2] JQPTYAILLJKUCY-UHFFFAOYSA-N 0.000 description 1
- 229940014662 pantothenate Drugs 0.000 description 1
- 235000019161 pantothenic acid Nutrition 0.000 description 1
- 239000011713 pantothenic acid Substances 0.000 description 1
- 230000036961 partial effect Effects 0.000 description 1
- 230000037361 pathway Effects 0.000 description 1
- 239000000312 peanut oil Substances 0.000 description 1
- 239000001814 pectin Substances 0.000 description 1
- 235000010987 pectin Nutrition 0.000 description 1
- 229920001277 pectin Polymers 0.000 description 1
- 235000019371 penicillin G benzathine Nutrition 0.000 description 1
- 125000001147 pentyl group Chemical group C(CCCC)* 0.000 description 1
- 150000002978 peroxides Chemical class 0.000 description 1
- JRKICGRDRMAZLK-UHFFFAOYSA-L peroxydisulfate Chemical compound [O-]S(=O)(=O)OOS([O-])(=O)=O JRKICGRDRMAZLK-UHFFFAOYSA-L 0.000 description 1
- 229950010879 phenamine Drugs 0.000 description 1
- LQJARUQXWJSDFL-UHFFFAOYSA-N phenamine Chemical compound CCOC1=CC=C(NC(=O)CN)C=C1 LQJARUQXWJSDFL-UHFFFAOYSA-N 0.000 description 1
- DDBREPKUVSBGFI-UHFFFAOYSA-N phenobarbital Chemical compound C=1C=CC=CC=1C1(CC)C(=O)NC(=O)NC1=O DDBREPKUVSBGFI-UHFFFAOYSA-N 0.000 description 1
- 229940049953 phenylacetate Drugs 0.000 description 1
- WLJVXDMOQOGPHL-UHFFFAOYSA-N phenylacetic acid Chemical compound OC(=O)CC1=CC=CC=C1 WLJVXDMOQOGPHL-UHFFFAOYSA-N 0.000 description 1
- 239000010452 phosphate Substances 0.000 description 1
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 1
- XYFCBTPGUUZFHI-UHFFFAOYSA-O phosphonium Chemical compound [PH4+] XYFCBTPGUUZFHI-UHFFFAOYSA-O 0.000 description 1
- 229910052698 phosphorus Inorganic materials 0.000 description 1
- 239000011574 phosphorus Substances 0.000 description 1
- XKJCHHZQLQNZHY-UHFFFAOYSA-N phthalimide Chemical compound C1=CC=C2C(=O)NC(=O)C2=C1 XKJCHHZQLQNZHY-UHFFFAOYSA-N 0.000 description 1
- 230000036314 physical performance Effects 0.000 description 1
- 239000002504 physiological saline solution Substances 0.000 description 1
- 239000011591 potassium Substances 0.000 description 1
- 229910052700 potassium Inorganic materials 0.000 description 1
- 229960003975 potassium Drugs 0.000 description 1
- 229910000027 potassium carbonate Inorganic materials 0.000 description 1
- 230000003389 potentiating effect Effects 0.000 description 1
- 238000003825 pressing Methods 0.000 description 1
- 230000003449 preventive effect Effects 0.000 description 1
- MFDFERRIHVXMIY-UHFFFAOYSA-N procaine Chemical compound CCN(CC)CCOC(=O)C1=CC=C(N)C=C1 MFDFERRIHVXMIY-UHFFFAOYSA-N 0.000 description 1
- 229960004919 procaine Drugs 0.000 description 1
- 230000001737 promoting effect Effects 0.000 description 1
- VVWRJUBEIPHGQF-UHFFFAOYSA-N propan-2-yl n-propan-2-yloxycarbonyliminocarbamate Chemical compound CC(C)OC(=O)N=NC(=O)OC(C)C VVWRJUBEIPHGQF-UHFFFAOYSA-N 0.000 description 1
- UORVCLMRJXCDCP-UHFFFAOYSA-N propynoic acid Chemical compound OC(=O)C#C UORVCLMRJXCDCP-UHFFFAOYSA-N 0.000 description 1
- 150000003163 prostaglandin D2 derivatives Chemical class 0.000 description 1
- YIBNHAJFJUQSRA-YNNPMVKQSA-N prostaglandin H2 Chemical compound C1[C@@H]2OO[C@H]1[C@H](/C=C/[C@@H](O)CCCCC)[C@H]2C\C=C/CCCC(O)=O YIBNHAJFJUQSRA-YNNPMVKQSA-N 0.000 description 1
- 108090000623 proteins and genes Proteins 0.000 description 1
- 125000001042 pteridinyl group Chemical group N1=C(N=CC2=NC=CN=C12)* 0.000 description 1
- 125000000561 purinyl group Chemical group N1=C(N=C2N=CNC2=C1)* 0.000 description 1
- 125000003226 pyrazolyl group Chemical group 0.000 description 1
- UBQKCCHYAOITMY-UHFFFAOYSA-N pyridin-2-ol Chemical compound OC1=CC=CC=N1 UBQKCCHYAOITMY-UHFFFAOYSA-N 0.000 description 1
- 125000000714 pyrimidinyl group Chemical group 0.000 description 1
- 229940043131 pyroglutamate Drugs 0.000 description 1
- 125000000168 pyrrolyl group Chemical group 0.000 description 1
- 229940076788 pyruvate Drugs 0.000 description 1
- 125000002294 quinazolinyl group Chemical group N1=C(N=CC2=CC=CC=C12)* 0.000 description 1
- 125000002943 quinolinyl group Chemical group N1=C(C=CC2=CC=CC=C12)* 0.000 description 1
- 150000003254 radicals Chemical class 0.000 description 1
- 238000001953 recrystallisation Methods 0.000 description 1
- 230000003252 repetitive effect Effects 0.000 description 1
- 230000001850 reproductive effect Effects 0.000 description 1
- 238000004366 reverse phase liquid chromatography Methods 0.000 description 1
- 230000002441 reversible effect Effects 0.000 description 1
- YGSDEFSMJLZEOE-UHFFFAOYSA-M salicylate Chemical compound OC1=CC=CC=C1C([O-])=O YGSDEFSMJLZEOE-UHFFFAOYSA-M 0.000 description 1
- 229960001860 salicylate Drugs 0.000 description 1
- 238000007790 scraping Methods 0.000 description 1
- 229940076279 serotonin Drugs 0.000 description 1
- 229910052710 silicon Inorganic materials 0.000 description 1
- 239000010703 silicon Substances 0.000 description 1
- 239000000377 silicon dioxide Substances 0.000 description 1
- 238000002603 single-photon emission computed tomography Methods 0.000 description 1
- 210000003491 skin Anatomy 0.000 description 1
- 150000003384 small molecules Chemical class 0.000 description 1
- WRIKHQLVHPKCJU-UHFFFAOYSA-N sodium bis(trimethylsilyl)amide Chemical compound C[Si](C)(C)N([Na])[Si](C)(C)C WRIKHQLVHPKCJU-UHFFFAOYSA-N 0.000 description 1
- WBHQBSYUUJJSRZ-UHFFFAOYSA-M sodium bisulfate Chemical class [Na+].OS([O-])(=O)=O WBHQBSYUUJJSRZ-UHFFFAOYSA-M 0.000 description 1
- 239000012312 sodium hydride Substances 0.000 description 1
- 229910000104 sodium hydride Inorganic materials 0.000 description 1
- RSIJVJUOQBWMIM-UHFFFAOYSA-L sodium sulfate decahydrate Chemical compound O.O.O.O.O.O.O.O.O.O.[Na+].[Na+].[O-]S([O-])(=O)=O RSIJVJUOQBWMIM-UHFFFAOYSA-L 0.000 description 1
- 229940063675 spermine Drugs 0.000 description 1
- 210000000278 spinal cord Anatomy 0.000 description 1
- LBJQKYPPYSCCBH-UHFFFAOYSA-N spiro[3.3]heptane Chemical group C1CCC21CCC2 LBJQKYPPYSCCBH-UHFFFAOYSA-N 0.000 description 1
- 239000008107 starch Substances 0.000 description 1
- 235000019698 starch Nutrition 0.000 description 1
- 239000008117 stearic acid Substances 0.000 description 1
- 239000010959 steel Substances 0.000 description 1
- 238000005728 strengthening Methods 0.000 description 1
- 229910052712 strontium Inorganic materials 0.000 description 1
- CIOAGBVUUVVLOB-UHFFFAOYSA-N strontium atom Chemical compound [Sr] CIOAGBVUUVVLOB-UHFFFAOYSA-N 0.000 description 1
- 238000007920 subcutaneous administration Methods 0.000 description 1
- KDYFGRWQOYBRFD-UHFFFAOYSA-L succinate(2-) Chemical compound [O-]C(=O)CCC([O-])=O KDYFGRWQOYBRFD-UHFFFAOYSA-L 0.000 description 1
- 239000005720 sucrose Substances 0.000 description 1
- IIACRCGMVDHOTQ-UHFFFAOYSA-M sulfamate Chemical compound NS([O-])(=O)=O IIACRCGMVDHOTQ-UHFFFAOYSA-M 0.000 description 1
- 238000010189 synthetic method Methods 0.000 description 1
- 239000003826 tablet Substances 0.000 description 1
- 239000000454 talc Substances 0.000 description 1
- 229910052623 talc Inorganic materials 0.000 description 1
- 235000012222 talc Nutrition 0.000 description 1
- 229950002757 teoclate Drugs 0.000 description 1
- XIRUXUKRGUFEKC-SSDOTTSWSA-N tert-butyl (2r)-2-(hydroxymethyl)azetidine-1-carboxylate Chemical class CC(C)(C)OC(=O)N1CC[C@@H]1CO XIRUXUKRGUFEKC-SSDOTTSWSA-N 0.000 description 1
- LFKDJXLFVYVEFG-UHFFFAOYSA-N tert-butyl carbamate Chemical compound CC(C)(C)OC(N)=O LFKDJXLFVYVEFG-UHFFFAOYSA-N 0.000 description 1
- YBRBMKDOPFTVDT-UHFFFAOYSA-N tert-butylamine Chemical compound CC(C)(C)N YBRBMKDOPFTVDT-UHFFFAOYSA-N 0.000 description 1
- 125000003718 tetrahydrofuranyl group Chemical group 0.000 description 1
- 125000005958 tetrahydrothienyl group Chemical group 0.000 description 1
- 229910052716 thallium Inorganic materials 0.000 description 1
- BKVIYDNLLOSFOA-UHFFFAOYSA-N thallium Chemical compound [Tl] BKVIYDNLLOSFOA-UHFFFAOYSA-N 0.000 description 1
- 125000001984 thiazolidinyl group Chemical group 0.000 description 1
- 125000000335 thiazolyl group Chemical group 0.000 description 1
- DDWBRNXDKNIQDY-UHFFFAOYSA-N thieno[2,3-d]pyrimidine Chemical compound N1=CN=C2SC=CC2=C1 DDWBRNXDKNIQDY-UHFFFAOYSA-N 0.000 description 1
- MKYRMMMSZSVIGD-UHFFFAOYSA-N thieno[3,2-c]pyridine Chemical compound N1=CC=C2SC=CC2=C1 MKYRMMMSZSVIGD-UHFFFAOYSA-N 0.000 description 1
- 125000001544 thienyl group Chemical group 0.000 description 1
- 238000004809 thin layer chromatography Methods 0.000 description 1
- 125000004568 thiomorpholinyl group Chemical group 0.000 description 1
- DSNBHJFQCNUKMA-SCKDECHMSA-N thromboxane A2 Chemical compound OC(=O)CCC\C=C/C[C@@H]1[C@@H](/C=C/[C@@H](O)CCCCC)O[C@@H]2O[C@H]1C2 DSNBHJFQCNUKMA-SCKDECHMSA-N 0.000 description 1
- KJAMZCVTJDTESW-UHFFFAOYSA-N tiracizine Chemical compound C1CC2=CC=CC=C2N(C(=O)CN(C)C)C2=CC(NC(=O)OCC)=CC=C21 KJAMZCVTJDTESW-UHFFFAOYSA-N 0.000 description 1
- 238000012549 training Methods 0.000 description 1
- WBYWAXJHAXSJNI-VOTSOKGWSA-M trans-cinnamate Chemical compound [O-]C(=O)\C=C\C1=CC=CC=C1 WBYWAXJHAXSJNI-VOTSOKGWSA-M 0.000 description 1
- 238000012546 transfer Methods 0.000 description 1
- 125000001425 triazolyl group Chemical group 0.000 description 1
- ITMCEJHCFYSIIV-UHFFFAOYSA-M triflate Chemical compound [O-]S(=O)(=O)C(F)(F)F ITMCEJHCFYSIIV-UHFFFAOYSA-M 0.000 description 1
- 229960000281 trometamol Drugs 0.000 description 1
- ZDPHROOEEOARMN-UHFFFAOYSA-N undecanoic acid Chemical compound CCCCCCCCCCC(O)=O ZDPHROOEEOARMN-UHFFFAOYSA-N 0.000 description 1
- 210000002700 urine Anatomy 0.000 description 1
- 229940070710 valerate Drugs 0.000 description 1
- NQPDZGIKBAWPEJ-UHFFFAOYSA-N valeric acid Chemical compound CCCCC(O)=O NQPDZGIKBAWPEJ-UHFFFAOYSA-N 0.000 description 1
- 108700026220 vif Genes Proteins 0.000 description 1
- 125000000391 vinyl group Chemical group [H]C([*])=C([H])[H] 0.000 description 1
- 239000011782 vitamin Substances 0.000 description 1
- 235000013343 vitamin Nutrition 0.000 description 1
- 229940088594 vitamin Drugs 0.000 description 1
- 229930003231 vitamin Natural products 0.000 description 1
- 239000001993 wax Substances 0.000 description 1
- IKVDXUFZJARKPF-UHFFFAOYSA-M zinc;cyclopropane;bromide Chemical compound Br[Zn+].C1C[CH-]1 IKVDXUFZJARKPF-UHFFFAOYSA-M 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Veterinary Medicine (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Pulmonology (AREA)
- Neurology (AREA)
- Physical Education & Sports Medicine (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Hospice & Palliative Care (AREA)
- Psychiatry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
Applications Claiming Priority (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201762518779P | 2017-06-13 | 2017-06-13 | |
| US62/518,779 | 2017-06-13 | ||
| US201762522869P | 2017-06-21 | 2017-06-21 | |
| US62/522,869 | 2017-06-21 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| TW201908311A true TW201908311A (zh) | 2019-03-01 |
Family
ID=62948277
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| TW107119972A TW201908311A (zh) | 2017-06-13 | 2018-06-11 | 化合物 |
Country Status (9)
| Country | Link |
|---|---|
| US (1) | US11149035B2 (OSRAM) |
| EP (1) | EP3638672A1 (OSRAM) |
| JP (1) | JP2020523367A (OSRAM) |
| CN (1) | CN110753692A (OSRAM) |
| BR (1) | BR112019026452A2 (OSRAM) |
| CA (1) | CA3066979A1 (OSRAM) |
| TW (1) | TW201908311A (OSRAM) |
| UY (1) | UY37764A (OSRAM) |
| WO (1) | WO2018229629A1 (OSRAM) |
Families Citing this family (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP3724197A1 (en) * | 2017-12-13 | 2020-10-21 | GlaxoSmithKline Intellectual Property Development Ltd | Fused pyridines which act as inhibitors of h-pgds |
| JP2022506850A (ja) * | 2018-11-08 | 2022-01-17 | グラクソスミスクライン、インテレクチュアル、プロパティー、ディベロップメント、リミテッド | 化学化合物 |
| CN109651241B (zh) * | 2018-12-27 | 2021-02-09 | 上海毕得医药科技股份有限公司 | 一种4-溴-6-氯烟醛的合成方法 |
| US20230339937A1 (en) | 2020-06-19 | 2023-10-26 | Sato Pharmaceutical Co., Ltd. | Condensed ring compounds that inhibit h-pgds |
| JP2023549540A (ja) | 2020-11-18 | 2023-11-27 | デシフェラ・ファーマシューティカルズ，エルエルシー | Ｇｃｎ２およびｐｅｒｋキナーゼ阻害剤およびその使用方法 |
| CN112430632B (zh) * | 2020-11-18 | 2022-09-13 | 上海合全药物研发有限公司 | 2-((反式)-4-氨基环己烷基)异丙醇的制备方法 |
| EP4450502A4 (en) | 2021-12-17 | 2025-06-11 | Sato Pharmaceutical Co., Ltd. | AZAINDOLE DERIVATIVE INHIBITING H-PGDS |
Family Cites Families (39)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1361768A (zh) | 1999-06-02 | 2002-07-31 | Nps药物有限公司 | 代谢移变的谷氨酸盐受体拮抗剂和它们治疗中枢神经系统疾病的用途 |
| US6576265B1 (en) | 1999-12-22 | 2003-06-10 | Acell, Inc. | Tissue regenerative composition, method of making, and method of use thereof |
| WO2002085908A1 (en) | 2001-04-24 | 2002-10-31 | Purdue Research Foundation | Folate mimetics and folate-receptor binding conjugates thereof |
| US7868204B2 (en) | 2001-09-14 | 2011-01-11 | Methylgene Inc. | Inhibitors of histone deacetylase |
| US8163769B2 (en) | 2002-03-12 | 2012-04-24 | Abbott Laboratories | Antibacterial compounds |
| JP2006503008A (ja) | 2002-08-13 | 2006-01-26 | ワーナー−ランバート カンパニー リミティド ライアビリティー カンパニー | マトリクスメタロプロテイナーゼ阻害物質としての４−ヒドロキシキノリン誘導体 |
| WO2004056744A1 (en) | 2002-12-23 | 2004-07-08 | Janssen Pharmaceutica N.V. | Adamantyl acetamides as hydroxysteroid dehydrogenase inhibitors |
| WO2005035526A1 (en) | 2003-10-09 | 2005-04-21 | Argenta Discovery Ltd. | Bicyclic compounds and their therapeutic use |
| WO2005094805A1 (ja) | 2004-04-01 | 2005-10-13 | Institute Of Medicinal Molecular Design. Inc. | イミン誘導体及びアミド誘導体 |
| TW200720255A (en) | 2005-07-13 | 2007-06-01 | Taiho Pharmaceutical Co Ltd | Benzoimidazole compound capable of inhibiting prostaglandin d synthetase |
| JP2007051121A (ja) | 2005-07-22 | 2007-03-01 | Taiho Yakuhin Kogyo Kk | プロスタグランジンｄ合成酵素を阻害するピリミジン化合物 |
| PE20110118A1 (es) | 2005-10-04 | 2011-03-08 | Aventis Pharma Inc | Compuestos de pirimidina amida como inhibidores de pgds |
| JP2010513458A (ja) * | 2006-12-19 | 2010-04-30 | ファイザー・プロダクツ・インク | Ｈ−ｐｇｄｓの阻害剤としてのニコチンアミド誘導体、およびプロスタグランジンｄ２の仲介による疾患を治療するためのその使用 |
| DK2142516T3 (da) | 2007-03-30 | 2013-04-15 | Sanofi Sa | Pyrimidinhydrazidforbindelser i ders egenskab af pgds-inhibitorer |
| GB0706793D0 (en) | 2007-04-05 | 2007-05-16 | Evotec Ag | Compounds |
| US9603848B2 (en) | 2007-06-08 | 2017-03-28 | Senomyx, Inc. | Modulation of chemosensory receptors and ligands associated therewith |
| WO2009153720A1 (en) * | 2008-06-18 | 2009-12-23 | Pfizer Limited | Nicotinamide derivatives |
| US20110306597A1 (en) * | 2008-06-18 | 2011-12-15 | James Michael Crawforth | Nicotinamide Derivatives |
| BRPI0919004A2 (pt) | 2008-09-22 | 2019-09-24 | Cayman Chem Co | composto de multiheteroarila como inibidores de h-pgds e sua utilização para o tratamento de doenças mediadas por prostaglandina d2 |
| AU2010222122B2 (en) | 2009-03-09 | 2013-06-27 | Taiho Pharmaceutical Co., Ltd. | Piperazine compound capable of inhibiting prostaglandin D synthase |
| JP2011042643A (ja) | 2009-07-24 | 2011-03-03 | Bayer Cropscience Ag | 殺虫性カルボキサミド類 |
| EP2487175A1 (en) * | 2009-10-06 | 2012-08-15 | Kyowa Hakko Kirin Co., Ltd. | Pharmaceutical product containing aromatic heterocyclic compound |
| BR112012007635B1 (pt) | 2009-10-08 | 2019-07-09 | Sanofi | Compostos derivados de feniloxadiazol como inibidores de pgds, composição farmacêutica compreendendo os mesmos e seus processos de preparação |
| EP2527340B1 (en) | 2010-01-22 | 2016-08-17 | Taiho Pharmaceutical Co., Ltd. | Piperazine compound having a pgds inhibitory effect |
| GB201007347D0 (en) | 2010-04-30 | 2010-06-16 | Karus Therapeutics Ltd | Compounds |
| EP2661265B1 (en) * | 2010-12-23 | 2017-03-08 | Merck Sharp & Dohme Corp. | Quinolines and aza-quinolines as crth2 receptor modulators |
| US20130072473A1 (en) | 2011-05-09 | 2013-03-21 | Proteostasis Therapeutics, Inc. | Compounds for treating protein folding disorders |
| WO2013102145A1 (en) | 2011-12-28 | 2013-07-04 | Global Blood Therapeutics, Inc. | Substituted heteroaryl aldehyde compounds and methods for their use in increasing tissue oxygenation |
| US9187474B2 (en) | 2012-03-07 | 2015-11-17 | Deciphera Pharmaceuticals, Llc | Raf inhibitor compounds |
| TWI631097B (zh) | 2012-07-27 | 2018-08-01 | 百健Ｍａ公司 | 作爲ｓ１ｐ調節劑及／或ａｔｘ調節劑之化合物 |
| WO2014018881A1 (en) | 2012-07-27 | 2014-01-30 | Biogen Idec Ma Inc. | Atx modulating agents |
| US10005720B2 (en) | 2013-04-05 | 2018-06-26 | North Carolina Central University | Compounds useful for the treatment of metabolic disorders and synthesis of the same |
| EP3080085B1 (en) | 2013-12-09 | 2019-08-14 | UCB Biopharma SPRL | Fused bicyclic heteroaromatic derivatives as modulators of tnf activity |
| CN106817900A (zh) | 2014-07-17 | 2017-06-09 | 默克专利有限公司 | 新颖的萘啶和异喹啉及其作为cdk8/19抑制剂的用途 |
| BR112017015760A2 (pt) | 2015-01-23 | 2018-03-27 | Gvk Biosciences Private Limited | inibidores de quinase trka |
| CN108430992A (zh) * | 2015-12-17 | 2018-08-21 | 阿斯特克斯医疗公司 | 作为h-pgds抑制剂的喹啉-3-甲酰胺 |
| JP6896701B2 (ja) * | 2016-02-26 | 2021-06-30 | 大日本住友製薬株式会社 | イミダゾリルアミド誘導体 |
| JOP20190072A1 (ar) * | 2016-10-13 | 2019-04-07 | Glaxosmithkline Ip Dev Ltd | مشتقات 1، 3 سيكلوبوتان ثنائي الاستبدال أو آزيتيدين كمثبطات للإنزيم المخلق للبروستاجلاندين d المكون للدم |
| EP3724197A1 (en) * | 2017-12-13 | 2020-10-21 | GlaxoSmithKline Intellectual Property Development Ltd | Fused pyridines which act as inhibitors of h-pgds |
-
2018
- 2018-06-11 EP EP18742598.8A patent/EP3638672A1/en not_active Withdrawn
- 2018-06-11 BR BR112019026452-3A patent/BR112019026452A2/pt not_active Application Discontinuation
- 2018-06-11 CN CN201880039565.7A patent/CN110753692A/zh active Pending
- 2018-06-11 JP JP2019568760A patent/JP2020523367A/ja not_active Ceased
- 2018-06-11 TW TW107119972A patent/TW201908311A/zh unknown
- 2018-06-11 CA CA3066979A patent/CA3066979A1/en not_active Abandoned
- 2018-06-11 UY UY0001037764A patent/UY37764A/es unknown
- 2018-06-11 US US16/621,927 patent/US11149035B2/en not_active Expired - Fee Related
- 2018-06-11 WO PCT/IB2018/054206 patent/WO2018229629A1/en not_active Ceased
Also Published As
| Publication number | Publication date |
|---|---|
| WO2018229629A1 (en) | 2018-12-20 |
| BR112019026452A2 (pt) | 2020-07-14 |
| JP2020523367A (ja) | 2020-08-06 |
| US20200123152A1 (en) | 2020-04-23 |
| CN110753692A (zh) | 2020-02-04 |
| CA3066979A1 (en) | 2018-12-20 |
| US11149035B2 (en) | 2021-10-19 |
| UY37764A (es) | 2019-01-02 |
| EP3638672A1 (en) | 2020-04-22 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN112752756B (zh) | 作为PD-L1免疫调节剂的四氢-咪唑并[4,5-c]吡啶衍生物 | |
| CN110753692A (zh) | 作为h-pgds抑制剂的化学化合物 | |
| CN104470919B (zh) | 作为pad4抑制剂的2-(氮杂吲哚-2-基)苯并咪唑 | |
| CN108430992A (zh) | 作为h-pgds抑制剂的喹啉-3-甲酰胺 | |
| JP6676541B2 (ja) | 置換された４−フェニルピペリジン、その調製及び使用 | |
| TWI662039B (zh) | 用於誘發軟骨生成之化合物及組合物 | |
| CN111954664A (zh) | 囊肿性纤维化跨膜传导调节蛋白调节剂和使用方法 | |
| CN114728975A (zh) | 唑稠合的哒嗪-3(2h)-酮衍生物 | |
| TW201414737A (zh) | 作爲激酶抑制劑之咪唑并三□甲腈 | |
| CN109641899A (zh) | 作为内体Toll样受体抑制剂的化合物及组合物 | |
| CN114728941A (zh) | 作为alk5抑制剂的经取代的1,5-萘啶或喹啉 | |
| CN113195467A (zh) | 适用作alk5抑制剂的萘啶和喹啉衍生物 | |
| JP2025526423A (ja) | 新規化合物 | |
| TW201446754A (zh) | 雜環化合物及其用途 | |
| JP2021519308A (ja) | 転写活性化タンパク質のイミダゾピペラジン阻害剤 | |
| CN110461842A (zh) | 作为tnf活性调节剂的稠合五环咪唑衍生物 | |
| TWI714528B (zh) | 甲醯胺衍生物 | |
| CN111212842B (zh) | 血管加压素受体拮抗剂以及与其相关的产品和方法 | |
| CN106661032A (zh) | 治疗或预防糖尿病、肥胖症和炎性肠病的1,3‑取代的2‑氨基吲哚衍生物及类似物 | |
| CN115348961A (zh) | 杂环pad4抑制剂 | |
| JP6587637B2 (ja) | カルボキサミド誘導体 | |
| CN107108627A (zh) | 作为沉默调节蛋白调节剂的取代的桥环脲类似物 | |
| CN114591352A (zh) | 一种三唑并哒嗪类化合物及其应用 | |
| CN111479814A (zh) | 作为h-pgds抑制剂的稠合的吡啶 | |
| CN112969698A (zh) | 化学化合物 |